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ABSTRACT
Components and regulators of yeast and mammalian RNA polymerase II
holoenzymes were isolated and characterized. First, subcomplexes and
components of the yeast RNA polymerase II holoenzyme were isolated and
identified. A complex containing SRB and SWI/SNF regulatory proteins was
purified over an affinity chromatography column containing the carboxyl
terminal repeat domain of RNA polymerase II. The SRB/SWI/SNF complex
stimulates transcription in vitro and contains chromatin remodeling and
CTD kinase activities. Additional components of the SRB/SWI/SNF complex
were identified by mass spectrometry. Second, hSRB7, a human homolog of a
yeast SRB gene, was identified as a component of a mammalian RNA
polymerase II holoenzyme. Finally, a yeast homolog of the mammalian
negative cofactor NC2 was purified and shown to repress transcription by the
RNA polymerase II holoenzyme in vitro.
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Chapter 1: Introduction: Factors involved in transcription initiation
Overview
The regulation of gene expression is fundamental to living processes. In
the simple eukaryote Saccharomyces cerevisiae, 4,665 genes give rise to a
steady state level of approximately 15,000 mRNA transcripts (Velculescu,
Zhang et al. 1997). The steady-state number of transcripts per gene per cell
varies from 0.3 to 200 copies (Velculescu, Zhang et al. 1997). The steady state
level of an average mRNA is 1 to 2 copies per cell (Struhl and Davis 1981).
The regulation of transcription initiation is thought to account for much of
the variation in transcript levels.
The RNA polymerase II holoenzyme is the apparatus that initiates the
transcription of mRNA in vivo. The holoenzyme contains RNA polymerase
II; the general transcription factors TFIIB, TFIIF and TFIIH; and regulatory
proteins such as the SRB and SWI/SNF proteins. Additional general
transcription factors and gene specific and general regulatory proteins also
play a role in initiating transcription.
As background, I describe our knowledge of the factors involved in
transcription initiation in Chapter 1. In Chapter 2, I describe the identification
and isolation of a complex containing SRB regulatory proteins. In Chapter 3, I
describe the identification of the SWI/SNF and other proteins as components
of the SRB complex. In Chapter 4, I describe the isolation of a human SRB
gene and its association with a mammalian RNA polymerase II holoenzyme.
In Chapter 5, I describe the purification and characterization of the negative
regulator NC2 from yeast. In Chapter 6, I discuss the RNA polymerase II
holoenzyme in the context of models for preinitiation complex formation
and transcriptional activation and as an example of a large protein complex
involved in processing regulatory signals.
1. Components of the RNA polymerase II holoenzyme
The best characterized form of yeast RNA polymerase II holoenzyme
contains RNA polymerase II; the SRBs; the general transcription factors
TFIIB, TFIIF and TFIIH; the SWI/SNF regulatory proteins; as well as GAL11,
RGR1, SIN4 and ROX3 (reviewed in Berk 1995; Koleske and Young 1995;
Halle and Meisterernst 1996; and Carey 1995). However, multiple forms of
RNA polymerase II holoenzyme have been isolated from yeast and
mammalian cells. All RNA polymerase II holoenzymes isolated so far
contain RNA polymerase II, at least one SRB protein, and at least one general
transcription factor. The subset of general transcription factors associated with
the holoenzyme appears to vary in the various preparations. One explanation
for these results is that there are different forms of holoenzyme in vivo. As is
the case with the SWI/SNF complex (Wang, Xue et al. 1996) and TFIID
(Dikstein, Zhou et al. 1996), there may be different forms of holoenzyme in
different cell types or under different physiological conditions. The
composition of the holoenzyme may also vary during the various steps in
transcription initiation and elongation. Another explanation is that the
various purified forms of holoenzyme represent artifactual subcomplexes of
what exists in vivo. The dilution, hydrodynamic shearing and extreme ionic
conditions of protein purification are likely to be extremely disruptive to
complexes accustomed to the concentrated environment of the nucleus. In
support of this notion, rapid immunoprecipitation procedures yield
holoenzyme complexes containing more general transcription factors than
versions purified by conventional chromatography (Ossipow, Tassan et al.
1996; Chris Wilson, unpublished). It is possible that improved purification
procedures will allow the isolation of more complete holoenzymes which
will provide an improved picture of the transcriptional apparatus in vivo.
RNA polymerase II
RNA polymerase II is the enzyme responsible for catalyzing the
production of mRNA from protein-encoding genes (Roeder and Rutter 1969).
A structure of RNA polymerase II at 16 angstrom resolution is available
(Darst, Edwards et al. 1991). Low resolution structures of RNA polymerase II
complexed with TFIIB and TFIIE and lacking a CTD are also available
(Leuther, Bushnell et al. 1996). These low resolution structures provide a
gross view of RNA polymerase II but provide little insight into how the
enzyme functions. With such low resolution, structural features cannot be
assigned to individual residues and cannot be interpreted in light of the
available genetic information.
The enzyme contains 12 subunits, ranging in size from 220 to 10 kD
(reviewed in Young 1991). The subunit composition reveals common
evolutionary origins and homologous functions among the three RNA
polymerases. Some of the RNA polymerase II subunits are shared with RNA
polymerases I and III, and some have homologous counterparts in the other
polymerases. The composition of core RNA polymerase II varies with the
physiological state of the cell. RPB4 and RPB7 form a subcomplex which can
be dissociated from the other RNA polymerase II subunits (Edwards, Kane et
al. 1991). Their addition to purified RNA polymerase II lacking these subunits
stimulates transcription in vitro (Edwards, Kane et al. 1991). In vivo, their
association with the other polymerase II subunits is increased by physiological
stress (Choder and Young 1993), an observation suggesting that the RPB4 and
RPB7 subunits couple RNA polymerase II activity with broad physiological
changes. Alterations in the subunit composition of RNA polymerase II may
represent a means for coordinately regulating entire sets of genes.
An interesting feature of RNA polymerase II is a structure found at the C-
terminus of its largest subunit. The carboxyl-terminal repeat domain (CTD)
consists of multiple heptapeptide repeat with the sequence YSPTSPS. The
sequence is conserved among eukaryotes but is absent from viral RNA
polymerases and RNA polymerase I and III (reviewed in Chao and Young
1991 and Corden 1990). There are 26 or 27 repeats in the yeast CTD (Allison,
Moyle et al. 1985) and 52 copies in the mouse version (Corden, Cadena et al.
1985; Allison, Wong et al. 1988). The length of the CTD increases roughly with
the genomic complexity of an organism while the conservation of the
individual repeats decreases. The evolutionary divergence of the CTD may
reflect the increased regulatory demands of coordinating transcription in
more complex genomes.
The CTD is required for the viability of yeast (Nonet, Sweetser et al. 1987;
Allison, Wong et al. 1988), Drosophila (Zehring, Lee et al. 1988) and
mammalian cells (Bartolomei, Halden et al. 1988). More specifically, the CTD
is involved in responses to transcriptional activators in both yeast (Allison
and Ingles 1989; Scafe, Chao et al. 1990) and mammalian cells (Gerber,
Hagmann et al. 1995). In these in vivo studies, mutants containing truncated
CTDs show a defect in the response to a subset of activators. Likewise, in vitro
studies indicate that the CTD is involved in transcription from some
promoters (Thompson, Steinberg et al. 1989; Liao, Taylor et al. 1991) but not
others (Zehring, Lee et al. 1988; Buratowski and Sharp 1990; Zehring and
Greenleaf 1990). These studies in vivo and in vitro indicate that different
promoters vary in their requirement for the CTD and provide support for the
notion that the influence of different regulatory mechanisms varies from
promoter to promoter.
Besides a role in transcription initiation, the CTD may play a role in
linking transcription with splicing. Several SR-related proteins have been
shown to interact with murine CTD in a two hybrid assay (Yuryev, Patturajan
et al. 1996). Consistent with these results, mammalian RNA polymerase II
containing a phosphorylated CTD associates with splicing factors in vitro
(Mortillaro, Blencowe et al. 1996; Kim, Du et al. 1997). At the subcellular level,
mammalian RNA polymerase II containing a phosphorylated CTD localizes
to subnuclear speckles containing splicing factors (Bregman, Du et al. 1995;
Mortillaro, Blencowe et al. 1996). Overexpression of the CTD alone appears to
disrupt the subnuclear localization of splicing factors and blocks the
accumulation of at least one spliced message (Du and Warren 1997). Besides
splicing, the CTD may also play a role in processing of the 3' end and
termination of transcription downstream of the poly(A) site of transcripts.
Cleavage and polyadenylation factors bind specifically to the CTD in vitro,
and, in mammalian cells, a mutant containing a truncated CTD is defective in
these processes (McCracken, Fong et al. 1997). Extending these observations to
the yeast system, where mutations in the CTD are more easily and directly
studied, would be helpful in substantiating their physiological significance.
However, the lack of yeast mutants that specifically disrupt CTD
phosphorylation and the technical challenge of observing speckles in the
small yeast nucleus represent significant obstacles.
A proportion of the RNA polymerase II molecules in cells are
phosphorylated on the CTD in vivo (Cadena and Dahmus 1987; Kolodziej,
Woychik et al. 1990, reviewed in Dahmus 1996). There is some controversy as
to which residues are phosphorylated in the CTD. RNA polymerase II CTDs
isolated by different procedures contain phosphoserine and
phosphothreonine in one case (Zhang and Corden 1991) and also
phosphotyrosine in another (Baskaran, Dahmus et al. 1993). The structural
consequence of CTD phosphorylation may be a conformational change.
While a synthetic CTD peptide appears to be mostly disordered in solution
(Cagas and Corden 1995), phosphorylation does lead to a significant increase
in the CTD's apparent molecular weight by gel filtration (Zhang and Corden
1991).
The role of CTD phosphorylation in vivo has been difficult to establish.
Phosphorylation of the CTD correlates with promoter clearance in vitro
(Payne, Laybourn et al. 1989; Laybourn and Dahmus 1990). In Drosophila cells,
the CTD becomes phosphorylated after RNA polymerase II switches from a
paused to an elongating form (O'Brien, Hardin et al. 1994). Furthermore, in
this system, the level of CTD phosphorylation varies from promoter to
promoter (O'Brien, Hardin et al. 1994). It is important to note that these
studies are correlative. They do not show that CTD phosphorylation is
required for promoter clearance or elongation. In fact, in one in vitro system,
phosphorylation of the CTD is not required for proper initiation, promoter
clearance or transcription of the Adeno Major Late promoter (Serizawa 1993).
In another in vitro system, CTD phosphorylation is required for transcription
of the DHFR promoter (Akoulitchev, Makela et al. 1995). The requirement for
CTD phosphorylation in crude in vitro transcription systems is likely to
involve factors absent from highly purified systems. In the yeast system,
transcription reactions reconstituted with crude fractions are sensitive to the
addition of a kinase inhibitor while reactions reconstituted with highly
purified factors are not (Li and Kornberg 1994). These in vitro results are
consistent with a model where a kinase phosphorylating the CTD overcomes
inhibition by a negative regulator. Confirmation of the existence and identity
of such a factor would provide useful insights into the physiological role of
CTD phosphorylation. Phosphorylation of the CTD also appears to inhibit the
binding of TBP to the CTD (Usheva, Maldonado et al. 1992), but there is not
yet any genetic data that supports a role for this interaction in vivo.
Several kinases with the ability to phosphorylate the CTD in vitro have
been identified. The yeast kinase CTK1 is the only kinase whose mutation
appears to affect on CTD phosphorylation in vivo. CTK1 phosphorylates CTD
in vitro (Lee and Greenleaf 1989) and has a very limited effect on CTD
phosphorylation in vivo (Lee and Greenleaf 1991). Yeast and mammalian
versions of the general transcription factor TFIIH both phosphorylate the CTD
in vitro (Feaver, Gileadi et al. 1991; Lu, Zawel et al. 1992), but whether the
CTD is a physiologically relevant substrate has yet to be shown. Other CTD
kinases include a CDK (Cisek and Corden 1989) and a Drosophila elongation
factor P-TEFb (Marshall and Price 1995; Marshall, Peng et al. 1996). In neither
case has the CTD kinase activity been shown to be physiologically relevant.
Mutations in SRB10 and 11, a kinase-cyclin pair, suppress CTD truncation
mutants. The CTD kinase activity of an RNA polymerase II holoenzyme
containing a mutant form of SRB10 is 10 fold lower than that of a wild-type
holoenzyme (Liao, Zhang et al. 1995). Mutations in SRB10 and 11 have not
yet been shown to affect CTD phosphorylation in vivo.
Studying the role of CTD phosphorylation in vivo has proven to be
challenging. One obstacle to genetic studies is difficulty in demonstrating that
mutation of any of the putative CTD kinases actually affects CTD
phosphorylation in vivo. One reason may be the presence of redundant
kinases, whose activity would make it difficult to observe effects when only
one kinase is mutated. Even if a mutation affecting CTD phosphorylation is
isolated, it may be difficult to distinguish between direct and indirect effects.
Given that CTD phosphorylation correlates with an elongating polymerase, it
is likely that any mutation blocking a step before elongation would indirectly
affect the steady state level of CTD phosphorylation.
SRB proteins
Mutants containing a truncated CTD are cold-sensitive, temperature-
sensitive (Nonet, Sweetser et al. 1987), unable to grow without inositol
(Nonet and Young 1989), and unable to use pyruvate as a carbon source
(Thompson, Koleske et al. 1993). The SRB (Suppressors of RNA polymerase II
or B) genes are allele-specific extragenic suppressors of a CTD-truncation
mutant (Nonet and Young 1989; Koleske, Buratowski et al. 1992; Thompson,
Koleske et al. 1993; Hengartner, Thompson et al. 1995; Liao, Zhang et al. 1995).
This genetic interaction between the SRBs and the CTD is consistent with the
biochemical observation that the SRBs bind to a CTD affinity column
(Thompson, Koleske et al. 1993). An interaction between the SRBs and the
CTD is also supported by the observation that SRBs are dissociated from RNA
polymerase II by treatment with a monoclonal antibody directed against the
CTD (Kim, Bjorklund et al. 1994).
The SRBs are a hallmark of the RNA polymerase II holoenzyme. The
holoenzyme contains approximately 20% of RNA polymerase II molecules
and 100% of the SRBs in the cell (Koleske and Young 1994). The RNA
polymerase II holoenzyme is responsive to the activator GAL4-VP16 in vitro
(Kim, Bjorklund et al. 1994; Koleske and Young 1994). A subcomplex
containing SRB proteins allows a reconstituted system containing purified
general transcription factors to respond to activators (Kim, Bjorklund et al.
1994; Hengartner, Thompson et al. 1995). Consistent with these functional
results, the RNA polymerase II holoenzyme and the SRB subcomplex can
bind to an activator in vitro (Hengartner, Thompson et al. 1995)
A shift to the non-permissive temperature leads to a rapid cessation of
mRNA synthesis in a cell containing temperature sensitive mutations in
SRB4 (Thompson and Young 1995). SRB4 activity is required for transcription
from 10 of 10 promoters examined. Temperature sensitive mutations in SRB6
show the same effect (Thompson and Young 1995). These results indicate that
the holoenzyme is the form of RNA polymerase II required for class II
transcription in yeast cells because all of the detectable SRB4 and SRB6 are
associated with the holoenzyme.
SRBs also show genetic interactions with additional genes. Mutations in
SRB8 and SRB9 (Song, Treich et al. 1996) and in SRB10 and SRB11 (Kuchin,
Yeghiayan et al. 1995) suppress mutations in SNF1, a gene involved in
regulation of the SUC2 gene. Mutations in SRB10 also suppress a mutation in
the ao2 gene, a gene-specific repressor (Wahi and Johnson 1995), and give rise
to defects in the levels of meiosis-specific transcripts (Surosky, Strich et al.
1994). SRB8, SRB9, SRB10 and SRB11 are similar in that their deletion
phenotype is slow-growth and flocculence and in that loss of function
mutations suppress the CTD truncation mutants (Hengartner, Thompson et
al. 1995; Liao, Zhang et al. 1995).
SRB10 and SRB11 encode a kinase/cyclin pair (Liao, Zhang et al. 1995).
Loss of function mutations in SRB10 can either increase or decrease
expression levels depending upon the promoter. Loss of SRB10 function leads
to increased transcription from the SUC2 promoter (Kuchin, Yeghiayan et al.
1995) and from the promoters of a-specific genes (Wahi and Johnson 1995). In
contrast, at the GALl-10 promoter, loss of SRB10 function leads to a decrease
in activated transcription (Liao, Zhang et al. 1995). It is not yet clear whether
SRB10 and SRB11 play a direct role in mediating transcriptional repression or
whether SRB10 and SRB11 play an indirect role by affecting the levels of
factors involved in repression. It has been difficult to reproduce the effects of
SRB10 mutation on transcription in vivo with an in vitro system. In a system
reconstituted with purified RNA polymerase II holoenzyme, a mutation
inactivating SRB10 has no effect on either basal or GAL4-VP16 activated
transcription. However, mutating SRB10 does decrease the holoenzyme's
CTD kinase activity (Liao, Zhang et al. 1995). It remains to be seen whether the
failure to observe transcriptional defects of SRB10 mutations in vitro results
from the absence of negative regulators, the use of an exceptionally powerful
viral activator, or some other factor.
A mammalian SRB homologue of SRB7 has been identified and used to
isolate a mammalian RNA polymerase II holoenzyme (Chao, Gadbois et al.
1996). Human SRB7 is present in two other preparations of holoenzyme
(Ossipow, Tassan et al. 1995; Maldonado, Shiekhattar et al. 1996; Cho,
Maldonado et al. 1997). CDK8 and cyclin C associate with RNA polymerase II
and have been proposed to be homologues of SRB10 and 11 respectively
(Tassan, Jaquenoud et al. 1995; Leclerc, Tassan et al. 1996). The tight sequence
conservation among members of the CDK and cyclin families makes it
difficult to establish whether CDK8 and cyclin C are actually functional
homologues of SRB10 and 11. There is, however, some circumstantial
evidence for a relationship. hSRB7, CDK8 and cyclin C have been reported to
cofractionate as a 1.5 MD complex in gel filtration experiments (Gold, Tassan
et al. 1996).
Some preparations of RNA polymerase II holoenzyme respond to the
activator GAL4-VP16 (Maldonado, Shiekhattar et al. 1996). Other preparations
fail to respond to activators in the absence of additional coactivators (Ossipow,
Tassan et al. 1995; Chao, Gadbois et al. 1996). The various forms of
mammalian RNA polymerase II are too poorly characterized to attribute
these differences to the presence or absence of specific proteins.
TFIIB
TFIIB is present in some preparations of yeast holoenzyme but not others
(Koleske, Chao et al. 1996). Yeast TFIIB has been cloned (Pinto, Ware et al.
1992) and purified (Tschochner, Sayre et al. 1992) and is a single subunit of 38
kD. It is extremely similar in sequence to human TFIIB (Ha, Lane et al. 1991).
The crystal structure of a complex containing TFIIB bound to TBP and DNA
(Nikolov, Chen et al. 1995) and the solution structure of a C-terminal
fragment (Bagby, Kim et al. 1995) are both known.
TFIIB is required for cell viability (Pinto, Ware et al. 1992) and is involved
in selection of the transcription start site. Mutations in TFIIB alter the
position of the start site in vivo (Pinto, Ware et al. 1992; Pinto, Wu et al. 1994)
Similarly, experiments swapping TFIIB and RNA polymerase II from
different species indicate that TFIIB is involved in selecting the start site in
vitro (Li, Flanagan et al. 1994). Affinity chromatography and surface-plasmon
resonance experiments demonstrate an interaction between TFIIB and RNA
polymerase II (Tschochner, Sayre et al. 1992; Bushnell, Bamdad et al. 1996) and
a low resolution two dimensional crystal structure shows TFIIB bound to
RNA polymerase II (Leuther, Bushnell et al. 1996). In vivo work also supports
an interaction between TFIIB and RNA polymerase II. A mutation in the
RNA polymerase II subunit RPB9 suppresses the start-site selection defect of a
TFIIB mutation (Sun, Tessmer et al. 1996). Furthermore, TFIIB mutants
defective in start-site selection in vivo show diminished binding to RNA
polymerase II in vitro (Bushnell, Bamdad et al. 1996).
Like many general transcription factors, TFIIB binds directly to a VP16
column (Lin, Ha et al. 1991). VP16 binding correlates with the ability of
mutant TFIIB molecules to support activated transcription in vitro (Roberts,
Ha et al. 1993). The interaction between VP16 and TFIIB increases the number
of functional pre-initiation complexes by recruiting TFIIB to the promoter
(Lin and Green 1991) and by causing a conformational change in TFIIB
(Roberts and Green 1994).
TFIIF
TFIIF is a component of all reported forms of yeast RNA polymerase II
holoenzymes (Kim, Bjorklund et al. 1994; Koleske and Young 1994; Koleske,
Chao et al. 1996).
Mammalian TFIIF has two subunits with molecular weights of 30 and 74
kD (Flores, Ha et al. 1990). Yeast TFIIF has three subunits with molecular
weights of 30, 50 and 105 kD (Henry, Sayre et al. 1992). The 50 kD and 105 kD
subunits are homologous to the small and large subunits of the mammalian
enzyme (Henry, Campbell et al. 1994). The 30 kD subunit is loosely associated
with the other two subunits. It is stimulatory but not essential for
transcriptional activity in vitro. The 30 kD subunit also associates with the
TBP-TAF complex and with the SWI/SNF complex (Henry, Campbell et al.
1994). One explanation for the presence of the same 30 kD subunit in all three
complexes is that the subunit performs an auxiliary function common to all
three complexes. Another explanation is that TFIIF, TAFs and SWI-SNF are
all part of a larger complex, such as the holoenzyme, and that the forms
observed in vitro represent different breakdown products of the larger
complex.
Mammalian TFIIF contains RAP30 (Sopta, Burton et al. 1989) and RAP74
(Flores, Maldonado et al. 1988; Finkelstein, Kostrub et al. 1992), proteins
associated with RNA polymerase II. TFIIF associates with RNA polymerase II
in a variety of experimental contexts, including affinity chromatography
(Sopta, Carthew et al. 1985), co-sedimentation (Flores, Maldonado et al. 1989;
Henry, Sayre et al. 1992) and surface plasmon resonance (Bushnell, Bamdad et
al. 1996). Rat TFIIF reduces the affinity of RNA polymerase II for free DNA, an
activity similar to that of bacterial sigma factors (Conaway and Conaway 1990).
Besides a role in initiation, TFIIF may play a role in elongation as it
stimulates elongation by RNA polymerase II in vitro (Flores, Maldonado et
al. 1989; Bengal, Flores et al. 1991).
The 50 and 105 kD subunits of yeast TFIIF are required for cell viability
(Henry, Campbell et al. 1994). In addition, genetic results suggest a functional
interaction between TFIIB and TFIIF. A mutation in the largest subunit of
TFIIF suppresses defective start-site selection in a TFIIB mutant (Sun and
Hampsey 1995).
In a two hybrid assay, the largest subunit of TFIIF also interacts with the
transcriptional activator Serum Response Factor, (Joliot, Demma et al. 1995).
Consistent with the two hybrid results, a mutation disrupting the interaction
in vivo supports responds to Spl but not the Serum Response Factor in a
reconstituted in vitro transcription system (Joliot, Demma et al. 1995).
TFIIH
TFIIH is found in some preparations of yeast RNA polymerase II
holoenzyme (Koleske and Young 1994; Koleske, Chao et al. 1996) but not in
others (Kim, Bjorklund et al. 1994).
Yeast TFIIH can be dissociated into three components: a five subunit core,
TFIIK and the SSL2 protein (Svejstrup, Wang et al. 1995). Mammalian TFIIH
is less well characterized than the yeast version but appears to have
homologous counterparts for most if not all of the yeast subunits (reviewed
in Svejstrup, Vichi et al. 1996).
Core TFIIH contains five subunits: RAD3, TFB1 and SSL1 and 50 and 38
kD subunits (Feaver, Svejstrup et al. 1993). The subunits of core TFIIH are
shared with the form of TFIIH involved in nucleotide excision repair
(Svejstrup, Wang et al. 1995). The role of TFIIH in DNA repair is reviewed in
Seroz, Hwang et al. 1995; Chalut, Moncollin et al. 1994; Hoeijmakers, Egly et
al. 1996; Svejstrup, Vichi et al. 1996.
The TFIIK subcomplex contains the kinase KIN28 (Feaver, Svejstrup et al.
1994) and its cyclin partner CCL1 (Svejstrup, Feaver et al. 1996). The
mammalian counterparts of KIN28 are CDK7 and cyclin H respectively (Roy,
Adamczewski et al. 1994; Serizawa, Makela et al. 1995; Shiekhattar,
Mermelstein et al. 1995). The crystal structure of cyclin H is similar to that of
other cyclins (Andersen, Poterszman et al. 1996; Kim, Chamberlin et al. 1996).
Mammalian TFIIH has CDK-activating kinase (CAK) activity in vitro (Roy,
Adamczewski et al. 1994; Serizawa, Makela et al. 1995; Shiekhattar,
Mermelstein et al. 1995) while an immunopurified complex containing
KIN28 and CCL1 does not (Cismowski, Laff et al. 1995). A temperature-
sensitive mutation in KIN28 shows a transcriptional defect but no defect in
the phosphorylation of CDC28, a target of CAK (Cismowski, Laff et al. 1995). In
contrast, yeast CAK1/CIV1, whose product has CAK activity in vitro, shows a
cell-cycle defect and reduced CDC28 activity but does not exhibit a
transcriptional defect (Espinoza, Farrell et al. 1996; Kaldis, Sutton et al. 1996;
Thuret, Valay et al. 1996). With the exception of the in vitro phosphorylation
data with CDK7-cyclin H, these results are consistent with roles for KIN28-
CCL1 and CDK7-Cyclin H in transcription but not cell-cycle regulation. An
alternative explanation including the in vitro CAK results is that CDK7-
Cyclin H plays a role in regulating the cell cycle in mammals, a role that
KIN28-CCL1 does not play in yeast. There is some precedent for homologous
CDKs playing different roles in mammalian and yeast cells. Determining
whether CDK7 and Cyclin H mutants have a cell-cycle arrest phenotype in
mammalian cells would help clarify the issue.
Besides CDC2/CDC28, another target for the TFIIH kinase may be the
CTD. Both yeast (Feaver, Gileadi et al. 1991) and mammalian (Lu, Zawel et al.
1992) TFIIH phosphorylate the CTD in vitro. More specifically, the TFIIK
subcomplex has CTD kinase activity in vitro (Feaver, Svejstrup et al. 1994).
The CTD kinase activity is stimulated by TFIIE in vitro (Lu, Zawel et al. 1992;
Ohkuma and Roeder 1994). In addition to the CTD, mammalian TFIIH
phosphorylates TBP, the large subunit of TFIIE and the large subunit of TFIIF
in vitro (Ohkuma and Roeder 1994).
Basal and activated transcription are normal in a purified system
containing a mutant TFIIH lacking CTD kinase activity (Makela, Parvin et al.
1995). Similarly, basal transcription is normal in a reconstituted system where
CTD kinase activity is inhibited by the nucleotide analog H-8 (Serizawa,
Conaway et al. 1993). However, in a cruder in vitro system, the CTD kinase
activity of TFIIH is required for transcription from the DHFR promoter
(Akoulitchev, Makela et al. 1995). TFIIH may be required to overcome a
negative regulator contaminating crude in vitro transcription systems.
Support for this notion comes from work in an in vitro transcription system
where TFIIH is not required. In this system, the addition of TFIIH overcomes
inhibition by the non-histone chromosomal protein HMG2 (Stelzer, Goppelt
et al. 1994).
Evidence also suggests that TFIIH plays a role in activation. Mammalian
TFIIH binds to the activators VP16 and p53 on affinity columns (Xiao, Pearson
et al. 1994). Certain activators stimulate transcriptional elongation(Yankulov,
Blau et al. 1994; Blau, Xiao et al. 1996). The strength of these activators
correlates with their affinity for TFIIH in vitro (Blau, Xiao et al. 1996).
Similarly, the transcriptional regulator HIV Tat stimulates both elongation
and phosphorylation of the CTD by TFIIH in vitro (Parada and Roeder 1996).
A role for TFIIH in elongation is also suggested by the observation that
microinjection of antibodies against TFIIH into Xenopus oocytes inhibits
elongation on test promoters (Yankulov, Pandes et al. 1996).
SWI/SNF proteins
Yeast and human SWI/SNF proteins can be isolated as an eleven subunit
complex (Cairns, Kim et al. 1994; Kwon, Imbalzano et al. 1994; Peterson,
Dingwall et al. 1994) or associated with SRB proteins and the RNA
polymerase II holoenzyme (Wilson, Chao et al. 1996). The composition of
mammalian SWI/SNF complex appears to be different in different human
cell types (Wang, Cote et al. 1996; Wang, Xue et al. 1996). SNF2/SWI2 appears
to be a part of a large protein family whose members contain DNA-dependent
ATPase activities (Laurent, Treich et al. 1993). Other members of the
SNF2/SWI2 family have been identified as components of other chromatin
remodeling activities such as NURF (Tsukiyama, Daniel et al. 1995) and RSC
(Cairns, Lorch et al. 1996).
Purified SWI/SNF complex (Cote, Quinn et al. 1994; Imbalzano, Kwon et
al. 1994; Kwon, Imbalzano et al. 1994), SRB/SWI/SNF complex and RNA
polymerase II holoenzyme (Wilson, Chao et al. 1996) all exhibit ATP-
dependent nucleosome disruption activity. SWI/SNF complex promotes the
binding of TBP (Imbalzano, Kwon et al. 1994) and GAL4 (Cote, Quinn et al.
1994; Kwon, Imbalzano et al. 1994) to chromatin DNA templates. The
disrupted nucleosome structure around DNA-bound Gal4 persists after
removal of the SWI/SNF protein from the template (Owen-Hughes, Utley et
al. 1996).
SWI/SNF genes influence the expression of the SUC2 and the HO genes
(reviewed in Winston and Carlson 1992) and are required for normal
transcription of at a large number of genes (Laurent, Treitel et al. 1990;
Laurent and Carlson 1992; Peterson and Herskowitz 1992).
The nucleosome disruption activity of the SWI/SNF complex is
consistent with the genetic interactions observed between the SWI/SNF
genes and histone genes. Mutations in SNF2/SWI2, and SNF5, and SNF6 are
suppressed by mutations in histones H2A and H2B (Hirschhorn, Brown et al.
1992), and mutations in SWI1/SNF2/SWI2 and SWI3 are suppressed by
mutations in histones H3 and H4 (Kruger, Peterson et al. 1995).
Two aspects of the SWI/SNF proteins are controversial. The first is the
number of SWI/SNF proteins per cell. One estimate is that there are
approximately 100 copies of SWI/SNF complex in yeast cells (Cote, Quinn et
al. 1994). This estimate is derived from calculations of the relative yield of a
purification procedure. Another estimate is that there are at least 2000
(Wilson, Chao et al. 1996). This estimate is derived from quantitative
Western data. Given the assumptions required for estimates based on
recovery from purification procedures, it is likely that the estimate of 2000
molecules of SWI/SNF per yeast cell is more accurate. The second
controversial aspect of the SWI/SNF complex is its association with the RNA
polymerase II holoenzyme. The SWI/SNF proteins coimmunoprecipitate and
copurify with the RNA polymerase II holoenzyme in one report (Wilson,
Chao et al. 1996) and do not copurify with the holoenzyme in another report
(Cairns, Lorch et al. 1996). It is not yet clear whether these differences result
from different purification procedures or from some other reason.
Other regulators
GAL11 is a component of the RNA polymerase II holoenzyme and
mediator subcomplex (Kim, Bjorklund et al. 1994). GAL11 is required for
proper expression of enzymes metabolizing galactose (Suzuki, Nogi et al.
1988) and is required for appropriate transcription from a promoter
containing a Ty element (Fassler and Winston 1989). Mutations in GAL11
affect a broad spectrum of genes in vivo (Fassler and Winston 1989). A
mutation in GAL11 called GAL11P suppresses mutations weakening the
transcriptional activator GAL4 (Himmelfarb, Pearlberg et al. 1990) apparently
by creating a fortuitous interaction between GAL11 and the dimerization
region of GAL4 (Barberis, Pearlberg et al. 1995).
SIN4, RGR1 (Li, Bjorklund et al. 1995) and ROX3 (Gustafsson, Myers et al.
1997) are also components of the RNA polymerase II holoenzyme and a
subcomplex called the mediator. SIN4 is involved in transcription from
multiple promoters, including HO, Ty, and GALl (Jiang and Stillman 1992).
RGR1 also appears to regulate several promoters (Jiang, Dohrmann et al.
1995). Furthermore, there is a genetic interaction between RGR1 and SIN4 as
overexpression of RGR1 suppresses a SIN4 deletion (Jiang, Dohrmann et al.
1995).
The presence of these genes in the RNA polymerase II holoenzyme is
consistent with their involvement in transcriptional regulation in vivo but
their functional role is not yet clear.
2. Other transcription factors
TATA binding protein (TBP)
TBP is a general transcription factor that binds to a promoter element
called the TATA box (Sawadogo and Roeder 1985; Nakajima, Horikoshi et al.
1988). The yeast protein of 27 kD shares significant sequence homology with
the human protein of 37 kD (Hahn, Buratowski et al. 1989; Hoffman, Sinn et
al. 1990; Kao, Lieberman et al. 1990; Peterson, Tanese et al. 1990). The crystal
structures of TBP (Nikolov, Hu et al. 1992; Chasman, Flaherty et al. 1993), TBP
complexed with DNA (Kim, Nikolov et al. 1993; Kim, Geiger et al. 1993), TBP
and TFIIB and DNA (Nikolov, Chen et al. 1995), and TBP and TFIIA and
DNA (Geiger, Hahn et al. 1996) are available.
TBP is a good example of the evolutionary conservation among class II
transcription in eukaryotes. Yeast and human TBP can substitute for each
other in in vitro transcription reactions (Buratowski, Hahn et al. 1988;
Cavallini, Huet et al. 1988; Flanagan, Kelleher et al. 1990; Kelleher, Flanagan
et al. 1992). Consistent with the in vitro results, human TBP modified to
recognize a mutant TATA box supports basal and GCN4 activated
transcription in yeast cells (Strubin and Struhl 1992).
TBP is also a good example of the evolutionary conservation among class
I, II and III transcription. TBP is involved in transcription by all three
eukaryotic RNA polymerases; it is a component of the RNA polymerase I
factor, SL1 (Comai, Tanese et al. 1992), and the RNA polymerase III
component, TFIIIB (Kassavetis, Joazeiro et al. 1992). Consistent with these
observations, temperature sensitive mutations in TBP are defective in
transcription by all three RNA polymerases (Cormack and Struhl 1992).
TBP binds to TBP with a kD of 2 nM with a tl/2 off of approximately 50
minutes (Hahn, Buratowski et al. 1989; Hahn, Buratowski et al. 1989). TBP
binds to the TATA as a monomer (Horikoshi, Yamamoto et al. 1990), bends
DNA (Horikoshi, Bertuccioli et al. 1992) and binds in the minor-groove (Lee,
Horikoshi et al. 1991) as confirmed by crystal structures of TBP complexed
with DNA (Kim, Nikolov et al. 1993; Kim, Geiger et al. 1993). The isolation of
TBP as SPT15, a suppressor of Ty element insertions, provides genetic
evidence for TBP's role in binding the TATA box (Hahn, Buratowski et al.
1989).
Contacts between TBP and TFIIA and TFIIB are disrupted by alanine
substitutions (Tang, Sun et al. 1996) and more radical substitutions (Bryant,
Martel et al. 1996). Many of these contacts are apparent in the co-crystal
structures of TBP-TFIIB (Nikolov, Chen et al. 1995) and TBP-TFIIA (Geiger,
Hahn et al. 1996). TBP also binds to an affinity column of SRB2, a suppressor
of CTD truncations and a component of the RNA polymerase II holoenzyme
(Koleske, Buratowski et al. 1992) and co-immunoprecipitates with SPT3, a
suppressor of Ty transcription and an allele-specific suppressor of a TBP
mutant (Eisenmann, Arndt et al. 1992).
TBP also interacts with several activators in vitro. TBP binds directly to
GAL4-VP16 affinity columns (Stringer, Ingles et al. 1990). Furthermore, the
strength of TBP binding to VP16 correlates with the transcriptional activity of
VP16 mutants (Ingles, Shales et al. 1991). TBP also interacts with upstream
activators p53 (Truant, Xiao et al. 1993), Zta (Lieberman and Berk 1991) and
E1A (Horikoshi, Maguire et al. 1991) among others. A mutation in TBP
diminishes transcriptional activation from many class II genes in yeast and
can be suppressed by tethering TFIIA to TBP (Stargell and Struhl 1995).
Several other mutations in TBP affect transcriptional activation (Tansey,
Ruppert et al. 1994; Arndt, Ricupero-Hovasse et al. 1995; Lee and Struhl 1995).
Do the many interactions between TBP and other proteins in vitro have
physiological significance? One explanation for the many interactions
observed is that TBP is a sticky protein prone to artifactual interactions in
vitro. On the other hand, multiple interactions with TBP are consistent with
TBP's central role in the transcriptional apparatus. It is interesting to note that
the interactions between TBP and TFIIA and TFIIB occur through small
patches of residues. If TBP were to interact with other factors through patches
of roughly the same size, it could be possible for all of the various TBP-factor
interactions to occur simultaneously.
TBP also interacts with other transcriptional regulators, such as TBP
associated factors (TAFs), NOTs, and NC2 as will be discussed below.
TFIIE
TFIIE has been purified as a complex of 56 kD and 34 kD proteins from
humans (Inostroza, Flores et al. 1991; Ohkuma, Sumimoto et al. 1990) and as a
complex of 66 and 43 kD proteins from yeast (Sayre, Tschochner et al. 1992).
The sequences of the yeast subunits are similar to those of the human
subunits (Feaver, Henry et al. 1994; Ohkuma, Sumimoto et al. 1991; Peterson,
Inostroza et al. 1991; Sumimoto, Ohkuma et al. 1991). TFIIE associates with
RNA polymerase II (Flores, Maldonado et al. 1989) as is apparent in a 2-
dimensional crystal structure (Leuther, Bushnell et al. 1996). TFIIE also
associates with TFIIH (Bushnell, Bamdad et al. 1996) and stimulates its CTD
kinase activity (Lu, Zawel et al. 1992; Ohkuma, Hashimoto et al. 1995). In
addition to RNA polymerase II and TFIIH, TFIIE interacts with the repressor
Kruppel in vitro and this interaction appears to be important for
transcriptional repression (Sauer, Fondell et al. 1995).
In an in vitro system, transcription from the Adeno Major Late promoter
requires TFIIE while transcription from the IgH promoter does not (Parvin,
Timmers et al. 1992). These in vitro observations raise the possibility that
promoters vary in their requirement for TFIIE in vivo. Generating mutations
in yeast TFIIE and examining their effect on the transcription of a panel of
genes would be useful in exploring this possibility.
TFIIA
Yeast TFIIA is a complex of 32 and 14 kD subunits (Ranish and Hahn 1991;
Ranish and Hahn 1991). Human TFIIA is a complex of 35, 19 and 12 kD
proteins (Cortes, Flores et al. 1992; De Jong and Roeder 1993; Ma, Watanabe et
al. 1993; De Jong, Bernstein et al. 1995). The two larger subunits derive from a
single gene product in human (De Jong and Roeder 1993; Ma, Watanabe et al.
1993) and Drosophila (Yokomori, Admon et al. 1993) TFIIA. In vitro,
depletion of TFIIA from yeast (Ranish, Lane et al. 1992) and mammalian (De
Jong and Roeder 1993; Ozer, Moore et al. 1994) nuclear extracts greatly
diminishes basal transcription. In vivo, both subunits of yeast TFIIA are
required for cell viability (Ranish, Lane et al. 1992).
TFIIA binds directly to TBP (Ranish and Hahn 1991; Usuda, Kubota et al.
1991; Cortes, Flores et al. 1992) and to the TBP-TATA complex (Buratowski,
Hahn et al. 1989) where it stabilizes the interaction of TBP with the TATA box
(Lee, De Jong et al. 1992). The contacts between TFIIA and TBP are evident in
the co-crystal structure of TFIIA, TBP and DNA (Geiger, Hahn et al. 1996).
The addition of TFIIA overcomes repression by transcriptional inhibitors
in vitro. TFIIA overcomes transcriptional inhibition by topoisomerase I
(Merino, Madden et al. 1993), NC2 (Kim, Parvin et al. 1996) and HMG-1 (Ge
and Roeder 1994).
In the mammalian system, TFIIA binds to the activator Zta and allows
Zta to promote the binding of TFIID to the TATA box (Lieberman and Berk
1994; Ozer, Moore et al. 1994). In the Drosophila system, TFIIA enhances
activation by VP16, Spl and NTF-1 (Yokomori, Zeidler et al. 1994). Mutations
in human TFIIA diminish activation in vitro (Ozer, Bolden et al. 1996). In
vivo, fusion of TFIIA to TBP rescues the activation defect of a TBP mutant
(Stargell and Struhl 1995).
TFIIA has not yet been well studied in vivo. A critical issue is whether
TFIIA is generally required at all promoters or plays a regulatory role at a
subset of promoters. Examining the transcriptional phenotypes of conditional
mutations in TFIIA subunits would be useful in exploring this issue.
3: TAFs and other TBP binding factors
TAFs
TBP is associated with factors called TBP associated factors (TAFs) in a
form called TFIID (reviewed in Burley and Roeder 1996; Verrijzer and Tjian
1996; Pugh and Tjian 1992; Tanese and Tjian 1993; Goodrich and Tjian 1994).
TBP and associated TAFs have been isolated from Drosophila (Dynlacht, Hoey
et al. 1991), human (Pugh and Tjian 1991; Tanese, Pugh et al. 1991; Takada,
Nakatani et al. 1992; Zhou, Lieberman et al. 1992) and yeast (Poon and Weil
1993; Reese, Apone et al. 1994). The composition of TFIID may not be uniform
in all cell types. Human TAF105 appears to be a component of TFIID
specifically in B-cells (Dikstein, Zhou et al. 1996). Like SWI/SNF and RNA
polymerase II, alterations in the subunit composition of TFIID may represent
a means of simultaneously regulating sets of genes.
Reconstitution of TFIID from its recombinant subunits reveals the
subunit-subunit interactions between TBP and various TAFs (Weinzierl,
Dynlacht et al. 1993; Chen, Attardi et al. 1994). One interesting structural
feature of TAFs is the presence of histone fold motifs, which allow TAFs to
form a histone octamer-like structure with other TAFs and even histones
(Hoffmann, Chiang et al. 1996). A crystal structure of a heterodimer of two
TAFs illustrates the contacts made between the histone folds of two TAFs
(Xie, Kokubo et al. 1996). It is not yet clear whether the histone-folds in TAFs
mediate protein-DNA in addition to protein-protein interactions, but it is
interesting to speculate that the histone-fold TAFs bind to and alter the
conformation of DNA near the TATA box.
Some Drosophila (Hoey, Dynlacht et al. 1990; Pugh and Tjian 1990;
Dynlacht, Hoey et al. 1991) and human (Hoffman, Sinn et al. 1990; Smale,
Schmidt et al. 1990) in vitro transcription systems reconstituted with TFIID
are responsive to multiple activators. In contrast, reactions reconstituted with
TBP are not responsive to activators in these systems. Consistent with a role
in activation, TAFs interact directly with activators in vitro. Human TAF155
binds to Spl, Tat, CTF, and ElA in vitro (Chiang and Roeder 1995) and TAF32
binds to VP16 (Klemm, Goodrich et al. 1995). In vitro, Drosophila TAF150
binds to NTF-1 (Chen, Attardi et al. 1994); TAF110 binds directly to Spl (Hoey,
Weinzierl et al. 1993); TAF60 and TAF40 bind to p53 (Thut, Chen et al. 1995);
and TAF110 and TAF60 bind to bicoid (Sauer, Hansen et al. 1995). In in vitro
systems, the pattern of transcriptional activation mediated by subsets of TAFs
is consistent with the results of the interaction studies.
In human cells, a temperature sensitive mutation in TAF250 arrests
growth at the G1 stage of the cell cycle but does not show a global defect in
activated transcription (Wang and Tjian 1994). Similarly, inactivation or
depletion of TAFs in yeast fails to cause global defects in class II transcription
(Apone, Virbasius et al. 1996; Moqtaderi, Bai et al. 1996; Walker, Reese et al.
1996). At the non-permissive temperature, conditional mutations in different
TAFs do, however, cause cells to arrest at G1, G2 and G2/M (Apone, Virbasius
et al. 1996; Walker, Reese et al. 1996). Mutating TAFs in Drosophila causes
defects in promoters activated by bicoid, but not other activated promoters
(Sauer, Wassarman et al. 1996). These results suggest that, while TAFs are not
generally required for activated transcription, they may be required for the
response to certain activators. The cell-cycle phenotype of TAF mutants may
indicate a requirement for TAFs for proper transcription of genes involved in
regulating the cell-cycle.
TFIID and TAFs also appear to be required for initiator driven
transcription. Mammalian in vitro systems reconstituted with TFIID are able
to transcribe promoters with an initiator but no discernible TATA box
(Smale, Schmidt et al. 1990; Pugh and Tjian 1991; Martinez, Chiang et al.
1994). In contrast, TBP alone is unable to support transcription from these
promoters. Likewise, Drosophila in vitro systems reconstituted with TAFs but
not TBP alone are able to distinguish between core promoter elements in
various promoters (Hansen and Tjian 1995; Verrijzer, Chen et al. 1995).
Consistent with this functional requirement, Drosophila TAF150 binds
directly to core promoter DNA in vitro (Verrijzer, Yokomori et al. 1994).
Furthermore, studies in yeast indicate that depletion of TAFs causes
transcriptional defects at the HIS3 +1 and TRP3 promoters, which contain
non-consensus TATA boxes (Moqtaderi, Bai et al. 1996).
Other biochemical observations suggest additional functions for TAFs.
There is some evidence that TFIID may be directly involved in recruiting and
modifying general transcription factors. Human TAF250 interacts directly
with RAP74, the largest subunit of TFIIF (Ruppert and Tjian 1995) and
contains two kinases which phosphorylate RAP74 in vitro (Dikstein, Ruppert
et al. 1996). TFIID may also be involved in modifying chromatin as TAF250
also contains a histone acetyl transferase activity (Mizzen, Yang et al. 1996).
The physiological significance of these activities is not yet clear.
Other TBP associated complexes
Another complex containing TBP is called B-TFIID. This complex
contains a 170 kD protein in addition to TBP, supports transcription in vitro,
and contains an ATPase activity (Timmers, Meyers et al. 1992). A speculation
is that the yeast equivalent to B-TFIID is a MOT1-TBP complex. MOT1 forms a
complex with yeast TBP independent of TFIID (Poon, Campbell et al. 1994). It
is 170 kD, about the same size as the larger subunit of B-TFIID. MOT1 also
contains an ATPase, inhibits the binding of TBP to DNA in an ATP
dependent fashion, and inhibits transcription in vitro (Auble and Hahn 1993;
Auble, Hansen et al. 1994). Twenty sequenced ESTs from mammals match
MOT1 with a p-value less than 10- 9 (Chao, unpublished). It will be interesting
to determine whether the largest subunit of B-TFIID is a MOT1 homologue
and matches some of these ESTs.
Genetic results suggest that MOT1 is not simply a transcriptional
inhibitor. A mutation in MOT1 increases expression of many genes (Davis,
Kunisawa et al. 1992) while other MOT1 mutations decrease the expression of
many other genes (Madison and Winston 1997). In addition, MOT1 mutants
show an SPT phenotype in suppressing the transcriptional effects of a delta
insertion (Madison and Winston 1997). An interaction between MOT1 and
TBP is supported by the observation that overexpression of TBP suppresses
growth inhibition by a MOT1 dominant negative mutant (Auble, Hansen et
al. 1994). What might MOT1 be doing in vivo? One possibility is that MOT1 is
a specificity or recycling factor. MOT1 might help recycle TBP by removing it
from TATA boxes after several rounds of transcription. MOT1 might also
increase the specificity of TBP binding by removing TBP non-productively
bound to non-promoter DNA.
Topoisomerase I is another factor associated with TBP. It binds TBP in a
gel-shift assay and far Westerns, and substoichiometric levels co-
immunoprecipitate with TBP (Merino, Madden et al. 1993). Topoisomerase I
represses basal transcription and modestly stimulates activated transcription
(Kretzschmar, Meisterernst et al. 1993; Merino, Madden et al. 1993).
Topoisomerase activity is not required for the repressing activity, which can
be overcome by TFIIA and activators (Merino, Madden et al. 1993). It is
possible that the in vitro observations of inhibition and coactivation by
topoisomerase I are an artifactual result of its non-specific DNA-binding
activity. There is not yet evidence that topoisomerase I influence
transcription in vivo.
4. Other coactivators
Mammalian PC4 confers responsiveness to the activator GAL4-VP16 in a
system reconstituted with TFIID and general transcription factors (Ge and
Roeder 1994; Kretzschmar, Kaiser et al. 1994). PC4 binds directly to VP16 and a
TBP-TFIIA complex in vitro (Ge and Roeder 1994). PC4 may be negatively
regulated by phosphorylation in vivo as phosphorylated PC4 is
transcriptionally inactive (Ge, Zhao et al. 1994). Yeast TSP1/SUB1, a protein
with sequence similarity to PC4, stimulates basal transcription in vitro
(Henry, Bushnell et al. 1996). TSP1/SUB1 lacks detectable coactivator activity,
but binds directly to an activator in vitro (Henry, Bushnell et al. 1996). In
addition to an activator, TSP1/SUB1 also binds to TFIIB (Knaus, Pollock et al.
1996). Consistent with this interaction, overexpression of TSP1/SUB1
suppresses mutations in TFIIB (Knaus, Pollock et al. 1996). However, the
effect of inactivating TSP1/SUB1 on transcription in vivo has not yet been
examined. It will be interesting to determine the spectrum of genes requiring
TSP1/SUB1 and to examine whether TSP1/SUB1 plays a role in basal or
activated transcription in vivo.
Mammalian HMG-1 and HMG-2 are members of a family of DNA-
binding proteins that have been called architectural factors because of their
ability to alter the conformation of DNA (Wolffe 1994). The yeast proteins
NHP6A and B are highly homologous to HMG-1 and HMG-2 (Paull, Carey et
al. 1996). In an in vitro transcription reconstituted with general factors and
TFIID, the addition of HMG-2 protein is required for transcriptional
activation (Shykind, Kim et al. 1995). HMG-2 appears to stabilize an
intermediate complex containing TFIIA, TFIIB, and TFIID bound to the
TATA-box. HMG-1 also supports activation in this system (Shykind, Kim et
al. 1995). In another system, HMG-1 can form a complex with TBP bound to
the TATA box (Ge and Roeder 1994). However, in this system, HMG-1
represses basal transcription in vitro, an effect overcome by the addition of
TFIIA (Ge and Roeder 1994). TFIIH may also be involved in overcoming
repression by HMG-1 proteins. In an in vitro transcription system where
TFIIH is not required, the addition of TFIIH overcomes inhibition by HMG-2
(Stelzer, Goppelt et al. 1994). Experiments with NHP6A and B in yeast cells are
consistent with a role for HMG proteins in activation. Deletion of both
NHP6A and B affects activated but not basal transcription from a variety of
genes (Paull, Carey et al. 1996). It will be interesting to determine the
promoter elements conferring a requirement for HMG like proteins and to
examine whether the requirement correlates with an unusual DNA
structure.
The expression of GAL4-VP16 is toxic in yeast cells (Berger, Cress et al.
1990). Mutations in the ADA genes allow yeast to survive high levels of
GAL4-VP16 expression (Berger, Pina et al. 1992). Several of the ADAs form a
complex that binds to activators in vitro (Silverman, Agapite et al. 1994;
Horiuchi, Silverman et al. 1995). At least two ADAs, ADA2 and GCN5, appear
to have counterparts in humans (Candau, Moore et al. 1996). Mutations in
GCN5 diminish transcriptional activation by the activator GCN4 and the
HAP activators (Georgakopoulos, Gounalaki et al. 1995). Both yeast and
human GCN5 also exhibit histone acetyl transferase activity (Brownell, Zhou
et al. 1996; Wang, Mizzen et al. 1997). GCN5 acetylates histone H3 and H4 at
lysines distinct from those acetylated by enzymes involved in chromatin
assembly (Kuo, Brownell et al. 1996). The identification of ADA5 as SPT20
also suggests a role for the ADAs in basal transcription from a Ty promoter
(Marcus, Horiuchi et al. 1996; Roberts and Winston 1996). Biochemical studies
of ADAs will be helpful in determining their role in basal and activated
transcription and chromatin modification.
Mammalian histone H1 is another non-specific DNA binding protein
affecting transcription in vitro. A yeast homologue of histone H1 has not yet
been identified, but a search of the yeast database reveals a match between
histone H1 and an uncharacterized protein called LPI17 with a low but
significant p-value of 10-6 (Chao, unpublished). In a crude system, the
addition of histone H1 represses basal and activated transcription (Croston,
Kerrigan et al. 1991). The addition of activators such as Spl and GAL4VP16
overcomes repression by H1 (Croston, Kerrigan et al. 1991). The packaging of
templates in nucleosomes appears to potentiate the effects of histone H1 in
this system (Laybourn and Kadonaga 1991).
Histone H1, together with the HMG proteins, topoisomerase I, and PC4,
represent examples of non-specific DNA binding proteins identified based on
their effect on in vitro transcription reactions. It will be interesting to
determine the nature and extent of their involvement in transcriptional
regulation in vivo. Given the unusual bent structure of the TBP-TATA
complex, it would not be surprising if many regulatory interactions turn out
to be mediated by interactions between proteins and DNA rather than
interactions between proteins. On the other hand, given the unusual
conditions in in vitro transcription reactions, it would not be surprising if
many of the transcriptional effects observed in vitro stem from artificially low
concentrations of DNA and protein.
5. Negative regulators
Mammalian NC2, also called Drl/DRAP1, is a factor which represses basal
transcription in vitro (Meisterernst and Roeder 1991; Inostroza, Mermelstein
et al. 1992; Mermelstein, Yeung et al. 1996). Human NC2 is a complex of two
subunits with molecular weights of 19 and 22 kD, both with histone fold
motifs. In yeast, NC2 contains subunits with similar sequences (Goppelt and
Meisterernst 1996; Gadbois, Chao et al. 1997; Kim, Na et al. 1997). NC2 binds
directly to TBP (Meisterernst and Roeder 1991; Inostroza, Mermelstein et al.
1992; Gadbois, Chao et al. 1997). More specifically, NC2 competes with TFIIA
for binding to TBP (Kim, Zhao et al. 1995) and prevents the association of
TFIIB with promoter-bound TBP (Goppelt, Stelzer et al. 1996). In vitro, TFIIA
overcomes the repression by NC2 in a promoter specific fashion (Kim, Parvin
et al. 1996).
Genetic evidence suggests that NC2 is a global negative regulator of class
II transcription. NC2 alleviates the global defects in mRNA synthesis caused
by a mutation in the RNA polymerase II holoenzyme component SRB4
(Gadbois, Chao et al. 1997). The presence of histone folds in the TBP-associated
proteins NC2 and TAFs is intriguing. These results are consistent with
models in which the activity of TBP is modulated by interactions of its
associated proteins with DNA. The structure of a TBP-NC2 complex is likely
to reveal an unusual architecture with significant regulatory implications.
The NOTs are a collection of four genes whose mutation increases the
transcription of a subset of genes (Collart and Struhl 1993; Collart and Struhl
1994). There are several genetic interactions between the NOTs, TBP, MOT1
and SPT3. Mutations in TBP or SPT3 suppress a NOT mutation (Collart 1996).
In addition, NOT mutations suppress the toxicity of TBP overexpression in a
MOT1 mutant background (Collart 1996). An understanding of the role of the
NOTs in transcriptional regulation awaits biochemical experiments that take
advantage of the genetic clues obtained so far.
6. Promoter elements
A typical eukaryotic promoter contains a TATA box, an initiator, and
regulatory elements. The TATA box is a loosely conserved sequence element
rich in thymidine and adenine (Breathnach and Chambon 1981). In
eukaryotes, the TATA box is typically 40 bp upstream of the transcription start
site in yeast and 25 bp upstream in mammals (Li, Flanagan et al. 1994). The
initiator (Inr) is a sequence element approximately 17 bp in length, located at
the transcription start site (Smale, Schmidt et al. 1990). Outside of model
promoters such as the Adeno Major Late and the terminal deoxynucleotyidyl
transferase gene, both the TATA box and Inr elements are imprecisely
defined. Yeast Upstream Activating Sequences (UASs) and eukaryotic
enhancers serve as binding sites for gene-specific transcriptional activators
and repressors. Enhancers can function at kilobase distances upstream or
downstream of the transcription start site (Banerji, Rusconi et al. 1981).
The availability of sequence information from the yeast genome project
and the development new technologies for examining transcription on a
genome-wide scale provide an opportunity to improve our understanding of
promoter sequence elements. The entire set of yeast promoters can be
compared to identify and define important functional elements whose
presence or absence can be correlated with relative differences in transcript
levels. This information could be used to develop what Eric Lander has called
"a periodic table" of promoter sequence elements. Such a periodic table would
be useful in identifying patterns and sequence elements in promoters and in
predicting the behavior of promoters under different physiological
conditions. There are at least two challenges that need to be overcome for this
analysis. The first is ignorance of the position transcription start sites. Few
start-sites have been mapped in yeast, and it is likely that useful comparisons
will require accurate definitions of the downstream end of promoters. The
second challenge is the lack of appropriate computer algorithms to identify
weak consensus sequences. These challenges do not seem insurmountable,
and there is little doubt that a "periodic table of promoters" would provide
profound insights into transcriptional regulation.
7. Chromatin
Besides the in vitro work discussed above, there is a great deal of in vivo
work implicating chromatin in transcriptional control. Depletion of histones
in vivo increases the transcription from many promoters, consistent with a
role for nucleosomes in repressing transcription (Han and Grunstein 1988).
The N-termini of histones H2A, H2B, and H3 and H4 are required for
repression of basal transcription (Lenfant, Mann et al. 1996). The N-terminus
of histone H4 also appears to play a role in transcriptional activation since
mutations in its N-terminus decrease activation at the GAL1 and PHO5
promoters (Durrin, Mann et al. 1991). Over or under-expression of either
histone H2A and H2B give rise to subtler effects. Both changes alter
transcription from mutant promoters with a delta element insertion (Clark-
Adams, Norris et al. 1988). Other genetic results suggest an interaction
between chromatin and components of the RNA polymerase II holoenzyme.
Mutations in histone H2A and B suppress mutations in SNF2/SWI2, and
SNF5, and 6 (Hirschhorn, Brown et al. 1992), and mutations in histone H3
and H4 suppress mutations in SWI1/SNF2/SWI2 and SWI3 (Kruger,
Peterson et al. 1995).
In addition to the SWI/SNF proteins, two other chromatin remodeling
activities have been described. Drosophila NURF is an ATP-dependent
chromatin remodeling activity containing four subunits (Tsukiyama and Wu
1995). One of these subunits, ISWI, is closely related to yeast SWI2/SNF2
(Tsukiyama, Daniel et al. 1995). Yeast RSC is another ATP-dependent
chromatin remodeling activity (Cairns, Lorch et al. 1996). Like NURF, RSC
also contains a homologue of SWI2/SNF2 (Cairns, Lorch et al. 1996). RSC also
contains at least three other proteins which are related to components of the
SWI/SNF complex (Cairns, Lorch et al. 1996). Whether these chromatin
remodeling complexes play a role in transcriptional regulation is not yet clear.
Chapter 2: Isolation and characterization of complex containing SRBs
Background
In the fall of 1992, there were several clues to the function of the CTD and
SRB proteins. Charles Scafe and I had extended Allison and Ingles' work
demonstrating the involvement of the CTD in transcriptional activation
(Allison and Ingles 1989; Scafe, Chao et al. 1990). Craig Thompson had
evidence that the various SRBs were allele-specific suppressors of CTD
truncation mutants. These genetic results suggested a close association
between the SRBs and CTDs. At the same time, Tony Koleske had
preliminary evidence from immunoprecipitation experiments that the SRBs
were associated with one another and was in the process of purifying what
later turned out to be the holoenzyme.
Because Craig Thompson had identified factors interacting with the CTD
genetically, I set out to complement his work by identifying factors interacting
with the CTD biochemically.
Results and Discussion
To identify proteins binding to the CTD, I applied a yeast extract to a CTD
affinity column (see Figure 7 in Thompson, Koleske et al. 1993). I found that
SRB2, SRB4, SRB5 and SRB6 bound specifically to the CTD column. These
biochemical results demonstrated an interaction between the SRBs and the
CTD and reinforced the genetic results obtained by Thompson and Koleske in
their suppression analysis.
I next set out to develop an assay for CTD binding proteins. I applied a
nuclear extract to a CTD affinity column and found that it was depleted of
transcriptional activity. Activity was restored when I added back material
bound to the column. With this assay in hand, I set out to purify the
reconstituting activity, which I suspected would contain the SRB proteins.
The reconstituting activity was purified over a CTD affinity column and
two ion exchange columns (See Figure 4, Wilson, Chao et al. 1996). As
expected, the activity coeluted with a complex containing SRB proteins and
CTD kinase activity. These results extended Thompson and Koleske's results
with SRB2 and SRB5 in vitro by demonstrating a requirement for a larger
complex of SRB proteins for transcription in vitro. This requirement for SRB
proteins in vitro was a prelude to Craig Thompson's later work
demonstrating a requirement for SRB proteins for transcription in vivo
(Thompson and Young 1995). Similarly, the observation of CTD kinase
activity in the SRB complex was a prelude to Liao and Zhang's identification
of SRB10/11 as a kinase-cyclin pair.
I next set out to determine the function of the SRB complex in activated
transcription. The depletion-reconstitution assay was not useful for this
purpose because there was no basal activity in the absence of SRBs. I spent the
next year developing a reconstituted in vitro system. I obtained RNA
polymerase II from Sha-Mei Liao and recombinant TBP and native TFIIE
from Tony Koleske. Michelle Sonu and I prepared recombinant TFIIB, and I
purified TFIIF and TFIIH.
When added to this reconstituted system, the SRB complex had a modest
affect on basal transcription. However, despite much effort, I was unable to
observe activated transcription in this system. In the meantime, Tony
Koleske had finished purifying the SRB complex and found that he had
isolated an RNA polymerase II holoenzyme responsive to activators. A little
later, Kim and Kornberg isolated the mediator, an SRB containing complex
which supported activated transcription in vitro (Kim, Bjorklund et al. 1994).
The mediator was dissociated from RNA polymerase II with a monoclonal
antibody directed against the CTD and subsequently purified by ion-exchange
chromatography. While both the mediator and SRB complex purified by CTD
affinity chromatography share at least some subunits, the extent of their
similarity is not yet clear.
In summary, my work on the SRB complex demonstrated a physical
association between the SRBs and the CTD, identified a multisubunit
complex containing SRBs, and demonstrated a requirement for the SRBs in
transcription in vitro.
Chapter 3: Identification of SWI/SNF proteins as components of the SRB
complex
Background
In the fall of 1995, the Green, Kingston and Peterson labs had isolated
complexes containing SWI/SNF proteins and shown that they could remodel
chromatin in vitro (Cote, Quinn et al. 1994; Imbalzano, Kwon et al. 1994;
Kwon, Imbalzano et al. 1994). These biochemical results were supported by a
great deal of genetic work implicating the SWI/SNF proteins in
transcriptional activation and chromatin remodeling (work from Herskowitz,
Winston, and Carlson labs reviewed in Winston and Carlson 1992; Peterson
and Tamkun 1995).
Tony Koleske and the Kornberg lab had both purified RNA polymerase II
holoenzymes and shown that they were responsive to activators in vitro.
Because the SRBs appeared to play a key role as a hallmark of the
holoenzyme, I set out to identify other proteins in the SRB complex.
Results and Discussion
I scaled up the purification procedure for the SRB complex and took three
approaches to identifying other proteins in the complex. First, I tried to obtain
microsequence data from the individual proteins in collaboration with Bill
Lane. These efforts were unsuccessful probably because the samples were
poorly resolved by SDS-PAGE; in a sample with such a large number of bands,
loading sufficient amounts of proteins caused smearing.
Next, I prepared polyclonal antibodies against the entire complex. Chris
Wilson used these antibodies to screen a phage expression library and
identified several SWI2/SNF2 as a reactive antigen. He later confirmed the
presence of SWI2/SNF2 and other SWI/SNF proteins in the SRB complex
and in the holoenzyme (Wilson, Chao et al. 1996). Tony Imbalzano and Bob
Kingston confirmed that both the SRB complex and the holoenzyme
contained the expected chromatin remodeling activity. The identification of
the SWI/SNF genes as components of the holoenzyme provides an
explanation for how chromatin remodeling activity is targeted to promoters.
Finally, I identified some of the proteins by mass-spectrometry. I did some
preliminary work with Paul Matsudaira and successfully identified an
abundant CTD-binding protein and several subunits of mammalian TFIIH.
Later, I collaborated with Jun Qin and Brian Chait to identify proteins in the
SRB complex with a new mass spectrometric technique. Qin and Chait had
developed a new method for identifying proteins with an instrument called a
Matrix Assisted Laser Desorption/Ionization Ion Trap or MALDI Ion Trap
(Qin and Chait 1996; Qin, Ruud et al. 1996). In collaboration with the Chait
lab, Chris Wilson and I identified several additional proteins in the SRB
complex (Qin et al., submitted). The identified proteins included SRB4, SRB5,
RGR1, and SIN4, proteins previously shown to be components of the RNA
polymerase II holoenzyme. The identified proteins also included SUB1, a
yeast homologue of the mammalian coactivator PC4, and UME6, a Zn-finger
protein, as well as 3 uncharacterized yeast proteins. SUB1, UME6 and the 3
other proteins have not yet been confirmed as components of the SRB
complex by other techniques. The mass-spectrometric technique was rapid
and sensitive but gave many false negatives. Despite indications of sufficient
quantity by multiple staining methods, many proteins did not give signals in
the mass-spectrometer for unknown reasons.
In summary, my work identifying the SWI/SNF protein and other
proteins in the SRB complex helped link the SRBs and holoenzyme function
to chromatin remodeling and coactivation.
Chapter 4: Isolation of a mammalian SRB gene and mammalian RNA
polymerase II holoenzyme
Background
In the fall of 1993, many believed that transcription in mammals was
fundamentally different from transcription in yeast. There were two apparent
differences. The first was a failure to observe TAFs in yeast. Buratowski and
Sharp purified TBP from yeast, and it appeared to be monomeric rather than
associated with TAFs (Buratowski, Hahn et al. 1988). Biochemical evidence
suggested that a role for TAFs and TFIID in activated transcription in
Drosophila and humans. Yeast seemed to be fundamentally different in
lacking TAFs. The second difference was a failure to observe a mammalian
version of the RNA polymerase II holoenzyme. The yeast RNA polymerase II
holoenzyme appeared to play a role in activated transcription. In contrast,
higher eukaryotes seemed to be fundamentally different in lacking SRBs. To
address this issue, our lab sought to identify and isolate a mammalian RNA
polymerase II holoenzyme.
Results and Discussion
I first attempted to purify a mammalian SRB complex by using the CTD
affinity chromatography procedure that had been effective in purifying yeast
SRBs. I was able to purify a complex that bound specifically to the CTD, but I
was unable to purify enough to obtain microsequence information. Probably
because of the small amounts available, Jeff Parvin was also unable to obtain
coactivating activity from the CTD-binding complex.
I next tried to purify large complexes containing mammalian RNA
polymerase II. I was successful in detecting large RNA polymerase II
complexes by gel filtration but had great difficulty in purifying them.
In parallel, I was trying to clone mammalian homologues of SRB genes by
database searching. Doug Bassett and Phil Hieter had just set up an automated
program for screening expressed sequence tag (EST) databases on a monthly
basis. A few months after we set it up, the program notified me of a match
between a newly sequenced EST and yeast SRB7. Peter Murray and I cloned
the full length version of this gene, which we called hSRB7 (See figures in
Chao, Gadbois et al. 1996). Ellen Gadbois and I checked whether hSRB7 could
complement a deletion of the yeast SRB7 gene. It could not, but we found that
chimeras of human and yeast SRB7 could complement the deletion. Michelle
Sonu and I demonstrated that mammalian SRB7 binds to a CTD affinity
column, as expected from work with yeast SRB7. Finally, using antibodies
raised against mammalian SRB7, I isolated a complex containing mammalian
SRB7, RNA polymerase II and substoichiometric TFIIE and TFIIH. Steve
Anderson and Jeff Parvin helped characterize the mammalian holoenzyme
complex with functional assays.
A few months before we published our work (Chao, Gadbois et al. 1996),
Ossipow and Schibler used a monoclonal antibody directed against TFIIH to
isolate a mammalian holoenzyme complex containing RNA polymerase II
and all the general transcription factors (Ossipow, Tassan et al. 1995). Later,
Vincent Ossipow used our antibodies to show that hSRB7 was also a part of
this immunoprecipitated complex. A few months after we published our
work, Maldonado and Reinberg used a monoclonal antibody directed against
TFIIF to isolate a mammalian holoenzyme complex containing RNA
polymerase II, TFIIE, F and H, and hSRB7 (Maldonado, Shiekhattar et al.
1996).
What accounts for the different forms of mammalian holoenzyme? One
reason could be destabilization of the holoenzyme by chloride ions. Michelle
Sonu and I found that chloride can dissociate yeast SRBs from a CTD column.
Other anions, such as sulfate or acetate, did not have this effect. Similarly,
mammalian proteins were dissociated from a CTD column by chloride but
not other anions. Because chloride salts are typically used when purifying
mammalian transcription factors, their destabilizing effect may have
hampered the isolation of intact holoenzymes. The destabilizing effect of
chloride may have also facilitated the purification of yeast TBP and delayed
the isolation of yeast TAFs. Yeast TAFs are dissociated from a TBP column by
chloride but not acetate (Reese, Apone et al. 1994). Buratowski and Sharp were
probably able to purify monomeric yeast TBP relatively easily because the
chloride used in their purification procedure dissociated TBP from TAFs and
other proteins (Buratowski, Hahn et al. 1988).
After the isolation of yeast TAFs by Reese and Green and Poon and Weil
(Poon and Weil 1993; Reese, Apone et al. 1994) and the isolation of a
mammalian RNA polymerase II holoenzyme by us and others, most in the
field became convinced that transcription is fundamentally the same in yeast
and mammals. However, some differences are still claimed. First, no
examples of the proline-rich or glutamine-rich type activators found in
higher eukaryotes have been reported in yeast. The classes of activators are
defined based on sequence composition rather than a functional test. Because
the definition of activator classes is vague, it is not yet clear whether the lack
of proline-rich and glutamine-rich activators in yeast is a significant
difference. Second, the existence of a histone H1 homologue in yeast has not
yet been demonstrated. Histone H1 appears to play an important role in
chromatin packaging and transcriptional regulation in higher eukaryotes so it
would be surprising if yeast lacked H1. However, there is an uncharacterized
gene with homology to histone H1 in the yeast database. LPI17 matches
histone H1 with a p-value of 10-6 (Chao, unpublished). It will be interesting to
determine whether LPI17 represents a yeast homologue of histone H1.
Chapter 5: Purification of yeast NC2
Background
In the summer of 1995, repressors had been well studied biochemically
but not genetically. Inostroza and Reinberg had described a TBP-binding
repressor called Drl (Inostroza, Mermelstein et al. 1992). Ge and Roeder had
described another protein with repressing activity called HMG-1 (Ge and
Roeder 1994). Besides histones, nothing was known about general repression
in vivo or in yeast.
In our lab, Craig Thompson had shown that the SRBs were generally
required for transcription in vivo. A temperature sensitive mutation in SRB4
was shown to shut-down transcription rapidly at the non-permissive
temperature (Thompson and Young 1995). Ellen Gadbois sought to identify
factors interacting with SRB4 by isolating suppressors of this ts mutation.
Results and Discussion
One of the SRB4 suppressors, which was later named NCB1, contained a
histone-fold motif. Because histones had been isolated in the SPT screen,
Ellen Gadbois contacted Fred Winston to determine whether NCB1
represented an unpublished SPT gene. Ellen Gadbois then learned that NCB1
had not been isolated in the SPT screen but had been isolated by Greg Prelich
in a screen for mutations bypassing the requirement for an upstream
activating sequence. Because TAFs and other coactivators had been shown to
bind to TBP, Ellen Gadbois collaborated with Joe Reese and Michael Green to
determine whether NCB1 bound to a TBP affinity column. NCB1 did in fact
bind to TBP. We soon learned that Danny Reinberg's lab had also isolated
yeast and mammalian NCB1 as proteins associated with the TBP-binding
repressor Dr1. It was also reported that Drl/DRAP1 was equivalent to
Meisterernst and Roeder's repressor NC2.
We now suspected that the SRB4 suppressor was the yeast homolog of a
mammalian negative regulator. While Ellen Gadbois performed genetic
experiments to confirm this notion, I began to study NCB1 in vitro. Using
TBP affinity column eluates from Joe Reese, I purified a complex containing
NCB1 and another protein (Gadbois, Chao et al. 1997). Ellen Gadbois
confirmed that this complex contains DRAP1 and Drl by Western blotting.
For simplicity, we decided to call this complex yeast NC2, with the large
subunit named NCB1 and the small subunit named NCB2.
The material from the TBP-affinity column was insufficient for
functional assays. I attempted to purify yeast NC2 from crude extracts but was
unsuccessful. I next tried to purify an epitope-tagged version of NC2 and was
successful. I then used this material to confirm that NC2 was able to repress
the transcriptional activity of the yeast RNA polymerase II holoenzyme in
vitro.
Our work was significant in demonstrating the conservation of NC2 from
yeast to humans and in demonstrating the physiological relevance of
repression by NC2. Ellen Gadbois' genetic work showed that NC2 was a
general negative regulator of transcription in vivo.
Chapter 6: Discussion
Models for assembly of the preinitiation complex
In vivo, how much of the preinitiation complex is assembled on the
TATA box and how much is assembled off of DNA? At one extreme,
transcription factors are proposed to assemble in a stepwise fashion. The
plausibility of this pathway has been demonstrated in vitro (Buratowski,
Hahn et al. 1989). At the other extreme, a subset of the transcription factors is
proposed to pre-assemble in a holoenzyme complex before final assembly on
the TATA box. The plausibility of this pathway has also been demonstrated in
vitro (Koleske and Young 1994). SRBs are generally required for transcription
in vivo (Thompson and Young 1995), but this general requirement does not
address the issue of whether the SRBs and RNA polymerase II assemble on
the DNA or off the DNA.
Whether transcription factors assemble sequentially or are preassembled,
their association and dissociation are likely to be dynamic. The number of
TBP molecules in the cell is estimated to be approximately 50,000 by
quantitative Westerns (Tony Lee, unpublished). This number of TBP
molecules is sufficient to allow TBP to remain stably bound at all promoters
in the genome. Consistent with this notion, TBP appears to remain bound to
the TATA box after RNA polymerase II clears the promoter in an in vitro
system (Zawel, Kumar et al. 1995). The number of holoenzyme molecules is
estimated to be approximately 2,000 to 4,000 per cell and the number of RNA
polymerase II molecules approximately 20,000 per cell (Koleske and Young
1994). These numbers are consistent with a cycle in which SRBs dissociate
from RNA polymerase II at some point after initiation and reassociate at
some point before reinitiation.
The sequential assembly model and the holoenzyme model represent two
extremes in a spectrum of possibilities. Much as different promoters require
different subsets of the basal transcription factors and are influenced to
varying degrees by various regulatory factors, it is possible that the
transcriptional apparatus assembles by different pathways at different
promoters.
Models for transcriptional activation
The various models for transcriptional activation can be classified into
three categories: recruitment, isomerization, and modification. I discuss these
models in the context of transcription initiation although it is clear that
regulation can occur at other steps in the transcription cycle (Yankulov, Blau
et al. 1994; Akhtar, Faye et al. 1996).
In the recruitment class of models, activators increase the rate of
transcription by recruiting components of the transcriptional apparatus to
promoters (Ptashne and Gann 1997). Any means of recruitment suffices for
activation in this model. Recruitment might occur through protein-protein
interactions. The many interactions between activation domains and various
general transcription factors and coactivators may reflect genuine interactions
involved in recruitment in vivo. Transcriptional stimulation by artificial
recruitment of transcription factors, such as GAL11 (Barberis, Pearlberg et al.
1995) and TBP (Chatterjee and Struhl 1995; Klages and Strubin 1995), is also
consistent with the recruitment model. Recruitment might also occur
through protein-DNA interactions. Architectural cofactors such as HMG
proteins change the conformation of DNA to recruit additional proteins to
the preinitiation complex via protein-DNA interactions (Shykind, Kim et al.
1995). It is interesting to note that many purified coactivators such as HMG1
and 2, topoisomerase I, and PC4, are non-specific DNA binding proteins.
In the isomerization class of models, activators increase the rate of
initiation by inducing a conformational change in the preinitiation complex.
This might be a change in a protein, such as TFIIB, (Roberts and Green 1994)
or it might be a change in the structure of promoter DNA. The closed to open
transition of promoters is a target for activators, and a similar transition has
been observed in mammalian extracts (Wang, Carey et al. 1992; Wang, Gralla
et al. 1992).
In the modification class of models, activators increase the rate of
initiation by inducing a post-translational modification of a component of the
preinitiation complex. The activity of at least two kinases, SRB10 and KIN28,
is essential for appropriate transcriptional regulation in vivo (Cismowski,
Laff et al. 1995; Liao, Zhang et al. 1995). Kinase (Dikstein, Ruppert et al. 1996)
and acetylase (Brownell, Zhou et al. 1996; Mizzen, Yang et al. 1996) activities
have also been detected in several other transcription factors. The exact role of
these enzymatic activities in transcriptional regulation is not yet clear but
they are likely to play an important role.
The three models of transcriptional activation are not mutually
exclusive. It is likely that transcriptional regulation involves multiple
mechanisms whose contributions vary from promoter to promoter. From an
evolutionary perspective, a diversity of regulatory mechanisms makes sense
if one considers promoters to be "selfish." If an individual promoter's
objective is to express its gene at the appropriate level and the promoter
competes with all other promoters in the genome to accomplish this
objective, one might imagine that promoters would evolve different
mechanisms to accomplish this goal. Promoters would evolve to use any
means available to ensure their proper expression. Because there would be
little evolutionary pressure for promoters to use the same mechanisms, a
diversity of regulatory mechanisms would result. The differential sensitivity
of promoters to particular mutations in vivo or to particular biochemical
manipulations in vitro argues that diverse regulatory mechanisms are at
work. Careful study of the details of transcriptional regulation at a few model
promoters will most likely provide multiple examples of the three classes of
regulatory mechanisms.
Conditions in vivo vs. in vitro
What is the nature of the milieu inside the eukaryotic nucleus? By
weight, a cell is estimated to be 70% water, 20% protein and 1% DNA. If the
density of water, protein and DNA is approximated at a 1 g/ml, then the
concentration of protein in the cell is approximately 200 mg/ml. If the
concentration of protein is assumed to be uniform throughout the cell, then
the concentration of protein in the nucleus is approximately 200 mg/ml. If
the nucleus is estimated to be 10% the volume of the cell, the concentration
of DNA is approximately 100 mg/ml (10 mg DNA/1 ml/0.1 cell volume=100
mg DNA/ml). The concentration of DNA and protein in the nucleus
approximates the concentration of proteins in crystals, which are
approximately 50% water. Principles gleaned from studying the behavior of
the dilute protein solutions in in vitro reactions are not likely to apply to the
behavior of proteins in the concentrated environment of the cell. A better
understanding of the biophysical behavior of concentrated solutions of
protein and nucleic acids would greatly aid the design of experiments
designed to recreate conditions in vivo.
How do standard transcription reactions compare with the conditions in
vivo? Estimates of the relative concentrations of RNA polymerase II and
template DNA in vivo and in vitro are revealing. If the average yeast cell is
assumed to be a sphere with a diameter of 5 gm, the volume of a yeast cell is
approximately 1 picoliter. If the nucleus is 10% the volume of the cell, then
the volume of the nucleus is 100 femtoliter. There are an estimated 20,000
molecules of RNA polymerase II in the cell (Koleske and Young 1994). Based
on these estimates, the concentration of RNA polymerase II is approximately
400 nM. What about promoters? The yeast genome (14X10 6 bp of DNA)
contains 5000 genes. If we assume 1 TATA box per gene, then 0.2% of the yeast
genome is a binding site for the transcriptional apparatus (5000 genes X 1
TATA box/gene/5 bp/TATA box / 14 X 106 bp=0.0018). The concentration of
TATA boxes in the nucleus is approximately 100 nM.
These estimates of polymerase and promoter concentrations are higher
than the amounts in typical in vitro transcription reactions. If the typical
reaction contains 500 ng of RNA polymerase II and 100 ng of DNA in a
volume of 20 gl, the concentration of RNA polymerase II in these reactions is
approximately 10 nM and the concentration of TATA boxes 1 nM. By these
calculations, there is a forty-fold lower concentration of RNA polymerase II
and a hundred fold lower concentration of promoters in in vitro
transcription reactions. Given these large differences, it is difficult to predict
what effect extreme dilution would have on the behavior of transcription
factors in vitro.
Besides concentration, another problem with in vitro transcription
reactions is their failure to recreate the internal architecture of the nucleus.
Some transcription factors are localized and concentrated in subnuclear
compartments. For instance, phosphorylated RNA polymerase II localizes to
speckles (Bregman, Du et al. 1995). Likewise, DNA may be packaged into
special domains or packaged into special forms of chromatin.
Large protein complexes
There are many examples where factors dedicated to a common function
are organized in large complexes. The ribosome, spliceosome and signal
recognition particle are groups of translation, splicing and translocation
factors organized in megadalton-sized complexes. Because a feature shared by
these three large complexes is the presence of structural RNAs, an interesting
speculation is that the RNA polymerase II holoenzyme might also contain a
structural RNA. Other processes once thought to involve the interaction of
proteins in solution may also involve large complexes. Recently, a large
complex of kinases involved in a signal transduction pathway has been
described (Choi, Satterberg et al. 1994).
Why might proteins be organized in large complexes? The need for rapid
and efficient catalysis may be one reason. In the case of RNA polymerase II,
proteins, nucleotides and DNA must be brought together to produce mRNA.
Organization of these macromolecules in an optimized configuration is likely
to increase the speed and efficiency at which catalysis is performed.
Assembling macromolecules in an organized structure reduces inefficient
side reactions from non-productive interactions and increases the speed of
reactions relative to random diffusion and collision. Given the extremely
concentrated environment of the cell, these considerations may be extremely
important for catalytic efficiency.
Another reason for large complexes may be the need to process regulatory
signals. An apparatus like the RNA polymerase II holoenzyme modulates its
catalytic output in response to multiple regulatory inputs. These inputs must
be processed by many sequential and concurrent protein-protein interactions
and post-translational modifications to achieve the appropriate output. It is
likely that the degree of processing that is possible is roughly proportional to
the size of the complex involved. For highly regulated processes like
transcription, megadalton-sized complexes, like the RNA polymerase II
holoenzyme, are likely to represent an evolutionary response to the
requirements of processing multiple regulatory signals.
In an extreme view, one might imagine that the large complexes
themselves are part of a higher order architecture. For example, an
extracellular signal could alter gene expression via a cascade of physically and
catalytically coupled events. Signals would be transduced through a complex
of physically associated kinases, which would activate the RNA polymerase II
holoenzyme to increase the transcription of target genes. The holoenzyme
would then transfer the induced mRNAs to processing complexes such as the
spliceosome, which would in turn transfer the mRNA to tracks. These tracks
would deliver the mRNA to waiting ribosomes for the production of the
required proteins. In this speculative pathway, efficiency is increased by
physically coupling the large protein complexes mediating signal
transduction and gene expression.
Much as the identification and characterization of individual subunits are
prerequisites for an understanding of large multisubunit complexes, the
identification and characterization of large multisubunit complexes are
prerequisites for an understanding of the higher order architecture inside
cells. The isolation and characterization of RNA polymerase II holoenzymes
thus provide valuable starting points for studies of the higher order
structures involved in transcriptional regulation.
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Activation without a vital ingredient
David M. Chao and Richard A. Young
The complicated machinery that initiates transcription of protein-coding genes contains components, known as TAFs,
that are held to be generally required for gene activation. Experiments in vivo change that view.
REGULATION of gene expression is funda-
mental to living processes, and much of it
occurs at the level of transcription initia-
tion. One form of regulation, called gene
activation, produces a marked increase in
the rate at which messenger RNAs are
copied from the gene. The textbook model
of gene activation, derived from studies in
vitro, is that gene-specific activators bind
to TBP-associated factors (TAFs), a set of
proteins that associate with TATA-binding
protein (TBP), thereby recruiting this
component of the transcriptional machin-
ery to promoter DNA1'2 . However, new
evidence, reported by groups led by
Michael Green and Kevin Struhl on pages
185 and 188 of this issue3'4, demonstrates
that gene activation can occur in living
cells in the absence of functional TAFs.
Does the textbook need revision?
Eukaryotic cells contain many thou-
sands of protein-coding genes, and the
task of transcribing them into messenger
RNA falls to RNA polymerase II. Genes
transcribed by RNA polymerase II (known
as class II genes) have several promoter
elements that are necessary for regulated
transcription initiation. Most promoters
contain a sequence element called a TATA
box (because it is rich in thymine and
adenine) that acts as the binding site for
TBP and the rest of the transcription-initi-
ation apparatus. The rate of transcription
of each gene is regulated by activator
proteins that bind to promoter DNA
sequences called enhancers, generally
located upstream of the TATA box.
Activators, which typically have a DNA-
binding domain and an activating domain,
are thought to stimulate gene express-
ion by interacting with components of
the transcription-initiation apparatus. As
with many other biological processes, our
understanding of this is due to the com-
bined efforts of biochemists and genet-
icists (see box overleaf).
Several important features of transcrip-
tional regulation have been re-created
in the test tube with purified RNA poly-
merase II and a set of proteins called
general transcription factors,'2. These
include TFIID (a complex of TBP plus
TAFs), TFIIA, TFIIB, TFIIF, TFIIE and
TFIIH, which are evolutionarily conserved
between yeast and humans. When RNA
polymerase II and general transcription
factors are added to a naked DNA tem-
plate, transcription can initiate at the
appropriate promoter site. The addition of
an activator can, under certain conditions,
increase the level of RNA synthesis.
The TAFs have been implicated in
transcriptional activation in vitro because
activators can stimulate transcription in
some systems reconstituted with mam-
malian RNA polymerase II and the gen-
eral transcription factors, but not when
TBP is substituted for TFIID (refs 1, 2).
The model derived from these studies is
these mutant TAFs can function appropri-
ately at one temperature, but not another.
The other approaches involved use of
molecular-genetic techniques to shut
down TAF synthesis and cause TAF
degradation.
In each of the experiments, TAF inacti-
vation or elimination led to cell death.
Surprisingly, however, the dying cells were
not compromised in gene expression
generally. Moreover, activation was
Regulation of gene expression. Signals from outside and inside the cell influence the rate of tran-
scription of class II genes. This is achieved by activators or other transcriptional regulators, which
are believed to act through components of the RNA polymerase II holoenzyme, coactivators and
TFIID (a complex of TATA-binding protein and associated factors known as TAFs). The involvement of
TAFs is now called into question by the experiments of Green, Struhl and colleagues3'4, discussed
here, which show that TAFs are not generally required for gene activation in vivo. Rather than play-
ing a general role, TFIID may be required for the
the cell cycle and development.
that activators bind to the TAF proteins
directly, thereby recruiting the TFIID
complex to promoter DNA. Support for
this model comes from experiments in
which the response to various activators
can be reconstituted with specific recom-
binant TBP-TAF subcomplexes. In sys-
tems reconstituted with highly purified
mammalian components, cofactors such
as PC4 and HMG2 are required in addi-
tion to TFIID to obtain activation in vitro.
The studies described by Green, Struhl
and their colleagues 3'4 were designed to
find out whether yeast TAFs are generally
required for class II gene expression and
regulation in vivo. Three different experi-
mental approaches were used to inacti-
vate or substantially reduce the levels of
TAFs in cells. In one, conditional muta-
tions in specific TAFs were employed;
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activation of genes that participate in controlling
unaffected at all of the promoters tested.
In contrast, mutations in most other com-
ponents of the transcription apparatus
have dramatically deleterious effects on
class II gene expression in vivo. The new
results raise two important questions.
What factors are required for gene activa-
tion at class II promoters if the TAFs are
not? And what do TAFs do in vivo?
Recent genetic and biochemical evi-
dence indicates that transcription is
initiated in vivo by a large complex of
proteins called an RNA polymerase II
holoenzyme 5'6 . This apparatus has been
isolated from yeast and mammalian cells,
and consists of RNA polymerase II, a sub-
set of general transcription factors and a
subcomplex containing many regulatory
proteins. Among these regulatory proteins
are Srbs, which were genetically identified
119
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Biochemistry and genetics: checks and balances
To study such complicated phenomena as
transcriptional activation, biologists turn
to two tried and true approaches - the
biochemical and the genetic.
Biochemists use a strategy of recon-
struction. They seek to reconstitute bio-
logical processes in test tubes. The first
step is to develop an assay that reveals
the activity of interest. The second is to
purify the components of the cell neces-
sary to reconstitute that activity from
crude cell extracts. Finally, the purified
proteins are studied individually and
together to determine what each one
does. Most of the three-dozen proteins
required for transcription of class II genes
were identified biochemically2 10,11.
Geneticists, on the other hand, employ
a strategy of destruction. They disrupt bio-
logical processes by making mutations
and examining the consequences in living
cells. The first step is to develop a screen
for cells exhibiting disruption in the
process being studied (transcription, pat-
tern formation, signal transduction or
whatever). The second is to pinpoint any
genetic mutations associated with that
disruption, then further characterize the
genes concerned to determine the func-
tions of their protein products. The funda-
mental mechanisms of transcriptional
regulation in bacteria were worked out in
this way 12.
as transcriptional regulators. Mutations in
yeast Srb genes, unlike TAF mutations,
generate global defects in class II gene ex-
pression and affect their ability to respond
to regulators in vivo. Purified yeast RNA
polymerase II holoenzyme can respond to
activators in vitro in the absence of TAFs.
In this context, it is possible that the
TAFs are indeed generally involved in the
response to activators in vivo but are ancil-
lary to the holoenzyme at most promoters.
Activators can interact in vitro with com-
ponents of the holoenzyme as well as
TAFs5'6 . Contact between artificial activa-
tors and almost any component of the
transcription-initiation apparatus is suffi-
cient to activate transcription in vivo7'8.
Another possibility is that the TAFs
function at only a small number of pro-
moters in vivo. Struhl and colleagues4
found two genes whose rate of transcrip-
tion decreases when expression of some
TAFs is shut down in vivo. It is intriguing
that the promoters of both these genes
have TATA boxes whose sequence
deviates from the consensus. TAFs
are required for transcription from such
promoters in vitro; furthermore, at least
one TAF binds directly to core promoter
elements expected to be important for
guiding transcription from promoters
lacking consensus TATA boxes'.
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But each approach has its limitations.
Reconstituted biochemical reactions are
usually a highly simplified version of what
goes on inside a living cell. The reaction
may be missing essential features of the
process as it occurs in vivo (which may
be poorly defined) or it may harbour hid-
den flaws - for example, TFIIC is missing
from the roll call of general transcription
factors because its identification was an
artefact of the in vitro assay conditions.
The problem for geneticists is that the
genes identified in genetic selections may
not always be directly involved in the
process of interest. Thus, the general
transcription factor TFIIB was inadver-
tently identified in yeast by a screen
intended to isolate translation factors.
Other transcription factors have been iso-
lated in screens for cell-cycle regulators
because of their indirect effects on the
expression of these regulators.
Some of these drawbacks can be over-
come by sharing tactics, as we have seen
in the transcription story. The chief weak-
ness of biochemistry - inability to dis-
criminate between what is real and what
is artefact - can be addressed geneti-
cally. A biochemist with a newly purified
enzyme can mutate the gene encoding
that enzyme. If the biochemist is correct
about the enzyme's activity, then muta-
tion of the gene should affect the cell's
The observation that inactivation or
elimination of TAFs is lethal to cells sug-
gests that TAFs are critical for the expres-
sion of certain essential genes. TAFs
appear to be involved in cell-cycle progres-
sion in yeast and mammalian cells. Green
and colleagues3 point out that inactivation
of particular yeast TAFs can cause growth
arrest at distinct stages in the cell cycle.
One of their temperature-sensitive yeast
TAF,1145 mutants has a phenotype re-
markably similar to that found in mam-
malian cells with a mutation in the homo-
logue TAF11250; the mammalian tempera-
ture-sensitive cell line arrests growth at the
G1 stage of the cell cycle when the tem-
perature is raised, but does not exhibit a
global defect in class II gene transcription
(ref. 9 and references therein).
Transcription in yeast and mammalian
cells almost certainly follows the same
fundamental principles, but there is no
doubt that mammalian cells need to
respond to more complicated and diverse
regulatory signals. For example, whereas
yeast have only a few developmental pro-
grammes, mammals have several hun-
dred. If TAFs are necessary for integrating
responses to diverse regulatory controls
such as those governing the cell cycle and
cell fate, they may be essential for expres-
sion of a higher proportion of genes in
ability to perform the reaction concerned.
Likewise, the chief weakness of genetics
- inability to distinguish direct from in-
direct effects - can be tackled biochemi-
cally. A geneticist with a newly identified
gene can set up assays to determine
the enzymatic properties of the protein
encoded by the gene. If the gene does
what the geneticist thinks it does in vivo,
then the protein encoded by that gene
should have the proper enzymatic activity
in vitro.
Of course, combining biochemistry and
genetics is not always so straightforward.
In some experimental animal systems,
genetic manipulation techniques are not
yet advanced enough to allow specific
mutations to be made in a particular
gene. Also, there are often difficulties in
developing biochemical assays for biologi-
cal processes that have not been fully
defined in vivo.
These challenges have been met, at
least in part, by molecular biologists, who
use recombinant DNA technology to iso-
late, mutate and analyse genes and their
protein products: molecular-biological
tools help to bridge the gap between bio-
chemistry and genetics. Indeed, it is now
the combination of biochemistry, genetics
and molecular biology that drives progress
in biology, each providing checks and bal-
ances on the others. D.M.C. & R.A.Y.
mammalian cells than in yeast.
The final textbook entry explainin!
exactly how and where TAFs functioi
in vivo remains to be written. Whatevei
the outcome, however, the history ol
gene-activation research underscores the
importance of combining genetic an,
biochemical approaches. C
David M. Chao and Richard A. Young are it
the Whitehead Institute for Biomedica
Research, Nine Cambridge Center, Cam
bridge, Massachusetts 02142, and the
Department of Biology, Massachusett,s
Institute of Technology, Cambridge, Mass-
achusetts 02139, USA.
Goodrich, J. A., Cutler, G. & Tjian, R. Cell 84, 825-830
(1996).
Burley, S. K. & Roeder. R. G. Annu. Rev. Biochem. 65,
769-799 (1996).
Walker. S. S.. Reese, J. C., Apone, L. M. & Green, M. R.
Nature 383, 185-188 (1996).
Moqtaderi, Z., Bai, Y., Poon, D., Well, P. A. & Struhl, K.
Nature 383, 188-191 (1996).
Koleske, A. J. & Young, R. A. Trends Biochem. Sci. 20,
113-116 (1995).
Halle, J.-P. & Meisterernst, M. Trends Genet. 12,
161-163 (1995).
Barberis, A. et al. Cell 81, 359-368 (1995).
Struhl, K. Cell 84, 179-182 (1996).
Wang, E. H. & Tjian, R. Science 263, 811-814 (1994).
Conaway, R. C. & Conaway, J. W. Annu. Rev. Biochem.
62, 161-190 (1993).
Zawel, L. & Reinberg, D. Annu. Rev. Biochem. 64,
533-561 (1995).
Jacob, F. & Monod, J. J. Mol. Biol. 3, 318-356 (1961).
NATURE - VOL 383 - 12 SEPTEMBER 1996
LETTERS TO NATURE
hSRB7
A mammalian SRB protein
associated with an RNA
polymerase II holoenzyme
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A LARGE multisubunit complex containing RNA polymerase II,
general transcription factors and SRB regulatory proteins initi-
ates transcription of class II genes in yeast cells"- . The SRB
proteins are a hallmark of this RNA polymerase II holoenzyme as
they are found only in this complex, where they contribute to the
response to regulators". We have now isolated a human homo-
logue of the yeast SRB7 gene and used antibodies against human
SRB7 protein to purify and characterize a mammalian RNA
polymerase II holoenzyme containing the general transcription
factors TFIIE and TFIIH. This holoenzyme is more responsive to
transcriptional activators than core RNA polymerase II when
assayed in the presence of coactivators.
A human complementary DNA clone encoding a protein
similar to Saccharomyces cerevisiae SRB7 was isolated from a
lymphocyte cDNA library by using information derived from
expressed sequence tags. The sequence of this human cDNA
clone (hSRB7) predicts a 144-amino-acid protein with a relative
molecular mass of 15,700 (15.7K) (Fig. la). The sequence of the
predicted protein is 35% identical to yeast SRB7 (ySRB7) (Fig.
lb). We tested hSRB7's ability to substitute functionally for
ySRB7 by determining whether hSRB7 could complement a
complete deletion of the yeast gene. Although full-length
hSRB7 failed to complement a ySRB7 deletion, several chimaeras
containing the amino terminus of the human protein and the
carboxy terminus of the yeast protein were able to do so (Fig. Ic,
d). The complementing chimaera with the largest amount of
hSRB7 contains 57% human sequence.
The yeast SRBs interact functionally and physically with the
RNA polymerase II C-terminal repeat domain (CTD: reviewed in
ref. 4). If the protein encoded by hSRB7 is a genuine homologue
of yeast SRB7, then it should be among a small subset of cellular
proteins capable of binding to a recombinant CTD column6.
Extracts were prepared from yeast, HeLa and calf thymus and
FIG. 1 a, Human SRB7 sequence (GenBank accession number u46837).
b, Human and yeast SRB7 alignment. Vertical lines indicate identity;
colons, comparison value > 0.5; and dots, comparison value > 0.1 as
defined by the program BESTFIT. c, Complementation of yeast SRB7
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deletion mutant by hSRB7-ySRB7 chimaera. Control: yeast with SRB7
deletion covered by ySRB7 plasmid and the indicated construct. Test: yeast
with SRB7 deletion and the indicated construct, d, Complementation by
hSRB7-ySRB7 chimaeras. Chimaeras are represented by normalized bars
showing human SRB7 sequences in black and yeast sequences in white.
METHODS. dbEST was screened with XREFdb for expressed sequence tags
similar to ySRB7 (ref. 20). A description of the cloning of hSRB7 and the
construction of hSRB7-ySRB7 chimaeras is available as Supplementary
Information at Nature's web site (http://www.nature.com). ySRB7 and
hSRB7 were aligned with BESTFIT (Genetics Computer Group, Inc.).
Plasmids containing chimaeras were shuffled into yeast strain Z704 (MATa
ura3-52, his3A200, leu2-3,112, srb7A1 (pCH7: SRB7 URA3 CEN)) 21. A
representative clone of each strain was tested by streaking or spotting.
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subjected to CTD-affinity chromatography (Fig. 2a). Western
blots of the column eluates confirmed that yeast SRB7 was
retained on a CTD column and showed that mammalian SRB7
from HeLa cells and calf thymus was also retained (Fig. 2b).
Because yeast RNA polymerase II holoenzyme can be immuno-
precipitated with anti-SRB antibodies, similar experiments were
used to investigate whether mammalian SRB7 associated with
components of the transcriptional apparatus in crude extracts.
Indeed, RNA polymerase II was specifically immunoprecipitated
by anti-hSRB7 antibody (Fig. 2c, d). In vitro transcription assays
confirmed the presence of RNA polymerase II and revealed the
presence of THIE and TFIIH activities in the anti-SRB7
immunoprecipitates (Fig. 2e). These results are evidence for a
mammalian holoenzymne complex containing at least SRB7, RNA
polymerase II, TFIIE and TFIIH.
The complex containing mammalian SRB7 and RNA poly-
merase II was purified over six columns (Fig. 3a). As shown by
western blotting, RNA polymerase II and SRB7 coeluted pre-
cisely from the last three columns of the purification. Analysis of
material from the last column revealed that SRB7 and RNA
polymerase II coeluted with subunits of TFIIE (p56) and TFIIH
(p89) (Fig. 3b, c and d). The number of coeluting polypeptides
present in the SRB7-RNA polymerase II complex is consistent
with the complex's estimated size of M, 2,000K, as determined by
gel filtration chromatography of crude extracts (data not shown).
The preparation appears close to purity as defined by coelution of
the same set of proteins over two columns. However, in vitro
transcription results indicate that TFIIE and TFIIH are sub-
stoichiometric (Fig. 4a), suggesting that a portion of their activity
was lost by dissociation or inactivation during purification.
We next compared the responses of purified mammalian
holoenzyme and core RNA polymerase II to the activator
Gal4-VP16 and the coactivators HMG2 (refs 9, 10) and PC4
(refs 11, 12). In four independent experiments, the holoenzyme
was more strongly inhibited by PC4 and HMG2 in the absence of
activator and showed a modestly enhanced response to activator
in the presence of these coactivators (Fig. 4b). Transcription by
core RNA polymerase II was mildly inhibited by PC4 and HMG2
(compare lanes 1 and 3) and was stimulated -2-fold by activator
(compare ratio of upper and lower bands in lanes 3 and 4).
Transcription by holoenzyme was more strongly inhibited by
PC4 and HMG2 (compare lanes 5 and 7) and was stimulated
,5-fold by the activator (compare ratio of upper and lower bands
in lanes 7 and 8). It will be interesting to study the holoenzyme's
response to other coactivators and cofactors, such as TBP-
associated factors (reviewed in ref. 13), topoisomerase I (ref. 14,
Drl/NC2 (refs 15, 16) and PC2 (ref. 17).
We have shown that hSRB7 shares sequence homology with its
yeast counterpart, that hSRB7-ySRB7 chimaeras functionally
complement a yeast SRB7 deletion, that hSRB7 is specifically
retained by a CTD column and, most important, that hSRB7
associates with a transcriptionally active 2,000K complex con-
taining RNA polymerase II and general transcription factors. We
conclude that hSRB7 is a genuine homologue of a yeast SRB gene
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FIG. 2 a, CTD-affinity chromatography procedure. b, Western blots of CTD-
column eluates. Onputs and eluates were probed with anti-ySRB7 or anti-
hSRB7. c, Immunoprecipitation procedure. d, Western blots of anti-hSRB7
immunoprecipitates. Onput and immunoprecipitates were probed with the
indicated antibodies. e, In vitro transcription assays with anti-SRB7
immunoprecipitates. Complete, reaction containing holoenzyme (2SRB7 IP),
TBP, TFIIB, TFIIE, TFIIF and TFIIH (top panel), or the same reaction with core
polymerase replacing holoenzyme and a control immunoprecipitate (IP)(blocked by peptide) replacing the anti-SRB7 IP (lower panel). In the other
lanes, the general factor indicated was omitted from the corresponding
complete reaction.
METHODS. Preparation of anti-hSRB7 antibodies, yeast, HeLa and calf
thymus extracts, CTD-column eluates and anti-hSRB7 immunoprecipitates
is described in Supplementary Information. Monoclonal antibody 8WG16
was used to detect the largest subunit of RNA polymerase II in western
blots22. In vitro transcription was assayed as described23. Immunoprecipi-
tates for transcription assay were prepared as for westem blotting, except
that washes were done with 0.5 ml 60 mM KCI, 50 mM Tris-CI, pH 7.9,
5 mM MgCI2, 2.5 mM MnCI, .
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FIG. 3 a, Procedure for purifying SRB7, b Silver staining of fractions eluted
from a Mono-Q column. c, Westem blotting of fractions eluted from
Mono-Q. Fractions were probed with the indicated antibodies. d, Proposed
identity of holoenzyme polypeptides. Bands that correspond in size to RNA
polymerase II, TFlIE and TFlIH subunits and mammalian SRB7 are indicated.
METHODS. The purification of mammalian holoenzyme is described in
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and that hRBS7 is a hallmark component of a mammalian RNA
polymerase II holoenzyme. We believe that the yeast RNA
polymerase II holoenzyme contains RNA polymerase II, SRB
proteins and the general factors TFIIB, E, F, and H in vivo.
Because different holoenzyme purification procedures cause the
loss of different subsets of the general transcription factors",2. 1
8
,
the forms of holoenzyme purified so far may be subcomplexes of a
Supplementary Information. Silver staining of purified holoenzyme has been
described'. For westem blotting, rabbit polyclonal anti-TFlIH p89 and anti-TFIE
p56 (gifts from J. Kim, B. Shykind and P. Sharp) were used at a dilution of
1: 500, 3 grl of each fraction was analysed. Identities of holoenzyme polypep-
tides were assigned based on published compositions of core RNA polymerase
1124, TFIIH 25, and TFIIE26.
FIG. 4 a, In vitro transcription assays. Reactions contained column-purified
holoenzyme, the general factors indicated, and the adenovirus major late
promoter with linear topology. b, Response of core RNA polymerase II and
column-purified holoenzyme to coactivators and activators. Reactions
contained core polymerase or holoenzyme, general transcription factors
and/or coactivators and Gal4-VP16. The upper transcript is derived from a
template containing the adenovirus major late promoter and three Gal4
binding sites; the lower transcript is derived from a control template
containing the same promoter with no Gal4 binding sites.
METHODS. Transcription reactions containing TFIIA, TFIIB, TFIID, TFIIE,
TFIIF and TFIIH have been described23. Holoenzyme was the peak fraction
from the Mono-Q column. Protein preparations for all of the basal factors
used here have been shown to be free of cross-contamination27 . HMG2
(30 ng per reaction) and PC4 (50 ng per reaction) were titrated for optimal
activation.
larger entity. In this context, it is not yet clear whether the yeast
holoenzyme contains TBP in vivo. Similarly, it remains to be
determined whether the in vivo form of the mammalian RNA
polymerase II holoenzyme contains all" or some of the general
transcription factors. The isolation of a human SRB gene and a
mammalian RNA polymerase II holoenzyme provides a means for
investigating these and other issues in transcriptional regulation
and extends the holoenzyme model from yeast to mammals. OI
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ABSTRACT Activation of eukaryotic class II gene expres-
sion involves the formation of a transcription initiation com-
plex that includes RNA polymerase II, general transcription
factors, and SRB components of the holoenzyme. Negative
regulators of transcription have been described, but it is not
clear whether any are general repressors of class II genes in
vivo. We reasoned that defects in truly global negative regu-
lators should compensate for deficiencies in SRB4 because
SRB4 plays a positive role in holoenzyme function. Genetic
experiments reveal that this is indeed the case: a defect in the
yeast homologue of the human negative regulator NC2
(Drl-DRAP1) suppresses a mutation in SRB4. Global defects
in mRNA synthesis caused by the defective yeast holoenzyme
are alleviated by the NC2 suppressing mutation in vivo,
indicating that yeast NC2 is a global negative regulator of class
II transcription. These results imply that relief from repres-
sion at class II promoters is a general feature of gene
activation in vivo.
Activation of class II gene transcription in eukaryotes involves
the recruitment of a transcription initiation complex that
includes the RNA polymerase II holoenzyme (1-6). The yeast
RNA polymerase II holoenzyme is a large multisubunit com-
plex containing RNA polymerase II, a subset of the general
transcription factors, and SRB regulatory proteins (7-11).
Mammalian RNA polymerase II holoenzymes have also been
purified, and an SRB7 homologue has been identified as a
component of those complexes (12-14).
For some class II genes, regulation appears to involve both
positive and negative transcriptional regulators. The negative
regulators that have been described include proteins purified
for their ability to inhibit transcription in vitro (15-21) and
genes identified because their products repress transcription
from a subset of class II genes in vivo (21-29). For example, the
human proteins NC1 (15, 16), NC2 or Drl-DRAP1 (16, 17, 20),
and DNA topoisomerase I (18, 19) repress basal transcription
in vitro. The products of the yeast genes MOT1 (21-24),
NOT1-4 (25-27), and SIN4 (28-29) negatively regulate at least
a subset of yeast genes in vivo. Whether any of these negative
regulators are generally employed for class II gene regulation
in vivo is not yet clear.
The RNA polymerase II C-terminal domain and the asso-
ciated SRB complex have been implicated in the response to
transcriptional activators (7-9, 30, 31). Two holoenzyme com-
ponents, SRB4 and SRB6, have been shown to play essential
and positive roles in transcription at the majority of class II
genes in Saccharomyces cerevisiae (32). We reasoned that a
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defect in SRB4 might be alleviated by defects in general
negative regulators and that knowledge of such regulators
could contribute to our understanding of the mechanisms
involved in gene regulation in vivo. Here we show that a
deficiency in yeast NC2 can compensate for the global tran-
scriptional defects caused by mutations in the SRB4 and SRB6
subunits of the RNA polymerase II holoenzyme and that NC2
is a global negative regulator of class II transcription in vivo.
MATERIALS AND METHODS
Genetic Manipulations. Yeast strains and plasmids are listed
in Tables 1 and 2, respectively. Details of strain and plasmid
constructions are available upon request. Yeast media and
manipulation were as described (9). Extragenic suppressors of
the temperature-sensitive phenotype of Z628 capable of
growth at the restrictive temperature of 360 C were isolated.
Dominant and recessive suppressors were identified by mating
to Z811 and assaying growth at 360 C on yeast extract/peptone/
dextrose (YPD). Complementation groups were established as
described (9).
To determine whether the NCBI gene is essential for cell
viability, the entire coding region was deleted on one of the two
chromosomes of a diploid cell, using a single step disruption
method (33) and the plasmid RY7136, which carries the
deletion allele ncblAl. Southern analysis was used to confirm
that a single copy of the NCB1 gene had been deleted. These
heterozygous diploid cells were sporulated, and tetrad analysis
was performed on YPD plates and scored for growth at a
variety of temperatures. Spores with the ncblAl allele did not
produce colonies, indicating that NCB1 is essential for cell
viability.
DNA Methods. DNA manipulations were performed as
described (34). PCR amplifications to produce RY7133,
RY7134, RY7136, RY7137, and RY7138 were performed
with Vent DNA polymerase (New England Biolabs) as de-
scribed by the manufacturer. The glutathione S-transferase
(GST) fusions were constructed as described (13), and the
ncblA1l allele was constructed as described (35).
Cloning and Sequence Analysis. The genomic clone of
NCB1 was isolated by complementation of Z804 with a
wild-type genomic library (35). The wild-type gene was further
localized by subcloning fragments of the genomic insert and
repeating the screen. The clone with the smallest insert,
RY7135, was sequenced. The genomic clone of NCB1 was used
to confirm the identity of each member of the complementa-
tion group and to identify additional members. RY7138 was
created from RY7135 in vivo by transforming Z804 with
Abbreviations: TBP, TATA box-binding protein; GST, glutathione
S-transferase.
Data deposition: The sequences reported in this paper have been
deposited in the GenBank database (accession nos. U18917 and
U32274).
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Table 1. Yeast strains
Strain Genotype
Z579 MATa ura3-52 his3A200 leu2-3,112 srb4A2::HIS3 [pCT127 (SRB4 LEU2 CEN)J
Z628 MA Ta ura3-52 his3A200 leu2-3,112 srb4A2::HIS3 (pCTI81 (srb4-138 LEU2 CEN)]
Z804 MATa uLra3-52 his3A200 1eu2-3,112 srb4A2::HIS3 ncbl-1 [pCT181 (srb4-138 LEU2 CEN)J]
Z805 MA Ta ura3-52 his3A200 leu2-3,112 srb4A2::HIS3 ncbl-1 [pCT15 (SRB4 URA3 CEN)]
Z806 MATc ura3-52 his3A200 leu2-3,112 ncblAl::HIS3 [RY7135 (NCBI URA3 CEN)I
Z807 MA Ta ura3-52 his3A200 leu2-3,112 ncblAl::HIS3 [RY7137 (NCBI 5' FLAG tag LEU2 CENV)j
Z811 MA Ta ura3-52 his3A200 leu2-3,112 srb4A2.:HIS3 [pCT181 (srb4-138 URA3 CEN)J
linearized RY7135 lacking NCB1 coding DNA and then
isolating the plasmid from a transformant that had repaired
the plasmid with the mutant ncbl-1 sequence from the chro-
mosome (33). NCB1 and ncbl-1 were completely sequenced on
each strand using DNA from RY7135 and RY7138, respec-
tively. Double-stranded sequencing with dideoxynucleotides
and Sequenase (United States Biochemical) was carried out as
described by the manufacturer using T3 and T7 promoter
primers and internal oligonucleotide primers. Sequence com-
parison analysis was performed at the National Center for
Biotechnology Information using the BLAST network service
(36). The ncbl-1 mutant allele contained a single base pair
deletion at nucleotide 340, causing a frameshift and a trans-
lational stop at nucleotides 347-349 (see Fig. Ib). Unlike the
RY7135 plasmid, RY7138 did not prevent growth at 360C
when transformed into Z804, indicating that the correct gene
was cloned.
Antibodies. Recombinant yNC2a and yNC2P proteins were
purified for generating polyclonal antibodies in rabbits. Re-
combinant proteins were derived from Escherichia coli con-
taining pGEX-4T-3 (Pharmacia) constructs RY7133 and
RY7134 as described (37). The antibodies were used to detect
yNC2a and yNC2P in Western blots at a dilution of 1:250 or
1:500.
Purification of Yeast NC2. TATA box-binding protein
(TBP) affinity chromatography was performed as described
(38) starting with 1.2 kg of cell pellet. Approximately 60% of
the total cellular amount of each NC2 subunit was eluted in 1
M KOAc. One-half of the 1 M KOAc eluate (80 ml; 3.3 mg)
was dialyzed against buffer T plus 0.003% Nonidet P-40. The
dialyzed sample was applied at 1 ml/min to a 1-ml HiTrap SP
cartridge (Pharmacia), which was washed with 10 ml of buffer
A (20 mM K-Hepes, pH 7.6/1 mM EDTA/10% glycerol and
protease inhibitors) plus 100 mM KOAc. Bound proteins were
eluted with a 10-ml gradient of buffer A from 100 to 1.000 mM
KOAc at 0.25 ml/min. Peak NC2 fractions were pooled, frozen
in liquid nitrogen, and stored at -70 0 C until use. One-half of
the peak NC2 fractions (1 ml, 80 pg) was diluted with 2.7 ml
of buffer B (20 mM Tris.OAc, pH 7.8/1 mM EDTA/10%
glycerol) and applied to a DEAE 5PW 5/5 column (TosoHaas,
Montgomeryville, PA) at 0.5 ml/min. The column was washed
with 5 ml of buffer B plus 100 mM KOAc, and bound proteins
were eluted with a 12-ml gradient of buffer B from 100 to 1,000
mM KOAc. The peak of NC2 contained 50 tg of total protein.
SDS/PAGE and silver staining were performed as described(8).
Construction of FLAG-Tagged NC2a Yeast Strain. Plasmid
RY7137 was constructed by amplifying the NCB1 gene (in-
Table 2. Plasmids
Plasmid
RY7133
RY7134
RY7135
RY7136
RY7137
RY7138
Description
NCB1 in pGEX-4T-3 (Pharmacia)
NCB2 (amino acids 13-146) in pGEX-4T-3
NCB1 (1.3 kb) URA3 CEN
ncblAl::HIS3 in pBluescript II SK(+)
NCB1 5' FLAG tag (IBI) in pUN105
ncbl- (1.3 kb) URA3 CEN
cluding regulatory sequences) with two sets of overlapping
primers to add a FLAG epitope (IBI) to the N terminus of
yNC2a. The two PCR products were gel-purified and com-
bined, and the entire FLAG-tagged NCB1 gene was amplified
with primers adding 5' HindIII and 3' BamHI cloning sites.
The final PCR product was cloned into plasmid pUN105 (39).
RY7137 was transformed into a Z806, a yeast strain containing
the ncblAl deletion, by plasmid-shuffle techniques (40) to
produce Z807. The FLAG-tagged NCB1 was fully functional
and able to complement the ncblAl deletion.
Purification of FLAG-Tagged Yeast NC2 and in Vitro Tran-
scription Assays. Yeast strain Z807 was grown in YPD to late
log phase and harvested by centrifugation. The cell pellet (500
g) was resuspended in 500 ml of 150 mM KOAc/60 mM
K-Hepes, pH 7.6/3 mM EDTA and protease inhibitors. The
mixture was poured slowly into a bath of liquid nitrogen, the
excess liquid nitrogen was decanted, and the frozen cells were
blended for 4 min in a Waring blender. The blended cells were
stored at -70 0C until use. The frozen mixture was thawed at
550 C and centrifuged at 12,000 rpm for 30 min in a GSA
(Sorvall) rotor. One volume (600 ml) of buffer A plus 100 mM
KOAc and 300 g of damp-dry BioRex 70 (Bio-Rad) resin were
added to the supernatant. After stirring for 2 h. the BioRex 70
resin was washed with 1 liter of buffer A plus 0.1 M KOAc on
a Buchner funnel. The washed resin was packed into a 5 cm i.d.
column and washed with 0.5 liter of buffer A plus 0.1 M KOAc
at a flow rate of 10 ml/min. Bound proteins were eluted with
buffer A plus 1 M KOAc. Fractions containing protein (115 ml
at 4.1 mg/nrl) were pooled, frozen in liquid nitrogen, and
stored at -70 0 C until use. BioRex 70 (32 ml) eluate was thawed
and mixed with 160 ml of buffer B plus protease inhibitors. The
diluted eluate was centrifuged at 12,000 rpm for 30 min in a
GSA rotor. The supernatant was applied to a 2-ml FLAG
antibody M2 affinity column (IBI), the column was washed
with 100 ml of buffer B plus 150 mM KOAc and 10 ml of buffer
B plus 50 mM KOAc, and bound proteins were eluted with
buffer B plus 50 mM KOAc plus 50 MM FLAG peptide. The
eluate (8 ml) was filtered through a 0 .2 -gm filter and applied
to a Mono Q PC 1.6/5 column (Pharmacia) at a flow rate of
0.1 ml/min, the column was washed with 1 ml buffer B plus 50
mM KOAc plus 1 mM DTT, and bound proteins were eluted
with a 2-ml gradient of buffer B plus 1 mM DTT from 50 to
2,000 mM KOAc. SDS/PAGE, silver staining, and Western
blot analysis were as described in the Fig. 2 legend. In vitro
transcription reactions were performed with a yeast CYC1
promoter template as described (41) except that 3' O-MeGTP
was added to 40 MiM. T1 RNase was omitted, and ethanol
precipitations were performed with 400 instead of 600 Al.
Poly(A)+ Blots and S1 Analyses. Aliquots of cells were
removed from culture at the times indicated, total RNA was
prepared, and poly(A) ÷ blots, quantitation, and S1 protection
analysis were carried out as described (32).
RESULTS
Yeast ncbl-1 Is an Extragenic Suppressor of the srb4-138
Mutation. Since SRB4 plays an essential and positive role in
class II transcription, we reasoned that a defect in SRB4 might
3146 Genetics: Gadbois et At
Proc. Natl. Acad. Sci. USA 94 (1997) 3147
be alleviated by defects in general negative regulators (Fig. la).
To identify mutations that compensate for a defect in SRB4,
78 spontaneous extragenic suppressors of the temperature-
sensitive phenotype of the srb4-138 allele were isolated. Six-
teen of the suppressors were dominant, and 62 were recessive.
Five complementation groups were established among the
recessive suppressors. One of the recessive suppressing genes
was cloned by complementation using a wild-type genomic
DNA library and was sequenced. The sequence is identical to
the ORF YER159c, which predicts a 142-aa protein with a
molecular weight of 15,500 (Fig. lb). A search of the GenBank
database (June 7, 1996) revealed that the predicted protein
has 39% identity over 99 aa to the NC2a (DRAP1) subunit of
human NC2 (Drl.DRAPI), which binds to TBP and represses
transcription in vitro (16, 17, 20, 42-44, 47-50). The gene
encoding the putative yeast NC2a protein was named NCBI.
Deletion analysis revealed that NCB1 is essential for cell
viability (data not shown). The mutation present in the sup-
pressing allele, ncbl-1, produces a 27-residue C-terminal trun-
cation in the yeast NC2a protein (Fig. lb). Since NCB1 is an
essential gene, the truncation mutation must cause a partial
functional defect in the NC2a protein.
Human NC2 consists of two subunits, NC2a and NC2P, both
of which are necessary for maximal TBP binding and repres-
sion of transcription in vitro (42, 43). To determine if there is
a yeast homologue of the NC2P subunit, the GenBank data-
base was searched on June 7, 1996 with the human NC2P
amino acid sequence. An ORF, D9509.16. that predicts a
a Genetic Selection for Negative Regulators
RNA Polymerase 1
HoloenzymeTFIIF
SRB4ts RNAPIIMutantSRB/SW/SNFComplex TFIIH TFiIB
CTD
ýssor
repressor
CTBP)
b NCB1 gene sequence (yNC2a(/DRAP1 protein)
1 atggcagatcaagtaccagttacaacacaactaccaccaataaaacctgaacacgaggcaccacttgatgcggagggagtccagtaggtaacatggc::aact cg
M A D Q V P V T T Q L P P 1 K P E H E V P L D A G G S P V G N M G : S
109 aataacaacaacgagccaggtgatgtattcgacagaataaagacacac cccc ccggccaaggtaaagaaaataacgcagacagacgaggaataagaaga=tctca
NNNN E LG D V F D R IKTH F P P A K V K K I M Q T D ED I G K S
---------------------------------
helix 1
217 caagccacgcccgtaatagcgggcaggtccctagagtetcttatagcgtcattggtgaaaaaaagcggggagatggcaagaggacaaggaaccaagagaaaaccgcc
QATPVIAGRSLEFFIALLVKKSGEMARGQGTKR E M A R G Q G T K R
--------------------...................................................................
* * helix 2
325 gaaatataaaaaaaacaaccttaaacgacgaaaaaccga ttaagggaaggtctatgcgtagaagaaggccaaacacaaccggaggaagagaggczotgagca
E I L K K T I L N D E K F D F L R E G L C V E E G Q T Q P E E E S A
---------------------------------------------------
helix 3
c NCB2 gene sequence (yNC23/Drl protein)
1 atggctggagactccgataagtgtcgcttcccaagggatgttagtatattgtg•gcaaaactcaagcttgatgcgggtactgagcggtataz- a:_B:aga
M A G D S D N V S L P K A
109 gaaaacactgaatgatcttagcgaccgcacaaaagatgatatctgaaatactggaccagga t tgatgt t t accaaggatgcaagagaaaccatcatcaacz zzggca
TVQKMISE I L D Q D L M F T K D A R EI I N G I
helix 1
217 tagaattcataatgatcctgt ctcgatgg•tccgaaaggcggacaacgaggcaagaaaaccatagcgcccgagcacgtgateaaagcgctagaaga•tggagt
E F I M I L S SM A S E M A D N E A K K T I A P E H V I K A L E = Y
-- - - ------------------------- -- -- - -- -- - -- - -- -
- -- - -- -- - -- -
helix 2 helix 3
325 ataatgag t tataccattc tagaggaaatactactgaat t•taagggttcccagaaggtgaaagaaactagggactccaag•caagaagtcaggt czcggaag
N E F I P F L E E I L L N F K G S Q K V K E T R D S K F K K S G L S E E
433 aagagccgctacgacaacaagaggagttgtttagacagtcaaggtccagattacaccacaatagcgtatctgatccggtcaagtcggaggattcttctaa-agaag
ELLRQQEELF R Q S R S R H HN S V S D PVK SE S S
FIG. 1. Isolation of putative global negative regulators. (a) Genetic selection for suppressors of the temperature-sensitive (ts) SRB4 mutant RNA
polymerase II holoenzyme. (b) Sequence of NCB1 (ORF YER159c on chromosome V, GenBank accession no. U18917). The suppressing allele,
ncbl-1, was isolated by gap-repair techniques and sequenced. The suppressing mutation, a single base pair deletion at nucleotide 340, is noted in
boldface type. The deletion results in a frameshift causing a translational stop at nucleotides 347-349, also noted in boldface type. Underlined regions
indicate homology to a-helices in the histone H2A histone fold (42-44). (c) Sequence of NCB2 (ORF D9509.16 on chromosome IV, GenBank
accession no. U32274) with the first and last nucleotide of the intron sequence noted in boldface type. Underlined regions indicate homology to
a-helices in the histone H2B histone fold (42-46).
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146-aa protein with a molecular weight of 16,700 (Fig. ic) was
identified. The predicted protein has 37% identity to human
NC2P. The gene, named NCB2, contains consensus sequence
predicting an intron. Both DNA and cDNA clones containing
the coding sequence for NCB2 were isolated and sequenced,
and the intron structure produces a somewhat different amino
acid sequence than that predicted by GenBank (Fig. lc). The
human NC2 subunits each contain sequences predicting a
histone fold structure (42. 43, 51, 52); the yeast NC2 subunits
also exhibit this sequence relationship (Fig. 1 b and c; ref. 44).
Interestingly, the C-terminal truncation in the ncbl-1 suppress-
ing allele removes part of the histone fold in the yeast NC2a
subunit (Fig. lb). Deletions in the human NC2 histone folds
have been shown to decrease subunit association, TBP binding,
and transcriptional repression (42, 43).
Yeast NC2 Binds to TBP and Can Be Purified as a Two-
Subunit Complex. If the two yeast gene products are genuine
homologues of human NC2. they would be expected to copu-
rify as a complex and to bind to TBP. To determine whether
this is the case, a yeast whole-cell extract was subjected to GST
and GST-TBP affinity chromatography (Fig. 2a). Western blot
analyses of the column eluates confirmed that both yeast NC2a
and NC2P proteins were specifically retained on the GST-TBP
column. The eluate from the GST-TBP column was further
purified over two ion-exchange columns. Silver staining and
Western blot analyses showed that yeast NC2a and NC2P
coeluted over both columns and that the proteins appear to be
in equal stoichiometry (Fig. 2b and data not shown). Yeast
NC2a is not present in a purified RNA polymerase II holoen-
zyme preparation, so NC2 is unlikely to be a component of the
TBP Affinity Column
Western
yNC2 a -
yNC2P
DEAE 5PW Fractions
Silver stain
L 4 5 6 7 8 9 MW
* .200
*55
holoenzyme (data not shown). These data confirm that'the
yeast NC2a and NC20 proteins are stoichiometric subunits of"
a complex that can bind specifically to TBP.
Highly Purified Yeast NC2 Inhibits Transcription by RNA
Polymerase II Holoenzyme in Vitro. The observation that a
defective form of yeast NC2 can compensate for a weakened
RNA polymerase II holoenzyme suggests that yeast NC2
normally functions to repress holoenzyme activity. We tested
the ability of purified yeast NC2 to repress transcription by
yeast RNA polymerase II holoenzyme in virro. A preparation
of yeast NC2 from a strain containing an epitope-tagged NC2a
subunit (Fig. 3 a and b) gave us material of higher yield and
purity than from the TBP affinity column. In virro transcription
reactions were performed with a yeast CYC1 promoter tem-
plate, holoenzyme. and fractions from the final column of this
yeast NC2 purification (Fig. 3 c and d). Repression of tran-
scription correlated with the peak of yeast NC2 protein. When
an equimolar amount of NC2 was added to RNA polymerase
II holoenzyme and TBP, 50% of the maximal inhibition was
observed (Fig. 3d). The repression of RNA polymerase II
holoenzyme transcription by yeast NC2 is consistent with the
Mono 0 Fractions
Silver stain
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'97
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FIG. 2. Yeast NC2 binds to TBP and can be purified as a
two-subunit complex. (a) Western blot analyses of TBP column onput
and eluates with antibodies against yNC2a and yNC2I3. Bound pro-
teins were eluted with 2 M KCl. (b) Silver-stained SDS/
polyacrylamide gel and Western blot analyses of fractions from thefinal step of the purification (DEAE 5PW).
d In vitro transcription
0 0.5 1 2 0 gl fraction 13
Transcript j
FIG. 3. Highly purified yeast NC2 inhibits transcription by RNA
polymerase II holoenzyme in vitro. (a) Analysis of NC2 Mono Q
fractions by SDS/PAGE and silver staining. (b) Western blot analyses
of Mono Q fractions. (c) Influence of Mono Q fractions on in vitro
transcription by RNA polymerase II holoenzyme. (d) Inhibition of in
vitro transcription by RNA polymerase II holoenzyme with increasing
amounts of purified yeast NC2. Assuming a molecular weight of 64,000
for NC2, 0.5 pmol was required for 50% inhibition of an equimolar
amount of RNA polymerase II holoenzyme (estimated molecular
weight of 2 million) and TBP.
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ability of a partial loss-of-function NC2 mutation to suppress
a holoenzyme mutation.
NC2 Functions at the Majority of Class II Promoters in
Vivo. The observation that loss of NC2 function in yeast cells
can compensate for a defect in the SRB4 component of the
holoenzyme. together with previous evidence that SRB4 func-
tions globally at class II promoters (32), suggests that NC2 may
repress transcription at class II promoters in general. To
determine whether yeast NC2 functions at the majority of class
II promoters in vivo, we investigated whether the shutdown of
mRNA synthesis observed in cells with the SRB4 temperature-
sensitive mutant allele srb4-138 is reversed by the loss of NC2
function (Fig. 4). Upon shifting cells to the restrictive temper-
ature, the growth rate of the srb4-138 strain was severely
reduced, whereas the srb4-138 ncbl-1 suppressor strain was
only modestly affected (Fig. 4a). The levels of poly(A)' mRNA
in these cells were measured immediately before and at several
times after the shift to the restrictive temperature (Fig. 4b).
There was a significant decrease in the mRNA population in
the srb4-138 strain, as observed previously (32). In contrast,
there was only a modest decrease in mRNA levels in the
srb4-138 ncbl-1 strain after the temperature shift. Thus, the
ncbl-1 mutation suppresses the general defect in transcription
of class II messages caused by the srb4-138 mutation. Further-
more, the ncbl-1 mutant in an otherwise wild-type background
showed 27% higher levels of poly(A)I mRNA compared with
the wild-type strain under normal conditions (Fig. 4c). This
result is consistent with the partial loss-of-function of a class
II global negative regulator. S1 analysis of individual class II
transcripts confirmed that the decline in specific mRNAs in the
srb4-138 strain is reversed in the srb4-138 ncbl-1 strain (Fig.
4d). These results, together with previous evidence that NC2
functions as a repressor of multiple promoters tested in vitro,
argue that NC2 is a general negative regulator of class II gene
transcription.
DISCUSSION
Our results indicate that NC2 is an essential and conserved
negative regulator of class II gene transcription. These results
extend the known negative regulatory effects of NC2 on core
RNA polymerase II in vitro (16, 17, 20, 42-44, 47-50) and
confirm that this regulator can inhibit transcription by RNA
polymerase II in vivo.
Since SRB4 has an essential and positive role in transcrip-
tion at the majority of class II genes in yeast (32), we reasoned
that suppressors of a temperature-sensitive SRB4 mutant
should include negative regulators. In principle, such regula-
tors could repress most class II genes or they could repress
SRB4 specifically. Several lines of evidence argue that NC2
acts globally as a repressor of most, if not all, class II genes.
NC2 can repress transcription in vitro from a wide variety of
mammalian, viral, and yeast promoters (16, 20, 42-44, 50). The
NC2 suppressor mutation that compensates for reduced class
II gene transcription in vivo due to loss of SRB4 also com-
pensates for the global defect due to loss of SRB6 (data not
shown). Loss of function of NC2 in otherwise wild-type cells
results in increased levels of poly(A)+ mRNA. These data do
not prove that NC2 regulates all class II genes, but they are
most consistent with a global role for this repressor.
Mechanism of Yeast NC2 Repression. Much is already
known about the biochemistry of NC2 repression; NC2 binds
to TBP on promoter DNA and subsequently inhibits the
binding of TFIIA and TFIIB in vitro (16, 17, 42, 43, 50). NC2
binds to the same basic region of TBP as TFIIA (50), suggest-
ing that NC2 physically blocks TFIIA from binding to TBP.
The other proteins known to have global negative regulatory
properties are the histones (53, 54), which share notable
structural features with NC2/Drl.DRAP1. The presence of
the histone fold motif in NC2 raises the intriguing possibility
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FIG. 4. Loss of yeast NC2 function compensates for the global defect
in class II gene expression caused by the SRB4 mutant holoenzyme. (a)
ncbl-1 mutation suppresses the growth defect of the srb4-138 mutant
strain at the restrictive temperature. Growth of wild-type (Z579), srb4-138(Z628), srb4-138 ncbl-1 (Z804), and ncbl-1 (Z805) strains in YPD
medium at 300C and after shifting to the restrictive temperature of 35.50C.(b) The global decline in mRNA levels at the restrictive temperature in
srb4-138 mutant strain is alleviated by the ncbl-1 mutation. (c) Global
levels of mRNA are increased in the ncbl-1 strain relative to the wild-type
strain. (d) The decrease in synthesis of individual class II messages at the
restrictive temperature in the srb4-138 mutant strain is reversed by the
ncbl-1 mutation.
of interactions with other histone fold-containing proteins.
Histones H2A, H2B, H3, and H4 all contain histone folds (51),
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as do the yeast HAP3 and HAP5 activator proteins (CBF
proteins in mammals; ref. 52) and several TAFu1s (45, 46).
These TAFuIs and histones are able to interact with each other
in vitro through their histone fold regions (45). Thus. NC2
might introduce a nucleosome-like structure at the promoter,
either by itself or with other histone fold-containing proteins.
Transcription Activation and Relief from Repression. The
SRB components of the RNA polymerase II holoenzyme
contribute to the response to transcriptional activators (7-9).
We have shown that a partial loss in NC2 function compensates
for deficiencies in SRB4 and SRB6 functions. These results
indicate that relief from NC2 inhibition is a required step
during transcription initiation at most class II promoters in
vivo. Evidence consistent with this view has recently emerged
from a study of SUC2 gene regulation. Prelich and Winston
(55) isolated yeast mutations that suppress a deletion of the
upstream activating sequence in the SUC2 promoter. The
mutant genes that compensated for the absence of SUC2
activator function included several histones, certain SPT genes,
and other unidentified genes called BUR genes (Bypass UAS
Requirement). The bur6 mutant allele was recently found to be
a partial loss-of-function mutation in NCB1 (56). The obser-
vation that BUR6 is identical to NCBI indicates that a loss in
NC2 function can compensate for the loss of an activator.
These data support the model that activators function to
recruit the transcription apparatus, which must overcome
negative regulation by NC2 to initiate transcription.
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Association of an activator with an RNA
polymerase II holoenzyme
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RNA polymerase II holoenzymes have been described that consist of RNA polymerase II, a subset of general
transcription factors, and four SRB proteins. The SRB proteins, which were identified through a selection for
genes involved in transcription initiation by RNA polymerase II in vivo, are a hallmark of the holoenzyme.
We report here the isolation and characterization of additional SRB genes. We show that the products of all
nine SRB genes identified thus far are components of the RNA polymerase II holoenzyme and are associated
with a holoenzyme subcomplex termed the mediator of activation. The holoenzyme is capable of responding
to a transcriptional activator, suggesting a model in which activators function, in part, through direct
interactions with the holoenzyme. Immunoprecipitation experiments with anti-SRB5 antibodies demonstrate
that the acidic activating domain of VP16 specifically binds to the holoenzyme. Furthermore, the holoenzyme
and the mediator subcomplex bind to a VP16 affinity column. These results provide a more complete
description of the RNA polymerase II holoenzyme and suggest that this form of the transcription apparatus
can be recruited to promoters via direct interactions with activators.
[Key Words: RNA polymerase II; holoenzyme; carboxy-terminal domain; genetic suppressors; transcription
initiation; SRBs; transcription activation]
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Large multisubunit complexes containing RNA poly-
merase II, a subset of the general transcription factors,
and additional factors implicated in regulation of tran-
scription initiation in vivo, can assemble independently
of promoter DNA (Kim et al. 1994; Koleske and Young
1994). These complexes, termed RNA polymerase II ho-
loenzymes, have been purified from Saccharomyces ce-
revisiae. The larger form of holoenzyme contains RNA
polymerase II, TFIIB, TFIIF, TFIIH, and SRB (suppressor
of RNA polymerase B) proteins (Koleske and Young
1994). Another form of holoenzyme has been described
that contains RNA polymerase II, TFIIF, and SRB pro-
teins but lacks TFIIB and TFIIH (Kim et al. 1994). The
two holoenzyme forms may exist simultaneously in
vivo, or the isolation of the smaller complex may be a
consequence of the instability of the RNA polymerase II
holoenzyme during purification.
Selective transcription initiation in vitro by the 12-
subunit core RNA polymerase II was shown previously
to require the action of at least five general initiation
factors: TATA-binding protein (TBP), TFIIB, THIE,
TFIIF, and TFIIH (for review, see Conaway and Conaway
1993; Zawel and Reinberg 1993). Consistent with these
data, selective transcription initiation in vitro with the
larger form of RNA polymerase II holoenzyme required
TBP and TFIIE (Koleske and Young 1994), and initiation
with the smaller form required TBP, TFHIB, TFIIE, and
TFIIH (Kim et al. 1994).
The holoenzymes were discovered by virtue of their
association with SRB proteins. SRB genes were obtained
through a genetic selection designed to identify genes
involved in RNA polymerase II carboxy-terminal do-
main (CTD) function (Nonet and Young 1989; Thomp-
son et al. 1993). The CTD had been implicated in the
response to various transcriptional regulatory signals
(Allison and Ingles 1989; Scafe et al. 1990; Liao et al.
1991; Peterson et al. 1991), and the SRB alleles were
isolated by virtue of their ability to suppress the cold-
sensitive phenotype of cells containing CTD truncation
mutations. Purification of the products of the SRB2,
SRB4, SRB5, and SRB6 genes led to the observation that
the vast majority of these SRB proteins in cell lysates are
tightly associated with a portion of the RNA polymerase
II and general factor molecules (Thompson et al. 1993;
Koleske and Young 1994). These results, and evidence
that the SRB proteins have essential roles in transcrip-
tion in vivo, suggested that the holoenzyme may be the
form of RNA polymerase II that initiates transcription at
promoters in vivo. The results also suggested that the
isolation of more SRB genes might lead to the identifi-
cation of additional components of the holoenzyme, and
we show here that this is the case.
The RNA polymerase II holoenzymes are responsive
to activators (Kim et al. 1994; Koleske and Young 1994),
a feature not observed with purified RNA polymerase II
and general transcription factors alone (Flanagan et al.
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1991, 1992). Thus, these holoenzymes contain compo-
nents necessary and sufficient for some level of response
to transcriptional activators. A subcomplex, called the
mediator of activation, can be dissociated from the RNA
polymerase II holoenzyme by using monoclonal anti-
CTD antibodies (Kim et al. 1994). The purified mediator
contains SRB2, SRB4, SRB5, SRB6, SUG1, GAL 11, TFIIF,
and as yet unidentified polypeptides and is capable of
reconstituting the ability of purified RNA polymerase II
and general factors to respond to transcriptional activa-
tors. Genetic studies suggested previously that GAL11,
SUG1, and the SRB proteins are involved in transcrip-
tional regulation (Suzuki et al. 1988; Fassler and Win-
ston 1989; Himmelfarb et al. 1990; Nishizawa et al.
1990; Vallier and Carlson 1991; Swaffield et al. 1992; Yu
and Fassler 1993).
The mechanisms involved in transcriptional activa-
tion are not yet clear. Transcriptional activators gener-
ally contain separable DNA-binding and activation do-
mains (Ptashne 1988; Mitchell and Tjian 1989). It is be-
lieved that transcriptional activators function in part by
binding to promoter elements and to components of the
transcription initiation apparatus, thereby contributing
to their stable binding to the promoter (for review, see
Struhl 1989; Ptashne and Gahn 1990; Roeder 1991;
Drapkin et al. 1993). For example, evidence for interac-
tions between transcriptional activators and general fac-
tors has come from the analysis of TFIID, where physical
and functional interactions have been reconstituted with
recombinant TBP and TAFs (Dynlacht et al. 1991;
Tanese et al. 1991; Gill and Tjian 1992; Goodrich et al.
1993; Hoey et al. 1993; Chen et al. 1994; Gill et al. 1994;
Jacq et al. 1994).
Transcriptional activators have been reported to inter-
act with additional general factors. For instance, the
herpes simplex virus (HSV) trans-activator VP16
(Triezenberg et al. 1988) has been shown to interact with
TFIIB (Lin et al. 1991; Goodrich et al. 1993) and TFIIH
(Xiao et al. 1994). This raises the possibility that some
transcriptional activators can interact simultaneously or
sequentially with multiple components of the transcrip-
tion initiation apparatus. These results have generally
been interpreted in the context of a model in which each
of the general transcription factors and RNA polymerase
II assemble onto the promoter in a stepwise fashion (Bu-
ratowski et al. 1989; Flores et al. 1991; Conaway and
Conaway 1993; Zawel and Reinberg 1993; Buratowski
1994).
The identification of RNA polymerase II holoenzymes
that contain a subset of the general factors and are capa-
ble of responding to activators suggests a different model
for transcriptional activation. In this model, transcrip-
tional activator proteins first contribute to the establish-
ment of a promoter-bound TFIID complex. The activa-
tors then interact with the holoenzyme to facilitate its
association with the TFIID/promoter complex.
In this report we describe the isolation and character-
ization of additional SRB genes and show that the prod-
ucts of all nine SRB genes identified thus far are compo-
nents of the RNA polymerase II holoenzyme and the
mediator of activation subcomplex. We also show that
the transcriptional activator VP16 binds to the holoen-
zyme and the mediator subcomplex in vitro, thus pro-
viding evidence consistent with the model that tran-
scriptional activators interact with the holoenzyme.
Results
Extragenic suppressors of RNA polymerase II CTD
truncation mutations
Extragenic suppressors of a S. cerevisiae RNA polymer-
ase II CTD truncation mutant were isolated to identify
components of the transcription apparatus involved in
initiation. The cold-sensitive phenotype of rpblAl04
cells containing RNA polymerase II CTDs with 11 intact
heptapeptide repeats was used to obtain 75 independent
suppressing isolates. Genetic analysis revealed that mu-
tations in a total of nine SRB genes suppress growth de-
fects of cells containing a truncated CTD (Table 1). Pre-
viously, we described the isolation and characterization
of SRB2, SRB4, SRB5, SRB6, SRBIO, and SRB11 (Nonet
and Young 1989; Koleske et al. 1992; Thompson et al.
1993; Liao et al. 1995). Thorough genetic analysis of the
75 independent suppressing isolates led to the identifi-
cation of three additional genes: SRB 7, SRB8, and SRB9.
Table 1. SRB gene summary
Dominant Recessive Deletion Chromosomal Protein SDS-PAGE
Gene alleles alleles viability location mass (kD) mobility (kD) pI References*
SRB2 3 0 conditional VIII 23 27 5.2 1-4
SRB4 14 7 inviable V 78 98 5.1 3,4
SRB5 7 0 conditional VII 34 38 4.7 3,4
SRB6 4 2 inviable II 14 15 4.6 3,4
SRB7 0 3 inviable IV 16 19 4.8 5
SRB8 0 4 conditional III 144 160 5.7 5
SRB9 0 26 conditional IV 160 180 5.5 5
SRB10 0 4 conditional XVI 61 68 9.6 6
SRB11 0 1 conditional XIV 38 33 7.0 6
'(1) Nonet and Young (1989); (2) Koleske et al. (1992); (3) Thompson et al. (1993); (4) Koleske and Young (1994); (5) this paper; (6) Liao
et al. (1995).
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The suppressing alleles of SRB2, SRB4, SRBS, SRB6,
SRB10, and SRB11 were found to suppress the condi-
tional phenotypes associated with the CTD truncation
mutation rpblAl04 but did not suppress similar condi-
tional phenotypes caused by other mutations in RPB1
(Nonet and Young 1989; Koleske et al. 1992; Thompson
et al. 1993; Liao et al. 1995). Similarly, the mutations
srb7-1, srb8-1, and srb9-1 were also specific in suppress-
ing conditional phenotypes attributable to CTD trunca-
tion mutations (not shown). This specificity of suppres-
sion suggests that the SRB gene products and the CTD
are involved in the same process in transcription initia-
tion.
Genomic DNA clones containing SRB7, SRB8, and
SRB9 were isolated by genetic complementation. Se-
quence analysis revealed that SRB7, SRB8, and SRB9 are
all newly identified genes. The predicted SRB7 protein is
140 amino acids long and has a molecular mass of 16 kD
(Fig. 1). Physical mapping showed that SRB7 is located
on the right arm of chromosome IV, -45 kb distal to
GCN2 (X clone 6118). Partial sequence analysis of the
II
Xhol Aflll
0.5 kb
srb7d I::URA3hisG
SRB8-coding sequence revealed that it is identical to
open reading frame (ORF) YCR81W on chromosome III
(Oliver et al. 1992). The SRB8 protein is predicted to be
1226 amino acids in length with a molecular mass of 144
kD (Fig. 2). The predicted SRB9 protein is 1420 amino
acids long and has a molecular mass of 160 kD (Fig. 3).
SRB9 maps to the right arm of chromosome IV, -35 kb
centromere distal to ADE8 (X clone 5513). A search of the
sequence data banks revealed that SRB7, SRB8, and SRB9
do not have significant sequence similarity to previously
identified proteins.
To determine whether the SRB genes are essential for
cell viability, most or all of the coding regions were de-
leted, producing srb7dl (Fig. 1A), srb8l1 (Fig. 2A), and
srb9l1 (Fig. 3A). Heterozygous diploid cells containing
these deletion alleles were sporulated, and tetrad analy-
sis was carried out. The results revealed that SRB7 is
essential for cell viability. In contrast, cells lacking ei-
ther SRB8 or SRB9 are viable, but flocculate and exhibit
mild cold-sensitive and temperature-sensitive pheno-
types.
Hindlll, Spel Sphl Hindill Afill EcoRV
IhisG I URA3 Kanr hisG
0.5 kb
TCGATGATGTTCTTTATTCTTTCAACCAGCTCGAGCCCCTGCAAACTTAAGCTAAGGACAGAAAATGAAAAAAAA
AAAAAAAAAAAATTCAAAGAATCAGCTTATAAAACATATTCAAGGACCCATCTGAAGTATCATTCATTCCCTCTTTCTTCTTCTTTTTT
ACTCGTTAATCTCATTCATTCGTTTCCTCATTCTTTTTTCTTTGTTCTTTATTTCGGCTATTTTTTCACTATTAA
AATAACTAGAGCTAACAATATTATTTCTTCTGCTTTAGTTACAAAACAAGGACATTCATTTAACTTGGCGTTATC
CCATACATTCGTTTATTATATCTTCTTTTAAAACACAATTTCTTTTACAGTTAAACTTTTCTGATTTATTATATA
TTACTTAAGATTGTTCATATAACTAACATTTATATGCTTATATGCGTGAAGTGCGCTTTTGTAGAACATGTGGCT
GTTTCTGTAGAAGCCTTGTCTTTCTCTGTAATTCTTAAAGGCCAACCGTACGTGCTTAATTACAAGCTTTGTTC
GCATTGCAAGAAAGTTAGAAAAAAAATCAATTCTGAAAGATAATTATAATTCAAACGGTAAACCATTGGTTAAAA
GAGGGACATAACATTTCACTAGTTCAATACATTATATGCTCTTTAACAATGACAGATAGATTAACACAATTGCAG
MT DR L TQ LQ
A(srb7-1)
28 ATATGTTTAGACCAAATGACGGACAATTCTGTGCTACTTTAAACTACATAGATAAGAACCATGGTTTTGAACGA
I C L D Q M T E Q F C A T L N Y I D K N H OG F R
103 TTGACCGTAAATGAACCTCAGATGTCCGATAAGCATGCCACAGTAGTACCTCCTGAGGAATTTTCTAACACGATA
L TV NE P QM SD K H A T V V P P F S N T I
178 GATGAGCTATCCACGGACATTATACTTAAAACAAGACAATAAACAAGCTTATTGACTCGTTACCTGGTGTTGAC
D E L S T D I I L K T R 0 I N K L I D S L P G V D
253 GTTTCAGCTGAAGAGCAATTAAGGAAGATTGATATGTTGCAGAAAAAGCTAGTTGAAGTGGAAGACG TT
V S A Z E Q L R K I D M L 0 K K L V E V E D E K I
328 GAGGCCATCAAAAAGAAGGAGAAACTTTTAAGGCACGTTGATTCTTTAATTGAAGATTTTGTAGATGGCATTGCA
E A I K K K E K L L R H V D S L I E D F V D G I A
403 AACTCAAAAAAGAGCACATAAACTTAAGTTACAAAGAAATTTGCGAACAGAGGACAGAAAATGTACTATAGTT
N S K K S T *
ATATGGCAGAGTTAAGCGTATGTATGTTATTCTTATAAATATTATTGTGCTACTCTATTTGTACCGGAGAATTATTG
MAGCMAATGGGAGAAAAATCATMAATGGAGAAAATCTTTCTACGAGTTACTTTGCAAGGCAATCTAACGATTCTAAA
AGACACAATACACTAAAGAAAAAACTTTGGAAGTACAGTTTTTTCCCCAAGTTGAAGTGTGGACTCATTGTGAAG
A AGTAAAAATGTAAAAACCAACCGACAATGCACTCCCAGCCAAATTCATTGTAGACCTCCCATTTGATAGAAAAG
GAAGGTTCAGCAGTTGTCCACGGATTCCAAGATATCATTCT CTTACAT;AGUACoi . AI
Figure 1. Map and sequence of the SRB7 gene.
(A) Restriction map of a 2.0-kb DNA fragment
from pCH7 containing the SRB7 gene. The entire
coding region of SRB7 was replaced with a 5.5-kb
DNA fragment containing the URA3 and kana-
mycin genes flanked by direct repeats of Salmo-
nella hisG DNA to create the deletion allele
srb7Al::URA3hisG. (B) Sequence of the SRB7
gene and adjacent DNA. The predicted 140-
amino-acid sequence of the SRB7 protein is
shown below the sequence of the gene. Positive
numbering of the nucleotides begins with the
predicted start site of translation. The srb 7-1 mu-
tation is a G -- A transition (nucleotide 61) that
changes amino acid 21 from Ala to Thr.
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TCAATCCAACATTCTTTCCCAGCAATTCGACAAAATTATCAAGATTAGAGAAGACCACATTAATAAGATCCCCTC
AAATTCC AC ACATTCACOGGCCTOO TTT TCTAT AACCCTTACTGATCATAGAAAGL
AACOTOOTTOCATGAATTGAGATTCOTCTCACAC.TCGACDGGTCAAAATTGGCAAGTTTATACCTCACGGCTTO
AAAAG OAAGOTCATCOACAGTOCTATTTAAAATTTATACCATTDAAAAODOCGATTTOGTT0ATAAAGTGC
TGCTAVTTATCCGAATGAAATCAACCACAAAAA AAATGCTCTOGGCAGATOATOCCATTTCC
ATOCACCTOCTAAAGGOOACTOGACGGATACCTTTGTAACATCCTGAAAAGCTCATCTTTGATATGACAAATCAC
VM L L E ON T D T V Y I LK K L I F D X T N H
TATAACOATTCTCAACAACTGCOTACGTGGAAGAGGCAGATTTCTTATTTTTTAAAACTTTTGGGGAATTGCTAC
Y N D S 00 L R T W K R Q S YT F L K LL G N CT
TCACAA TATATAAGGAAATCTTTCATCAGGCTTGTGATTTATAAATAAGATGGAAAACTTCGAA
S L R LI N K I FR NWLV K? F N EVE SN K
TTTTTGCCATTATCTTTACATTTTTTGATGATOTTT.TOAACGACATCTGCCAAATTGATACAAATOCTCCTOTT
F L P L S L H I L I V F W N D I C 0 0 D T N A P V
GCOGCTACAATAACATCAAGCAAAAAAGAOCCCTTC'TTCTGGTAACAAAAATCACTOGTATOCTATTGCACAAA
A A T I T S SO K I P F F L V T K I T DV L L ER
TATTATATTGTTTCCAGCAGCAAATCAATOATAAATGACGAGAACTACATCATCAATGATATAAAGAAAAACAAC
Y Y I VS SS KIS I NDE N I NDI EEN N
AAGATAAAGTTGAATATTCTCAAAATATTLTC CAG TAATTTTAATTTTCAAGACAATCTTTAOAGGTG
E I K L N I L K I L S S L I L XK I F • Q S LE V
TTTATATTTCCCACATCTAACTGGGAAATTTACAAGCCCTTACTTTTTGAAATAGTCTCAAACGCCGACACTAAT
SI F P T S N w N I T K P L L F E I V S N A D T N
CAAAATTCTGATAAAAAAAAATTGAOTTAA TTACAGAAACGAGTCATTGAAAAATAATTCTTCTATA
0 N S DV KE K L K L I S Y R N E S L K N N S S I
CGAAACGTAATAATGTCTGCCAGCAACGCAAATGAC C ATTAACTATCOTCACCTGTAAACAATTTCCAAAA
R V IMS A SNANI D LT I VTC EQ F P
CTATCATQCATTCAATTAAATTOTATAOATACTCAGTTCACCAAGCTACTGGACGATAACCCTACAGAATTCATV
L S C 10 L N C I D T 0 F T E L L D D N P T Z F D
TGGCCCACTTACGTTGACCAAAATCCCCTTACAATGCATAAAATTATTCAATTAATTCTCTOGTCCATACATCCA
W P T Y V D 0 N P L T N 3 KS I 1 Q L I L W S I N P
TCAAOGGCATTGATCACTATGAATCTAATCAAC"OGTAGCGAAATTATTACTATTGCGAATAAATTCAACAGAT
S R 0 F DS Y Z S N0 L V A X L L L L R I N S T D
GAGGATTTOCACGAATTCCAGATAGAAGATOCCATOGOTCATTGGTTTTCCAATTAGCCAAAATTTTTCOCC
E D L H N E Q I l D A I V S L V F O L A K N F S A
CAAAAGGAOGTGGTATCATATATGATGCCTTCTT1GATCGCCOTGCTTAATATACTAATTACTTATGGCATCATT
QKKVVSTVVMPS LYRL L N ILI VTYQ I I
AAGGTCCCTACGTATATCAGAAAGCTAATCAGTTCCGGCCTACTTTATCTCCAAGATTCCAATGATAAGTTTGTG
SVP T Y I R L I S S G L L Y L D S ND V
CATGTCCAGCTOTTAATTAACTTGAAAATTTCACCGTTVATGAAAAOTCAATACAATATGTATTGAGGAACGTT
N V Q L L I NL I S P LXM KS 0 Y NMVL N V
ATGGAATATGACOTTAAATTTTATGAAATTTTTAATiTCGACCAACTCGTGGAAATCACAGAACAAATCAAAATG
N V Y D V P Y El V•NVDQ LVZE IVT EZQ I XN
CGAATACTCTCCAATGATATAACTAATTTGCAACTGTCGAAAACTCCTCTAGCATTAAAATCATGGTTCAGAA
R I LS ND ITN L S T L S I K IMKVA
TGOACTATCACATTTATGTTCCTATOCOTATTTATCAGTGTTAACCGCACAGTOTTOCTAAAAATATTCAAGATT
W Y L S LC SGI L S S V N R T V L I F I
TTTGTATCGATCTGGAGGOTTTTCCACCACTTTTTTAAGTGGATCOAGTTATTGTCTACCATCAATTGCTAAGT
• C CI D L KV VF NH EFFrT• ENKa N I Va 1t V YT KaOLLs
OGATATAGAATCTCTGGAGGOOCATTGATGACATCVTT TATCTACCAAAATTOTTCTCACATTCATTATC
Figure 2. Map and sequence of the SRB8 gene. (A) Restriction map of a 6.0-kb DNA fragment from pSL311 containing the SRB8 gene.
The entire coding region of SRB8 was replaced with a 5.5-kb DNA fragment containing the URA3 and kanamycin genes flanked by
direct repeats of Salmonella hisG DNA to create the deletion allele srb8Ad ::URA3hisG. (B) Sequence of the SRB8 DNA and adijacent
DNA. The predicted 1226-amino-acid sequence of the SRB8 protein is shown below the sequence of the gene. Positive numbering of
the nucleotides begins with the predicted start site of translation. The SRB8-coding sequence is identical to ORF YCR81W (Oliver et
al. 1992).
All nine SRBs are components of an RNA
polymerase II holoenzyme
An RNA polymerase II holoenzyme has been purified
and shown to consist of RNA polymerase II, the general
transcription factors TFIIB, TFIIF, and TFHIH and the SRB
proteins SRB2, SRB4, SRB5, SRB6, SRBIO, and SRB11
(Thompson et al. 1993; Koleske and Young 1994; Liao et
al. 1995). We investigated whether SRB7, SRB8, and
SRB9 are also components of this holoenzyme. Rabbit
polyclonal antibodies were generated against recombi-
nant SRB7, SRB8, and SRB9. Column fractions from the
final purification step of the RNA polymerase II holoen-
zyme were tested in reconstituted transcription reac-
tions and subjected to Western blot analysis with anti-
sera specific to RNA polymerase II and SRB proteins (Fig.
4A). SRB7, SRB8, and SRB9 coeluted with the other SRB
proteins, RNA polymerase II, and transcriptional activ-
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GATTAGAATCTCTGGAGGCATTAATOACATCTTGCTATGCTACCAAAAATTGTTCTCACAATTCA??AATGAC
D I E S L E A L N D I L L C Y Q K L V S O F : K D
CATATm" ACAC AGACGWTTATAnTCATTTACAAAAAGTTGCA.- ATAAT
H ILF T K TF IFIT Y R V LEE K DV PAT N
GTGACTTCATTTATOCCATTCTOGOAATATTTTATAAAAACTTCCCCTTTTGTTTTAAAGOTO GAAcAT TA
VT Sr P Wxr K ••mxP K NV P V L K V D D L
AGGATTGAOTTACAATCTGTTTACAATGAAGAAAATTAAAACTOAGA CTA GAATGATAAA AAGTC
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AT O CATGTOT A TCAATAATTCAAACCAAM TGTTACAGACTTGATTTTCCCAG
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L K VY SMI NN S N QAVG 0 Q T N P 7F•Q
GTAAACATCAOOTTTCTACTACACAACTCCAOATCATTGATACAAATACAAGCAAACAGTTCCAZAAAGCACOA
V N I R F L L N N SE I O 0 T N T SK Q K F : A R
AACAATGTCATGCTTTTGATTGCCACTAACTTGAAOGGATACAATAAATTTATGTCCATTTICTC2AAAAGGAAA
M N V L LI A T N L KEY N N S I F L K R K
GACTTTACTAACAAAAATTTAATTCAATTGATCTCTCTAAAACTTCTAACTTTTGAAGTGACGCASAAQ'GTTG
D FT N K N L I 0 L I S L E L L T F R V T Z X V L
GGOCTCGAOTATTATTCGATTATTACCAATAAACTTOAAAATAATOACGGCTCATA ... -..... A
G OL Y I I L L P I V LEN ND O S Y O l L K
TATCATAAAGAACAATTCATAAAGTCAAATTTTOAGAAATTTTACTTACATGTTATGAATTAGAAAAAAATAT
yV K 0 F I K S N F K I L L T C Y • LK I ETY
CATGGCAACGAATGTGAAATAAATTATTATGAGATCCTATTGAAAATTTTAATAACTTATGG-TCA CAA
H NON C K I N Y KyZ ILL XI L IT V OGS S3 K
TTACTTGCAACATCTACAAAAATCATTATGTTGTTATTGAATGATACOGTGOAAAACTCATCTAA"A ---- G
L L AT STE I I K L L LN D S V E N9S SN. L
GATATTTTOTACTACTCAACTTGTCCOTCOGAAACCGATCTTAACOATATTCCATTGTAOTG ACCAGAC
DI L Y Y S T C P S ET DLUN D P LO S 3 P D
AATGACACTGTTGTAACCAACGATGATAAAAOTGACGTGATGATACACACAOTCOACGAAATTDGAT'AOA
N T V V T NODOKS DDDDN TV KD : S1E1V •
TATTACGTTATOATGAGCTTTGCCAATCTTTGGOTTTTCCAAGCGTTTACCTGTTTCTGCATCAA"AA TG
Y Y V V K0F A N LNW V F•Q A F T C V C I X X 1KE
GGAATAATGAOCCAGCAATGGCAATOGGAAGACTTOAAGAACTTCATATTCCAAATTATCOAAAAA-AATTCT
SN N EPA NAVEZ DL XK NVF I7QI1 E : TNXS
AATGATTTATGTTCACAAATATTTGACCAACTGAAGGAATOCAGACCATTGAGATGATAACCCAAADTOGAG
N D LC SO ?1 D Q L E DVO TIZ• N I T !: VZ
AAAGATTTCTGCACTTCTTOTTTOCAAAAC AACAACCAAAAATAATATAATTACATCGTT- .ATCGAG
E D F C T S C L Q SN NO KX IDD NT I V 7- - E
ATTATAACGTCATTATCGATGAGGTTTCAAAGAGAAACTTCTGGTATGATAGTTATTTCCATOGGAaA-ATCAT
l I T S L SN IXRF Q OK K VT SOG N IV ISV KI•1 9TER
TTACTAATAAAGATCATAAGACAATTAAGTGAACTGAACGAAGGAAATTTATCTAAGAGAGAAA•CAAATAGAT
L L I XK IIKRO L SEZ L NEZ G N L SK K KRZ:; -; ID
GCCGTCTTGAAAATTTTTAGCTTTCATCAGGATTCCATTTTCCAACOCATCATCGCTGATTTAVCA3IDATAAA
A V LEX I F•S? •FN OQD S I O Q R I I AOV L $3A D K
CCCACAAGTCCATTCATTCATGCAAGCTGTTTGATAAAATATCATTTAATTTAAGAT- -- C
P T S P I D S C ELrF DK IS N L R K L LF
TTGTACGAAATTTTGTCTTCATTGAAATCATTCGCCATCTATTCATCCACAATTGATGCCCCAGA-TC-
A
A
L Y E I L S L KS A I Y S S T I D A P A F T
AGCGGTAAGGTCGAACTACCGAAGAAATTGCTGAACTTACCACCATTCCAAGTOTCCTCTTTC -GAA3AACA
S GKXV KZ L P IKE L L N L P P • Q V 5S F • 7 I K T
AAACTTCATAGTGGCGACTACGGGGAGAAGAAGAATGCAGACCAAGAAGAATCGTTTAGTTTAAA"-
- --
A. TC
K L V S G D Y G O E E DA D E Q K S F S LN L GI
GGCATAGTTGOATACGCACGAAAACGAACAGAAATGGCTCATTTATGACAAGAAAGATCATAAA"AGTCTGC
G I VE I A HN EN Q K W L I T K K D T V C
ACATTTTCCATGOOACCTTACCACTTCATCTCCAACTATAATACCAAGTACACAGATGACATGGCA CGT
T S PY H F I S N Y N T K Y T 0 D M A 3S
AATOATACGACTGCGTTTAACGATTCCTGTOTAAACCTOAGTCTTTTTGATGCTCGOTTTGAOGAOGAAMTCCA
N D T T A F NO SC VS NL S LV F I•0 A E KE•X P
CATTGATCTCAGAATATATCCAAATGGATAAATTAAATTTACCAATAACAGTAATTATGTOTCA=-MTTAATA
H *
CCCAACCAATTGATTCCTCTAAATGATACCOTACCAAATGACATGTTTGCCACCCATTATAAAACT OAT
OAOGCGATOGGTTAAAoGATTAAGACAAADTOCTCATCCQCTTACAAGATCATACT TGTACCCTATT
TAAACTGGAATGATCACCCCAAAGGAAC OCACATTOT AAGTTTCAAT" AAATGACCTOA~CAAGAT
CTCGAT 3971
Activator binding to holoenzyme
-I sR5 8 3,
I I I I Ir I I
EcoF Spl EcoN ECOa EcoM Ba - Sadl Xh
0.5 kb
hisG URA3 Ka r hisG srtd 1::URA3hisG
0.5 Ikb
B
-147 GATCAAGTAGTGTAOTATTTA TTGTAGTACACTCTTACAACAACCCTTTAAGACGAATGGTTGAAATCGGAAAT
-72 TACTTTT TAATTCTA TA GTTTAAGCTGGATATCAAGATCTAGGAGOTATAT
K
4 AOTTCTACGCTTCCACGTACAAC CTTGAATGTTTTATCCAGCTTCTATAGAGTGGAGAAAATCAAAAGATC
S S D A S T Y R L E D V L S S F Y R V AE Z A K !
79 AACTATCATCAGTACATTTCTAAAGCCCAAAACGATCAATGGTCTATCCAAATGGAATTCATGCTACGSAAGCAG
N Y 80 Q Y I S K A N D 0 W S 1 Q M E F P L R K Q
154 GATCCAAAGACTCTAOGCGCTGCTSC TCAAGOSATTTATSGTGTTTCASTATAAATGATGATCCSSTACCSACA
D P T L VALL S R D L W C F I N D D P V P T
229 CCTCCTGCGATAGAACATAAACCAOTAGCCCAGATAAAATCGGAACTTTCACTGCCGATTATTCAAAGCCAAAC
P P A I• S X P V S P D T 1 G T F T A D Y S X P N
304 TTACCGCCACACTATCTCTTTTTTAAAAGCTT TAAGMAAGAAAATTTACATTAATTTOCATTAGTTCACAC
L P P YM A L F L K A AK R R I Y I N L A L 8 S
379 ATAAGCTAATACAATTTGGGAATGCCTOCATATCATTAAGCGGAGTGCCAAATTATCTCGTACACTAAACCA
N K L I F Q G N A C I S L S 0 V P N Y L V Q L E P
454 CACCTTTTTGTAAACGSAATCTCACAGTGTCGTTATSTGCCAASAACATSOATTASTACCAATSAGGAGGAA
HL FI V N D L V S L C A IEMN LVPMA Z E S
529 AATTTGGAAGAATCTTTCCTTTCAAAGCATGCGCTTTATAGCACCATCTGGAAAGGATOCATTTGGCCT
N L E E S F L S K A A L Y L A P S G I R M X L A P
604 GCTTCCAAGCAAGGATACTTGATAACGCCACCAAAACATACAGAACTTCTCTTGACGACGTTAAGTGTATCTCAT
A 8 X 0 YT L I T P PA S TE L L L T T L I V S H
679 OGGTATAAACTTACAAAATAAAAAAAATTTGAAATTGTTGCTGTTGTTCCTGACTTAGGACATCTCAACGGCCAC
G "r N 1 L N K N L X W V A V V P D L 0 L N G 0
754 ACACCTACTATAGCTTCGTATTTAACTCCCTTACTTGAACAAAAAGCTAGTATGCCGCTGCATTTAATCTTC
T P T I A S Y L T P L LE A K K L V W P L8 L •F
829 OCCCAACCAGTAGCTGATAGAAAAATTCTACTTCCGGATCCATCAGAATTTCACTGTTTCAAGATCTCTG
A Q P V A D I E N S T S G D P S E F H C L 0 D A L
904 OATOCCATTATGATTATCACAATAAA AACACTCCTATAMSACTCC AATTCCCTATTAOC
DA X OOrI QL 0 T A A Y R T P G S B SOIVLS
979 AGTAATATTGCTOGGTACAAATCCCTTAAGCTCAGATGAGCATATACAGAACAGTTTCAACATTATAAGAACAAC
8 N I A G T N P L S O8 D G A Y T E Q0 F E Y X N N
1054 TCAATTAOTTCTCAACCCOCTTCTTATCATTCTGTCCAAGAAACTAATAAGATATCTCCGAAAOTTTCTCCCCT
S I S S O P A 5 Y f S V Q E T N M I S P K D S 8 P
1129 AATTTCACAGGCATTGATAAATTAATOCTOTCGCCCAGCGATCAATTTOCTCCAGCTTTCTTAAATACCCCTAAT
N F T 0G D K L M 8 P S D 0 F A P A P L 9 T P N
1204 AATAACATCAATGAGAATGAATTATTTAATGATAGGAAACAAACTACAOTATCAAATGACTTAAAACACCCA
N N I N E N E L F N D R A Q T T V 8 N D M LE S S P
1279 CTOAAAACOTAACTGGAGGCAAATGTAGATCACTCGAAAGGTAAATAATTCCGTGAGCAAGACASGAASCGTA
L K T X L E A N G R S L E K V N N ES V A T 0 8 V
1354 GACACACTTCATATAAAGAGAAACTOGGMA ACMGAAACAGAACA G A ATCTCCAA TAAAA
D T L X N K E G T L E Q R E Q N E N L P B D X S D
1429 TCTATOGTAGACAAGGAATTGTTTGGTGAGGATGAGOATGAGOATTTATTTGGCGATAGCAATAAATCGAATTCT
S X V D Z E L F GI E D E D D L F G D S A N S N S
1504 ACAAACGAATCGAACAAAAOTATATCOGACGAAATTACCSAGOATATOTTCOAAATGTCTGATAA AAAT
T N B S N K S O D S E I T S D F EM Bm S D E 1 E N
1579 AATAATATACAAGOAAATOCATACTATCTTGTAAAGATATTCCATTTTTTCCC
N N A SI S N EX N N lE S X 8 T D L G K D I P Fl P
1654 TCATCTSAAAAACCGAATATCCGTACSATA GSC ATACAnaATTAAATOA AAATATTTOGAT
SS K PN IRA TM S3 T T R L O ERA KYILD
1729 ATTCCGATAGATOAAATGACCTTOCCAACGAGTCCATTATATATOACCCAGOTOCSCCACTCCCTSTGGAAACA
I P DEM T L PT S PLY MD P GAP L PV T
1804 CCCCGCGATAGACGCAAAAGTGOTTTCOCTCCACTGAATTTTAACCCCATAATAGAAAACAATOTTSATAACAAA
P RD RR S V 7 A P L N I NP IXI EN NVD
____
L-1
4654 AAGTTCTCTTGATTAGCAAGTAGTTCTTACATCGCAGOAATCTTATOTT 4702
Figure 3. Map and sequence of the SRB9 gene. (A) Restriction map of a 7.3-kb DNA fragment from pCH47 containing the SRB9 gene.
Most of the coding region of SRB9 was replaced with a 5.5-kb DNA fragment containing the URA3 and kanamycin genes flanked by
direct repeats of Salmonella hisG DNA to create the deletion allele srb9Al::URA3hisG. (B) Sequence of the SRB9 DNA and adjacent
DNA. The predicted 1420-amino-acid sequence of the SRB9 protein is shown below the sequence of the gene. Positive numbering of
the nucleotides begins with the predicted start site of translation. A sequence encoding a polyglutamine repeat, a motif found in several
transcription factors (e.g., Spl, dTAF,110, OCT2), is underlined (Clerc et al. 1988; Courey and Tjian 1988; Hoey et al. 1993).
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TACAAATCTGASGGGAAATTTTCCTTCAGTCCGTTSCAAAAGGAGGAACCATTAAACTTTGATATTTCTATGGCO
Y I S B O O F S F S P 1 0 x E E A L N F D I S H A
GATCTTTCTAGCTCT0,AAGAGGAASAGATGOAAG G ACGOTAGCAGCGATGA'GATCTAAAGTCATTGAAC
GTACGCGACCACATOAAACCTTCTOATAACATCAGTACTATACTAATATTCA-SAGCCTCAATACATAAATTAC
SV R D DS A P S 0D I S ST T N I S P F0 T I N T
TCTTCCATCCCAAOTCTACAAGACTCTATTATAAACcAAAAAATTTCAATTCAGTAAACGATCTAATATCACT
S S I PSL0D I8 1K 0Q SNF N S7NDA N IT
AGCAATAAGGAAGGCTTCAACTCTATTTGGAAAATTCCTCAAAATGATATACCACAACCGAGTCACCACTGAAG
S 1 K E G • N 1S W K I P 0 N D I P Z T E S P L K
ACCOTTGATTCATCTATTCAACCCATAGAATCCAATATATAATGaACCTTGAAGATAATAATGTTACCAGTAAT
T V D S S P1 FI ZR OS N! IRKET L 515Z N N V T S N
CCOTCCGAAT'TTACGCCGAATATOGTAAATTCTGAAATTTCTAACCTACCAAAGGACAAGAGTGGTATCCCGAA
PS F T P N M V N S I S N L P S IP
TTCACACCGGCGGACCCCAATTTATCTTTTGAATCATCAAGTAGTCTACCGTTSICA"AGAGACACATGCCGCTA
F T P A D P N L S F E S S S S L P F L L R H M P L
GCATCTATACCGGACATTTTCATCACGCCTACTCCCGTTGTTACAATTTCAGAAAAAGAACAAGACATCTTAGAT
A SIP DI FI T P T P V VT I Q D L
TTAAMTTCAGAACAAGTCGTCACTGATTATAATATCTTAGGAAACCTCOSTAT MCA AGATCSCCTATAGO
L I A £0 V V T D Y N I L G N L G I P X I AI R G
GTTAAAGATTGCCAAGAAGGTTTAATAACAACCACAATOTTACAGTTATTTTCCACmTCGGATAGATTAAATGGC
V K D C 0 G L T TT L S L F 7F D R L NG
AATGATACGATCTCCAAATTCTATAACATGAAGCAGCCGTACGTTTTTGTAAAGAAACATCACGAACTAATCAAA
N D T I S F Y N N Q P Y V V K Ka a ELI X
GTCAAACACGACTCTCAGCCATTTATTAAGTTCCTCAATTTTCGCCCTCCAAATGGATAAAAAACTTCAAATCC
V K I D S Q P F IX F LN FR P PM 3 I X N F KS
TTATTATTAAGTTCATCTTTCAAAGAAGATTGTCTGTCATTTGCGCCAACTCTATC'rAAACATATATTAATCAA
L LL S S S OFAS DCLS FA P 1T BS TY IN 0
GAGTTAGGGTTTTGTGAGTTGCTTAAACTAACTAATGAAGACCCGCCCGGACTGAT"TACTTGAAGOCATTTGAT
SL F C E L L L T NE DP P L X Y L KA D
AAAAACAAGTTACTGGTTAGCTGCCAGATTGTTTCATACTGTTCTAATAATAAGAACTCCATCAAAAACGOT
A S LLL L L A A IVS C S N N K N NV
CCACCAATATTAATAATTTTACCCTTOGATAATCAACTCAC G ATTAGTAGACAAGGCGAATATTTTTCAG
PP ILII P L D N A T T L V DKANX F O
GTGATCAAGAACGAAGTTTGTOCAAGATGCCTAACATTGAACTATATTTGAAAGTATTCCTATGGATTTCATT
V I K N E V CA MP N I L Y L V Z P D I
AGAAACGTACTGGTGACAGTGGATCAGTACOTCAACGTAGCAATTTCTATATATAACATCTGCCGCCAAAATCT
R N V L V T V D YV NV A I S IY It M L PP KS
GTAAAGTTCACCCACATTGCGCATACGCTGCCGGAGAAAGTGAATTTCAGAACCATOCAGCAGCAAATGCAA
V FK TH I A H T L P E V N F R T X 0 QQ MQ
CAGCACAACCAACAGCAACAGCASCAGCAATAACAGTACAGGATCATCTTCTATAATATATTATGACTCGTAC
Q 0 0 Q 0 0 0 Q QQ N N S T G S S S : Z Y Y D 8 Y
ATCCACCTGOCAGACTCCTAGTTATA AArT TTTTTCAGCTCTTTCATAGCTATACAAO
IT L AY S R S V D E W Y FAA LS D S Y G 0 G
AGCATGACGAAAACGTGGTACGTCGGGAATTCCAGAGGAAAATTTGACGACGCATGTAATCAAATATGGAATATC
S N T T W Y V G NS R GK F D D C N NI
GCCCTAAATTTAGOCTCTAAAAAATTCGGAAMATATGTCTAATTTTAACTAGAT7*AATGGCATACTGCC"AT
A L N L A S G I CL I L TR G IL P D
GATGAATTGAATGAATTGAGAG ACTTTCTGGTAGGAATATACATCTTGCTGTGGT,..GGTGGATGACAACTCT
D E L M N W R R LS G RN I L AV VCV D D N S
AAAATCTCCTTCATAGATGAWGACAAATTGTACCCTAGTTTCAAGCCGATCTACAAAGACACTAGOTTTGGGGA
X IS F D03ZD0 L Y P S F APVI IA D TAR F SOG
CGCATGGATATGACCAGATTATACGACTATAAATATAGGGATATAGACCAGGACATCCATGGAATAGTATTTCAG
R D M T R L Y D Y IR DID 0 DI G V F 0
CACCCSTTCCCACTGGCACACTCACCACATCGCTTSCTATTA TOCT TGATCAAATTCAAAAAATSC
RPFF PLKA S Q O R C AIR SoA LI:K FAR C
GACGGTGATACGGTTTGGGACAAATTCGCAOTCAACCTTTTAAACTOTCCACATTCTSATAGTACACAATTGCTO
DOG D T V W D FA V N L NC P S 0 S T LL
GAAACCATCTTAGAGAGTTCGCAACCTCTCTCTAACGTTGOTACMTTC-CC - CGA TOC
S T I L F R NL A A L NV W YGLSDGE OD
CATATTCCATAGCATATCCTAGCCGTGAAAAAAATATGAACACTCTTGTGCACACCAGAOTAAAAATTOCTAAT
H I P W H I L A V KX N N T L V H TRVK I AN
ACTTCCGCCSCTACTGTSCATACCSCTACTTCTTCATCAATTATTCTCTCGGATAAATAAACTTTTTCCGGCAAC
T S A A TIV B TAT SBS S I9 L S D
GTTTTCCTGCTCATCTTACCCTATTTACCATTTTGTTTTAGTATTATTCCGGG ACCCATTTT TTTAAGTCT
ATTTCTCCAGTCGGATTTATAAAAACAhAACCGOAAGCGGGGCO OTACGGCATTTTCACTGTGATGCACGCCCA
rCOTGTASTCCSAGACAATTTCCACAG CAACCRTGATTO CTTTAASGCTSTAT TTCAAGGCACA G
CGGCCACOTGGGTCTGCGATGOTGTGTTOATCATGTCAAGAATGGTATCATACTCCGTATAAGOTTATGTAATCG
GAAGTCGCGATTC TTTATTCAATT TTTTTTCT C TC TTTCTCTC TAAAATTGTTG
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Figure 4. All SRBs are components of an
RNA polymerase II holoenzyme. (A) RNA
polymerase II holoenzyme was purified as
described (Koleske and Young 1994). Ho-
loenzyme loaded onto a Mono S column,
the last chromatographic step in the purifi-
cation procedure, was eluted with a 0.1-1.0
M gradient of potassium acetate. The onput
(OP) and flowthrough (FT) and a portion of
every other fraction eluting between 0.1
and 0.9 M potassium acetate were analyzed
for holoenzyme activity (top). These sam-
ples were also analyzed by Western blot for
the presence of RNA polymerase II and SRB
proteins. The Western blot for SRB11 was
done with an RNA polymerase II holoen-
zyme purified independently from cells
with an epitope-tagged SRB11 protein; the
purification and transcriptional properties
of this holoenzyme were identical to the
holoenzyme lacking the epitope tag (Liao et
al. 1995). (B) Polypeptide composition of
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RNA polymerase II holoenzyme. One microgram of purified holoenzyme was subjected to SDS-PAGE and stained with silver. Proteins
in the holoenzyme preparation that correspond in size to subunits of RNA polymerase II, SRB proteins, and general transcription
factors are indicated. The numbers used for the subunits of transcription factors TFIIF and TFIIH are from previous reports (Henry et
al. 1992; Feaver et al. 1993). The sizes of protein molecular mass standards are indicated in kD. This and Figs. 5-8 were prepared from
digital replicas of primary data scanned using a UMAX UC840 Max Vision digital scanner.
ity. Thus, all nine SRB genes identified through our ge-
netic selection encode components of the RNA polymer-
ase II holoenzyme.
The most highly purified RNA polymerase II holoen-
zyme preparation was subjected to SDS-PAGE and silver
stained (Fig. 4B). The SRB proteins were assigned to pro-
tein bands based on Western blot analysis. RNA poly-
merase II and general transcription factor subunits were
assigned to protein bands based on their mobility and, in
some cases, on Western blot analysis. From this analysis,
many of the known components of the holoenzyme can
be accounted for, although a number of polypeptides re-
main unidentified. Some of these components may be
encoded by genes that have been identified through other
genetic screens (Fassler et al. 1991; Berger et al. 1992;
Amakasu et al. 1993; Pina et al. 1993).
SRB proteins are components of the mediator
of activation
A subcomplex of RNA polymerase II, named the medi-
ator of activation, can be dissociated from a preparation
of RNA polymerase II holoenzyme using anti-CTD
monoclonal antibodies (Kim et al. 1994). Purified medi-
ator contains SRB2, SRB4, SRB5, SRB6, SUG1, GAL11,
the general transcription factor TFIIF, and as yet uniden-
tified subunits (Kim et al. 1994). Because all nine SRB
proteins are components of the holoenzyme, and genetic
analysis suggests that the SRB proteins are involved in a
similar process in transcription, we investigated whether
SRB7, SRB8, SRB9, and SRB10 are also part of a mediator
preparation.
The mediator of activation was purified from commer-
cial baker's yeast as described (Kim et al. 1994). The
chromatographic behavior, yield and transcriptional ac-
tivities of the mediator preparation were similar to those
reported. Figure 5 shows the results of transcription and
Western blot analysis of fractions from the last chro-
matographic step in the purification. Fractions contain-
ing the mediator stimulated increases in basal and in
activated transcription, as described previously (Kim et
al. 1994). Western blot analysis with specific antisera
against SRB proteins showed that SRB2, SRB4, SRB5,
SRB6, SRB7, SRB8, SRB9, and SRB10 proteins all co-
eluted with the mediator activity. Our lack of anti-
SRB11 antibodies prevented us from assaying the pres-
ence of SRB 11 in the mediator, but evidence that SRB 11
is a component of the holoenzyme and binds directly
to SRB10 (Liao et al. 1995) argues that SRB11 is also a
component of the mediator. Thus, all nine of the SRB
proteins, together with SUG1, GALl 1 and TFIIF, can be
dissociated as a complex from the RNA polymerase II
holoenzyme to produce the mediator of activation.
Acidic activator VP16 coimmunoprecipitates
with RNA polymerase II holoenzyme
Two observations suggest that some acidic activators
may contact the RNA polymerase II holoenzyme di-
rectly. Both forms of RNA polymerase II holoenzyme
described thus far are able to respond to activators in
reconstituted in vitro transcription systems (Kim et al.
1994; Koleske and Young 1994). One form of RNA poly-
merase II holoenzyme contains TFIIB and TFIIH, two
factors that have been shown to interact with the VP16
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tated from a crude yeast protein preparation supple-
mented with recombinant glutathione S-transferase
(GST)-VP16 or GST-VPl6 4s56FP442 using affinity-puri-
fied anti-SRB5 polyclonal antibodies. Western blot anal-
ysis of the input, supernatant, wash, and pellet show that
the pellet contains components of the RNA polymerase
II holoenzyme, including the polymerase II subunit
RPB1, SRB proteins, and TFIIB (Fig. 6, IP 1 and IP 2). A
polyclonal control antibody directed against a human
transformation growth factor-P (TGF3) receptor did not
immunoprecipitate any RNA polymerase II holoenzyme
components (Fig. 6, IP 3). TBP, which is not a component
of purified holoenzymes, could not be detected in any of
the pellets, arguing against nonspecific aggregation of
proteins in the immunoprecipitation (Fig. 6, IP 1 and IP
2 pellets). As an additional control, SSA1, a yeast HSP70
protein, also fails to be immunoprecipitated. Thus, ho-
loenzyme components are specifically coprecipitated
with SRB5 from crude yeast proteins under these con-
ditions. The results also show that GST-VP16 is co-
precipitated with the holoenzyme, whereas GST-
VP16a 456FP442 is not.(Fig. 6, IP 1 and IP 2 pellets). We
IP 1 IP 2 IP3
ac-SRB5 ca-SRB5 ax-TGFi-RII Antibody
VP16 VP1 6A456FP442 VP16 GST-fusion
Figure 5. SRBs are components of the mediator of activation.
(A) In vitro transcription templates. (B) A mediator preparation
was loaded onto a MonoQ column, the last column in the pu-
rification procedure, and eluted with a 0.4-0.8 M gradient of
potassium acetate. Mediator activity peaked in fraction 25 (top).
This and nearby fractions were analyzed by Western blot for the
presence of SRB proteins.
activation domain (Lin et al. 1991; Goodrich et al. 1993;
Xiao et al. 1994). To investigate whether the holoenzyme
can bind to the acidic activation domain of the activator
VP16, we immunoprecipitated the RNA polymerase II
holoenzyme from a crude yeast protein preparation in
the presence of wild-type and mutant VP16 activator
proteins. The HSV trans-activator VP16 has been char-
acterized extensively, and analysis of VP16 mutants
suggests the presence of two activation subdomains
within the highly acidic carboxy-terminal 78 amino ac-
ids (Triezenberg et al. 1988; Regier et al. 1993). The
VP 1 6 A456FP442 mutant is defective in transcriptional ac-
tivation; one subdomain of transcriptional activation is
deleted (amino acids 457-490), and the second subdo-
main (amino acids 413-456) contains a single amino acid
substitution abolishing residual transcriptional activa-
tion activity (Phe-442 to Pro-442) (Cress and Triezenberg
1991; Regier et al. 1993).
RNA polymerase II holoenzyme was immunoprecipi-
g't, to 0l 1 4u 44
so aas* e ,ga
rl, - r ý UM-
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Figure 6. Coimmunoprecipitation of the VP16 activator with
the RNA polymerase II holoenzyme. IP 1, IP 2, and IP 3 repre-
sent three separate immunoprecipitation experiments. A yeast
whole cell extract was subjected to an ammonium sulfate cut
and fractionated by step elution from Bio-Rex 70 and DEAE-
Sephacel (Materials and methods); immunoprecipitations were
carried out with anti-SRB5 antibodies (IP 1 and IP 2), or a control
antibody, anti-hTGF3-RII (IP 3). Recombinant GST-VP16 was
added to the input of IP 1 and IP 3, whereas recombinant GST-
VP16 A456FP44 2 was added to the input of IP 2. Vso of the input (I)
and supernatant (S), and /s of the last wash (W) and pellet (P)
were subjected to SDS-PAGE and analyzed by Western blot us-
ing specific antibodies.
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estimate that the concentration of VP16 proteins was
similar to that of holoenzyme components in the crude
yeast protein preparation and that the ratio of GST-VP16
to holoenzyme molecules in the immunoprecipitate was
approximately 1:10.
A VP16 column selectively retains the RNA
polymerase II holoenzyme together with TBP
To confirm that the holoenzyme interacts specifically
with GST-VP16, the same crude protein preparation
used in the immunoprecipitation experiments was
passed over GST-VP16 or GST-VP16 A45 6FP 442 columns.
The columns were washed extensively and GST-fusion
and associated proteins were eluted with glutathione.
Components of the RNA polymerase II holoenzyme
bound to GST-VP16 but not to GST-VP16 a4 seFP 442 (Fig.
7). Consistent with previous reports, TBP also bound
specifically to the GST-VP16 (Stringer et al. 1990; Ingles
et al. 1991). SSA1 protein did not bind to either column,
arguing against nonspecific protein aggregation on the
GST-VP16 column. Thus, both immunoprecipitation
experiments and column chromatography support the
conclusion that the RNA polymerase II holoenzyme in-
teracts with the activation domain of VP16.
A VP16 column retains the mediator of activation
We investigated whether the mediator subcomplex in-
teracts with VP16 and, if so, whether the interaction
involves both VP16 activation subdomains. A mediator
preparation was passed over columns containing GST-
VP16, GST-VP164 456, or GST-VP16A456FP 44 2. The col-
umns were washed extensively and GST-fusion and as-
GST-VP16 GST-VP1 6 456FP442 Column type
- -
RPB1
SRB2
SRB4
SRB5
SRB7
SRB10
TFIIB
30
00
0 JV NMPa
..- TBP
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Figure 7. RNA polymerase II holoenzyme and TBP bind a
VP16 activator column. The DEAE-Sephacel fraction described
in Fig. 6 was loaded onto GST-VP16 and GST-VP16 se 6aP4 4 2
glutathione-agarose columns. After washing, the columns were
eluted with glutathione.1/2oo of the load (L) and the flowthrough
(FT), and 'Ao of the last wash (W) and the eluate (E) were sub-
jected to SDS-PAGE and analyzed by Western blot.
A
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Figure 8. Mediator of activation binds to VP16 activator col-
umn. (A) Mediator of activation (peak fractions from heparin
column) was loaded onto GST-VP16, GST-VPa456, and GST-
VP16A456FP442 glutathione-agarose columns. After washing, the
columns were eluted with glutathione. Viso of the load (L) and
the flowthrough (FT), and V6o of the last wash (W) and the eluate
(E) were subjected to SDS-PAGE and analyzed by Western blot.
(B) Mediator of activation is depleted for RNA polymerase II.
Mediator of activation (peak fractions from heparin column)
and pure RNA polymerase 1I holoenzyme (Koleske and Young
1994) were analyzed by Western blot for the presence of the
largest subunit of RNA polymerase II (RPBl) and for SRB2 and
SRB7 proteins. The lanes contained 0.8 and 0.32 ýLg of RNA
polymerase II holoenzyme, and 2.5 and 1 ig of mediator of
activation, respectively.
sociated proteins were eluted with glutathione. The on-
put, flowthrough, wash, and eluate fractions from the
three columns were subjected to Western blot analysis
(Fig. 8A). Components of the mediator were bound most
effectively by GST-VP16. In contrast, there was limited
binding of the mediator to GST-VP16A4 56 and no appar-
ent binding to GST-VP16A456FP442 . Figure 8B shows that
the mediator preparation lacks RPB1, confirming that it
contains little or no contaminating holoenzyme. These
results indicate that the VP16 activator binds to the me-
diator. Furthermore, both of the activation subdomains
of VP16 contribute to maximal binding of the mediator.
Discussion
The genetic and biochemical analyses reported here pro-
vide a more complete description of the RNA polymer-
ase II holoenzyme. The products of all nine SRB genes
described thus far are components of the holoenzyme.
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Activator binding to holoenzyme
All nine SRB proteins can be dissociated from the ho-
loenzyme in a subcomplex that functions in basal and
activated transcription and has been termed the media-
tor of activation. The ability of holoenzymes to respond
to activators suggests a model in which the holoenzyme
is recruited to the initiation complex through direct in-
teractions with activator proteins. We find that the VP16
activator can bind to the holoenzyme. Because VP16 can
bind the mediator, this subcomplex is among the com-
ponents of the holoenzyme that interact with VP16.
SRB components and the RNA polymerase II
holoenzyme
The nine SRB genes were identified through a selection
for genes whose products are involved in RNA polymer-
ase II transcription in vivo. Suppressing alleles of the
SRB genes were isolated by their ability to suppress the
cold-sensitive phenotype of yeast cells that contain RNA
polymerase II molecules with truncated CTDs. The iso-
lation of the SRB2, SRB4, SRB5, and SRB6 genes and the
biochemical analysis of their protein products originally
led to the discovery of the RNA polymerase II holoen-
zyme (Koleske and Young 1994). Two additional SRB
genes, SRB10O and SRB11, were described recently; they
encode kinase and cyclin-like polypeptides that are
tightly associated with the holoenzyme and appear to
have roles in CTD phosphorylation (Liao et al. 1995).
Analysis of all 75 independent suppressor isolates ob-
tained in the genetic selection has led to the identifica-
tion and characterization of three additional SRB genes.
We have summarized the data for the nine SRB genes
and proteins in Table 1.
Biochemical studies have shown that all nine SRB pro-
teins are integral components of the RNA polymerase II
holoenzyme. The SRB proteins copurify with RNA poly-
merase II, TFIIB, TFIIF, and TFIIH in conventional chro-
matography (Fig. 4A; Koleske and Young 1994). All SRB
proteins tested (SRB2, SRB4, SRB5, SRB6, SRB7, SRB10,
and SRB11) and other components of the holoenzyme
have been shown to coimmunoprecipitate with SRB5
(Fig. 6A; Koleske and Young 1994; Liao et al. 1995). Fur-
thermore, when we purify for any of these SRB proteins,
all of the SRB protein detected by Western analysis copu-
rifies with the holoenzyme (Koleske and Young 1994;
Liao et al. 1995; C.J. Hengartner and A.J. Koleske, un-
publ.).
A model depicting the RNA polymerase II holoenzyme
is shown in Figure 9. This complex consists of RNA
polymerase II, the general transcription factors TFIIB and
TFIIH, and the mediator of activation. The mediator of
activation contains the nine SRB proteins, TFIIF,
GALll, and SUG1 (Fig. 5; Kim et al. 1994). In cell ly-
sates, the SRB proteins are only found tightly associated
with the holoenzyme; the SRB-containing mediator of
activation can be dissociated from the holoenzyme by
anti-CTD monoclonal antibodies, indicating that the in-
teraction of these antibodies with the RNA polymerase
II CTD disrupts interactions between the CTD and the
mediator subcomplex.
RNA Pol II Holoenzyme
Figure 9. Model for interactions among activators, TFIID, and
the RNA polymerase II holoenzyme.
Several lines of evidence suggest that the RNA poly-
merase II holoenzyme is the form of the enzyme in-
volved in transcription initiation in vivo. Genetic anal-
ysis has indicated that the CTD and SRB gene products
have roles in transcription initiation and are essential for
normal yeast cell growth. Using temperature-sensitive
mutants, we have found that SRB4 and SRB6 are neces-
sary for transcription of most, if not all, genes tran-
scribed by RNA polymerase II in vivo (Thompson and
Young 1995). Because the vast majority of SRB protein in
cell extracts is tightly associated with the RNA polymer-
ase II holoenzyme, these results suggest that the holoen-
zyme is employed at most polymerase II promoters in
vivo.
What roles do the SRB proteins have in the holoen-
zyme? Some of the SRB proteins are likely to contribute
to interactions between RNA polymerase II and general
transcription factors. For instance, SRB2 and SRB5 are
essential for transcription in unfractionated in vitro sys-
tems, where they have roles in stable preinitiation com-
plex formation (Koleske et al. 1992; Thompson et al.
1993). Both SRB2 and SRB5 can bind to TBP in vitro
(Koleske et al. 1992; Thompson et al. 1993), raising the
possibility that they contribute to the stability of ho-
loenzyme-TBP interactions at the promoter. The medi-
ator subcomplex appears to act as a contact point for at
least some transcriptional regulatory proteins, and these
regulators may bind directly to specific SRB proteins.
The SRB-containing subcomplex may also function as a
signal processor in the response to transcriptional regu-
lators. SRB10 and SRB11 form a cyclin-dependent kinase
that has a role in CTD phosphorylation (Liao et al. 1995).
The role of CTD phosphorylation in transcription is not
yet clear, but it may serve to disrupt interactions be-
tween RNA polymerase II and general factors, which
may be necessary for promoter clearance.
Initiation complex formation with the holoenzyme
The identification of a yeast RNA polymerase II holoen-
zyme suggests a model for initiation complex formation
Hengartner et al.
in which the holoenzyme is the form of RNA polymer-
ase recruited to promoters. Activators are believed to
influence the rate of transcription of an adjacent gene in
part by interacting with components of the initiation
apparatus and affecting stable initiation complex forma-
tion. Figure 9 depicts a model that posits interactions
between activators and TFIID and between activators
and components of the holoenzyme. These interactions
could occur sequentially or simultaneously.
The portion of the model that depicts interactions be-
tween activators and TFIID has been proposed by others
and is supported by several lines of evidence. Activator
proteins can stimulate transcription in vitro in reactions
directed by the TFIID multisubunit complex, but they do
not stimulate transcription reactions directed by recom-
binant TBP alone (Pugh and Tjian 1990). Reconstitution
of activated transcription in vitro can be accomplished
by reconstituting TFIID using recombinant TBP and
TBP-associated factors (TAFs) (Dynlacht et al. 1991;
Tanese et al. 1991; Zhou et al. 1992; Chen et al. 1994).
These and other results support the idea that activators
interact with the TAF subunits of TFIID. A recent report,
however, indicates that TFIID may not be sufficient to
confer a response to an acidic activator in vitro in highly
purified systems (Kretschmar et al. 1994). It is possible
that TFIID is necessary but not sufficient for a response
to some activators.
The portion of the model in Figure 9 that depicts in-
teractions between activators and the RNA polymerase
II holoenzyme is supported by the following lines of ev-
idence. The RNA polymerase II holoenzyme contains
components necessary and sufficient for responding to
transcriptional activators in a reconstituted system, ap-
parently in the absence of TAFs (Kim et al. 1994; Koleske
and Young 1994). Genetic evidence suggests that GAL11
and SUG1, two components of the mediator, may inter-
act with certain activators (Nishizawa et al. 1990; Swaf-
field et al. 1992). We have shown that VP16 can bind to
the mediator subcomplex of the holoenzyme. Thus, the
activator VP16 has been shown to interact in vitro with
three components of the RNA polymerase II holoen-
zyme: the mediator subcomplex, TFIIB (Lin et al. 1991;
Goodrich et al. 1993) and TFIIH (Xiao et al. 1994).
The complexity of the transcription initiation com-
plex suggests that there are numerous molecular mech-
anisms involved in transcriptional regulation. Precise
identification of the interactions that regulatory proteins
have with components of the holoenzyme should lead to
a better understanding of the mechanisms that regulate
transcription initiation.
Material and methods
Genetic manipulations
Yeast strains and plasmids are listed in Tables 2 and 3, respec-
tively. Details of strain and plasmid constructions are available
upon request. Yeast medium was prepared as described iThomp-
son et al. 1993). Yeast transformations were done using a lith-
ium acetate procedure (Schiestl and Gietz 1989). Plasmid shuf-
fle techniques were performed as described (Boeke et al. 1987)
using 5-fluoro-orotic acid (5-FOA) as a selective agent against
URA3 plasmids. Plasmids were recovered from yeast as de-
scribed by Hoffman and Winston (1987).
Extragenic suppressors of the cold-sensitive phenotype of
Z551 were isolated as described previously (Nonet and Young
1989; Thompson et al. 1993). Dominant and recessive suppres-
sors were identified by mating to Z26 (Thompson et al. 1993),
selecting against the presence of pRP112 (Nonet et al. 1987)
using 5-FOA and assaying growth at 12*C on YEPD. Diploids
able to grow at 12°C contained a dominant suppressor. Diploids
unable to grow at 12°C contained a recessive suppressor.
Yeast strains of the opposite mating type of approximately
half of the dominant suppressors and half of the recessive sup-
pressors were generated by inducing a mating type switch by
expression of the HO gene placed on a plasmid under the con-
trol of a galactose-inducible promoter. Random spore analysis of
the dominantly suppressing mutations was used to determine
whether two independent isolates were likely to contain muta-
tions in the same gene. Haploids were mated to each other, each
containing the CTD truncation mutation rpblA104 and an in-
dependently isolated SRB mutation, to form diploids. These dip-
loids were sporulated on plates, and a small quantity of spores
was scraped off and shaken overnight at 300C in 0.5 ml of 30 mM
13-mercaptoethanol and 100 ng/ml of Zymolase 100 T (ICN).
Added were 0.5 ml of 1.5% NP-40 and 0.4 gram of glass beads,
and the mixture was incubated on ice for 15 min. The suspen-
sion was then vortexed for 3 min, incubated on ice for 5 min,
vortexed for 2 min, and the glass beads were allowed to settle for
10 min at room temperature. The supernatant was removed and
spun for 2 min, and the pellet was washed once in water, and
resuspended in water and a portion plated onto YEPD. Approx-
imately 50 of the haploid offsprings were assayed for their abil-
ity to grow at 12°C. If all haploids were able to grow at 12*C,
then the two SRB isolates were assumed to contain mutations
Table 2. Yeast strains
Strain Alias Genotype
Z694 S242 MATa ura3-52 his3,200 leu2-3,112 rpbl l 87::HIS3 srb7-1 [pC6 (LE U2 rpbl Al 04)]
Z695 S358 MATa ura3-52 his31200 leu2-3,112 rpb1Al87::HIS3 srb8-1 (pC6 (LEU2 rpbl1l04)]
Z696 S363 MATa ura3-52 his3A200 leu2-3,112 rpbl 187::HIS3 srb9-1 [pC6 (LEU2 rpbl.104)]
Z697 CHY102 MATa/MA Ta ura3-52/ura3-52 his3A200/his3A200 leu2-3,112/leu2-3,112 srb7Al:: URA3hisG/SRB7
Z698 SLY35 MATa/MATa ura3-52/ura3-52 his3A200/his3A200 leu2-3,112/leu2-3,112 srb8A1::URA3hisG/SRB8
Z699 CHY105 MATaIMATTa ura3-52/ura3-52 his3A200/his3A200 leu2-3,112/leu2-3,112 srb9dl::URA3hisGISRB9
Z700 SLY61 MATa ura3-52 his3.200 leu2-3,112 rpblAI87::HIS3 srb8Al::hisG [pRP114 (LEU2 RPB1)]
Z701 SLY76 MATa ura3-52 his3A200 leu2-3,112 rpblA187::HIS3 srb8dl::hisG [pC6 (LEU2 rpblA 04))
Z702 CHY113 MATa ura3-52 his3A200 leu2-3,112 rpbld187::HIS3 srb9Al::hisG [pRP114 (LEU2 RPB1)]
Z703 CHY116 MATa ura3-52 his3i200 leu2-3,112 rpbld187::HIS3 srb9dl::hisG [pC6U (URA3 rpbl Al04)
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Table 3. Plasmids
Plasmid Description
SRB7
pCH2 SRB7 (6.7 kb) URA3 CEN
pCH7 SRB7 (2.0 kb) URA3 CEN
pCH36 srb7-1 URA3 CEN
pCH34 SRB7 in pET-3a (Studier and Moffat 1986)
pCH46 srb7A:: URA3hisG in pSP72 (Promega)
SRB8
pSL301 SRB8 (9.0 kb) URA3 CEN
pSL311 SRB8 (6.0 kb) URA3 CEN
pSL307 SRB8 (encoding amino acids 868-1226) in
pET-3a (Studier and Moffat 1986)
pSL315 srb8AI::URA3hisG in pBSIISK
(+) (Stratagene)
pSL316 srb8-1 URA3 CEN
SRB9
pCH47 SRB9 (7.3 kb) URA3 CEN
pCH64 SRB9 (encoding amino acids 45-501) in
pGEX-1 (Smith and Johnson 1988)
pCH66 srb9A:: URA3hisG in pSP72 (Promega)
pJZ995 srb9-1 URA3 CEN
in the same gene. Genetic complementation of the recessive
alleles involved mating haploids to each other, each containing
the CTD truncation mutation rpblAl04 and an independently
isolated srb mutation, to form diploids and assess the ability of
these diploids to grow at 12*C. Diploids able to grow at 12*C
were assumed to contain srb mutations in the same gene. Ge-
nomic clones of each complementation group were used to con-
firm the identity of each member of the complementation group
and to identify additional members. Cells containing the CTD
truncation mutation rpblAl04 and a recessive srb allele were
unable to grow at 12'C and on pyruvate media when trans-
formed with the corresponding wild-type SRB allele.
Deletions of SRB7, SRB8, and SRB9 were created by a single-
step disruption method (Rothstein 1991). Z558 was transformed
with the desired DNA fragment and plated on SC - Ura media
(Thompson et al. 1993). Southern analysis was used to confirm
that a single copy of the desired SRB gene had been deleted. The
diploid was sporulated and tetrads dissected (>20) on YEPD
plates and scored for nutritional auxotrophies and growth at a
variety of temperatures. Z697 was created by transformation
with the srb7Al::URA3hisG fragment from pCH46. Two spores
from each tetrad were viable and these spores were uracil aux-
otrophs, indicating that SRB7 is essential. Z698 was created by
transformation with the srb8Al::URA3hisG fragment from
pSL315 and Z699 was created by transformation with the
srb9Al::URA3hisG fragment from pCH66. In each case, seg-
regants scored 2:2 for uracil prototrophy and all uracil prototro-
phs exhibited mild cold-sensitive, temperature-sensitive, and
slow-growth phenotypes, indicating that SRB8 and SRB9 dele-
tion strains are conditionally viable. srb8Al and srb9al strains
are also flocculent as are the suppressing isolates of SRB8 and
SRB9. Strains containing unmarked deletions of SRB8 and SRB9
were created by selecting for the excision of the URA3 gene by
growth on 5-FOA (Alani et al. 1987).
DNA methods
DNA manipulations were performed according to Sambrook et
al. (1989). Site-directed mutagenesis was performed as described
in Kunkel et al. (1987). PCR amplifications to produce pCH45
(srb71), pSL315 (srb841), and pSL307 (SRB8 in pET-3a) were
performed with Taq DNA polymerase (Perkin-Elmer) in 100 p.l
of buffer (provided by the manufacturer) supplemented with 200
mM dNTP for a total of 25 cycles. Primer concentrations were
0.5 mM with 50 ng of DNA, and cycling was at 94°C (1.0 min),
50*C (1.0 min), and 72*C (2.5 min).
Cloning and sequence analysis
Genomic clones of SRB7 (pCH2), SRB8 (pSL301), and SRB9
(pCH47) were isolated as described previously (Liao et al. 1995)
by transformation and complementation of Z694, Z695, and
Z696, respectively. When necessary, the wild-type genes were
further localized by subcloning fragments of the genomic in-
serts and repeating the screen. The clones with the smallest
inserts were sequenced. pCH36 was created from pCH7 in vivo
by transforming Z694 with linearized pCH7 lacking SRB7-cod-
ing DNA and isolating the plasmid from a Ura" transformant
that had repaired the plasmid with the mutant srb7-1 sequences
from the chromosome (Rothstein 1991). SRB7 and SRB9 were
completely sequenced on each strand using genomic DNA from
pCH7 and pCH47, respectively. Unidirectional deletions were
constructed using the Erase-a-Base system (Promega), and dou-
ble-stranded sequencing with dideoxynucleotides and Seque-
nase (U.S. Biochemical) was carried out as described by the
manufacturer using T3 and T7 promoter primers. Gaps in the
sequence were filled in by sequencing with internal oligonucle-
otide primers. Sequence comparison analysis was performed at
the National Center for Biotechnology Information using the
BLAST network service (Altschul et al. 1990).
The srb7-1 mutant allele obtained by plasmid gap repair in
vivo contained a single-point missense mutation changing Ala-
21 to Thr (Fig. IB). Unlike their wild-type counterparts, plas-
mids containing this mutation did not prevent growth at 120C
when transformed into yeast cells containing the CTD trunca-
tion mutation rpblA104 and srb7-1(Z694), indicating that the
correct gene was cloned. Similar results were obtained for the
srb8-1 and srb9-1 mutant alleles obtained by plasmid gap repair
in vivo.
The conditional phenotypes associated with CTD trunca-
tions are suppressed both by srb8-1 or by complete deletion of
SRB8 (Z695 vs. Z701). Similarly, the conditional phenotypes
associated with CTD truncations are suppressed both by srb9-1
or by complete deletion of SRB9 (Z696 vs. Z703). The mutations
in srb8-1 or srb9-1 are thus likely to have at least partially
destroyed gene function, as cells containing either the suppres-
sor or the deletion alleles exhibit very similar phenotypes.
The cloned genes were physically mapped using the prime X
clone grid filters of the yeast genome (provided by L. Riles and
M. Olson, Washington University, St. Louis, MOI.
Purification of recombinant proteins
Recombinant SRB proteins were purified for generating poly-
clonal antibodies in rabbits. SRB7 and a portion of SRB8 (amino
acids 868-1226) were purified from the bacterial strain
BL21(DE3) pLysS (Studier and Moffatt 1986) carrying the plas-
mids pCH34 and pSL307, respectively, in the same manner
SRB2 was purified (Koleske et al. 1992). A portion of SRB9
(amino acids 45-501) was purified as a fusion to GST from
DH5ao carrying pCH64 according to the method of Smith and
Johnson (1988).
GST-VPl6, GST-VP16 s456, and GST-VPl614 56 F6* * 2 recom-
binant proteins were purified from DH5a carrying pGVP,
pGVPA456, and pGVPA456-FP442 (provided by Michael Green,
Hengartner et al.
University of Massachusetts, Worcester), respectively, as de-
scribed (Smith and Johnson 1988).
Mediator purification and assay
Mediator was purified essentially as described (Kim et al. 1994).
In vitro transcription assay for mediator activity was performed
as described (Sayre et al. 1992) with modifications (Liao et al.
1995). GAL4-VP16, TBP, TFIIB, and TFIIE were prepared as de-
scribed (Liao et al. 1995). TFIIF and TFIIH were prepared as
described (Sayre et al. 1992). RNA polymerase II was prepared as
described (Edwards et al. 1990).
Western blot analysis
Western blotting was performed by standard methods (Harlow
and Lane 1988). RPB1 was detected via the CTD with 8WG16
monoclonal antibody ascites fluid (Promega). Polyclonal rabbit
anti-SRB2, anti-GST-SRB4, anti-SRB5, anti-GST-SRB6, anti-
SRB7, anti-SRB8 (amino acids 868 to 1226), anti-GST-SRB9
(amino acids 45 to 501), and anti-SRB10 (amino acids 1-271)
antiserum were used to detect the SRBs. TBP, TFIIB, SSA1,
and GST were detected using specific rabbit polyclonal antise-
rum. In all cases, bands were visualized by secondary probing
with alkaline phosphatase conjugated secondary antibodies
(Promega).
DEAE-400 fraction preparation
Two kilograms of dry yeast (Red Star) were disrupted essentially
as described (Thompson et al. 1993), except that the disruption
buffer was 1.2 M ammonium sulfate, 160 mM HEPES-KOH (pH
7.6), 4 mM DTT, 40 mM EDTA, 2 mM PMSF, 4 mM benzamidine,
2 p.M pepstatin A, 0.6 pM leupeptin, and 2 pg/ml of chymosta-
tin. After the initial centrifugation, 1/100 volume of 10% poly-
min P (pH 7.0) was added to the supernatant. The supernatant
was incubated for 10 min at 4*C and spun for 20 min at 5000
rpm in a Sorvall H6000A rotor. Solid ammonium sulfate was
added to 35% saturation, and the solution was incubated for 30
min. The suspension was centrifuged for 1 hr at 13,000 rpm in
a GSA rotor. The pellet was resuspended in 9.5 liters of buffer A
(20 mM HEPES-KOH at pH 7.6, 1 mM EDTA, 20% glycerol, 1
mM DTT, 0.5 mM PMSF, 1 mM benzamidine, 0.5 ý.M pepstatin
A, 0.15 ý.M leupeptin, and 1 pLg/ml of chymostatin) to a conduc-
tivity equal to buffer A-150 mM potassium acetate. The resus-
pended pellet was centrifuged for 20 min at 5000 rpm in a
H6000A rotor. The supernatant (6.14 grams) was incubated for
1.5 hr with 500 grams of damp Bio-Rex 70 pre-equilibrated in
buffer A-150 mM potassium acetate. The resin was collected by
filtration, washed with 3 liters of buffer A-150 mM potassium
acetate, and packed into a column (5 cm width). The column
was eluted with buffer A-600 mM potassium acetate at a flow
rate of 8 ml/min. The eluate (0.6 grams, 165 ml) was diluted
with 500 ml of buffer B (20 mM Tris-acetate at pH 7.8, 1 mM
EDTA, 20% glycerol, 0.01% NP-40, 1 mM DTT, and the same
protease inhibitors as in buffer A). The diluted eluate was cen-
trifuged for 10 min at 10,000 rpm in a GSA rotor. The superna-
tant was loaded onto a column (5 cm width) containing 100 ml
of DEAE-Sephacel pre-equilibrated with buffer B-200 mM po-
tassium acetate at a flow rate of 8 ml/min. The column was
washed with 200 ml of buffer B-200 mM potassium acetate and
eluted with buffer B-400 mM potassium acetate. The eluate
contained 150 mg of protein in 60 ml.
Immunoprecipitation
The DEAE-400 fraction (0.1 ml) was dialyzed against modified
transcription buffer (MTB) (50 mM HEPES-KOH at pH 7.3, 100
mM potassium acetate, 25 mM MgAc, 5 rMM EGTA. 1 r.M DTT,
10% glycerol, 0.01% NP-40, I mM PMSF, 2 mM benzamidine, 2
pM pepstatin A, 0.6 pM leupeptin, and 2 p.g/ml of chymostatin)
and subsequently diluted to 0.4 ml with MTB. One microgram
of either affinity-purified anti-SRBS antibodies or purified anti-
human TGF-3--RII peptide (amino acids 30-44) IgG. and lg of
recombinant GST-VP16 or GST-VP16 s4 6FP"' 2 were added to
the input. Immunoprecipitation was carried out essentially as
described (Harlow and Lane 1988). Thirty microliters of anti-
rabbit antibody linked to dynabeads (Dynal) was used as the
secondary reagent in the immunoprecipitation.
Affinity chromatography
One milliliter of the DEAE-400 fraction (for holoenrvme bind-
ing experiments) or 1 ml of the mediator preparation peak frac-
tions from the heparin column) was dialyzed for 2 hr against
MTB. The GST-VPl6, GST-VP16145 6 , and GST-VP161"s6 FP44 2
affinity columns were prepared by immobilizing GST fusion
proteins on glutathione-agarose beads as described 'Smith and
Johnson 1988). The columns contained 200 pld matrix and con-
tained -300 p.g of GST fusion proteins. The columns were
equilibrated with 6 ml MTB (minus DTT), loaded three times
over with 0.2 ml of dialyzed DEAE-400 fraction (for holoenzyme
binding experiments) or 0.37 ml of the dialyzed mediator prep-
aration (0.25 mg/ml), washed with 4 ml of MTB Iminus DTT)
followed by 2 ml of MTB (minus DTT and NP-401, and eluted
with buffer containing 50 mM Tris-Cl (pH 7.5), 0.1 mm DTT,
and 5 mm glutathione, eluting both GST-fusion proteins and
interacting proteins.
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For CTD phosphorylation assays, core or holo-RNA polymerase 1I (60
and 150 ng, respectively), TFIIH (30 ng), and 0.3 mCi of [y-32P]ATP are
incubated for 30 min at room temperature in 15 Itl of 20 mM HEPES-
KOH (pH 7.8), 7.5 mM magnesium acetate. 1 mM DTT, 1 mM ATP, and
120 mM potassium acetate, followed by addition of 5 4I of 5x SDS gel-
loading buffer and analysis by SDS-PAGE. Incorporation of 32P into the
largest polymerase subunit. Rpbl, is quantified with the use of a Phos-
phorImager (Molecular Dynamics), calibrated by liquid scintillation
counting.
[16] Purification of Yeast RNA Polymerase II Holoenzymes
By ANTHONY J. KOLESKE, DAVID NI. CHAO, and RICHARD A. YOUNG
RNA polymerase II can.be purified from yeast in a high molecular
weight complex called an RNA polymerase II holoenzyme.l ' 2 This form of
RNA polymerase II appears to be responsible for transcription initiation
in vivo.3 The holoenzyme form of RNA polymerase II contains multiple
general transcription factors and a large multisubunit regulatory subcom-
plex. This regulatory subcomplex, which can be dissociated from RNA
polymerase II with antibodies directed against the enzyme, contains the
general transcription factor TFIIF, the SRB (suppressor of RNA polymer-
ase B) proteins, and additional regulatory proteins, and has been called
the Mediator.' Transcription by the RNA polymerase II holoenzyme can
be stimulated by activator proteins,' a property that can be reconstituted
with purified RNA polymerase II, general transcription factors, and the
Mediator subcomplex.'
There are three forms of yeast RNA polymerase II holoenzyme that
have been detected thus far, each of which was purified on the basis of its
association with SRB proteins. The largest form contains RNA polymerase
II, the Mediator subcomplex, and the general transcription factors TFIIH
and TFIIB.' A second form of holoenzyme can be purified that has all
these components except TFIIB (D. Chao, unpublished observation, 1995)
and the third form lacks TFIIB and TFIIH.4 It seems likely that the isolation
of the smaller forms of the holoenzyme is a consequence of holoenzyme
' A. J. Koleske and R. A. Young, Nature (London) 368. 466 (1994).
2 A. J. Koleske and R. A. Young, Trends Biochem. 20, 113 (1995).
3 C. M. Thompson and R. A. Young, Proc. Natl. Acad. Sci. U.S.A. 92, 4587 (1995).
Y. J. Kim. et al., Cell 77(4), 599 (1994).
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instability. Such instability may be due to strain background. growth condi-
tions, and extract and purification procedures.
In this chapter. we describe methods for the purification and assay of
the two largest forms of RNA polymerase II holoenzyme from the yeast
Saccharomyces cerevisiae. Use of the purified holoenzyme for transcription
studies in vitro should yield new and exciting clues regarding the mecha-
nisms underlying transcriptional regulation.
Growth of Yeast
The distinguishing feature of an RNA polymerase II holoenzvme is its
association with multiple SRB regulatory proteins. The SRB proteins are
somewhat more abundant in yeast cells grown in minimal medium than
they are in cells grown in rich medium and it is possible that the largest
form of the holoenzyme is more stable in minimal medium.2 -5 The total
yield of yeast grown in minimal medium is only about 4 g (wet weight)/
liter, so considerable effort is necessary to prepare the 500 g of yeast that
is typically employed in the purification described here. We have used three
approaches to obtaining 500 g of cells: (1) prepare cells using the protocol
described below; (2) grow cells in a fermentor in rich medium: and (3)
purchase commercial yeast. Although it is considerably more laborious, we
find that the first approach is the most dependable in generating high-
quality yeast extracts.
To generate approximately 500 g of cells, we grow six 3-liter cultures
at a time. About 70 g of yeast (wet pellet weight) is obtained from six 3-
liter cultures, so this procedure is repeated until 500 g is obtained. Those
unfamiliar with the growth of yeast may wish to consult a reference before
getting started.6 The protease-deficient yeast strain BJ926 can be used to
minimize the protease content of whole-cell extracts.7
1. Two days before starting cultures, patch several single colonies of
freshly streaked BJ926 onto a rich plate (YPD) using a sterile toothpick.
Make dime-sized patches and incubate them at 30' overnight.
2. Inoculate each of two 300-ml cultures of YNB medium [0.15%
(w/v) Difco (Detroit, MI) yeast nitrogen base, 0.5% (w/v) ammonium
sulfate, 200 mM inositol, 2% (w/v) glucose] in 1-liter flasks with the yeast
scraped from a single patch with a sterile stick. Grow these cultures at 30',
shaking at approximately 200 rpm, for 20-24 hr.
5 C. M. Thompson, A. J. Koleske, D. M. Chao, and R. A. Young, Cell 73, 1367 (1993).
6 F. Sherman. Methods Enzymol. 194(1), (1991).
7 E. W. Jones, Methods Enzymol. 194(1). 428 (1991).
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3. Inoculate each of six 3-liter cultures of I x YNB (in 6-liter flasks)
with 100 ml of the 24-hr culture. Allow the yeast to grow at 300. shaking
at 200 rpm. to an OD,,,, of 4.0 to 4.5 (20- 4 hr).
4. Yeast cells are collected by centrifugation in six 1-liter bottles at
4000 rpm in a Sorvall (Newtown. CT) RC3B or similar centrifuge for 10
min at 4'. The supernatant can be carefully removed from the pelleted cells
and another liter of culture can be added to the bottle and spun down on top
of the previous yeast pellet. The pellets should be washed by resuspending in
100-200 ml of ice-cold buffer [20 mMe' ,V-2-hydroxvethylpiperazine-NV'-2-
ethanesulfonic acid (HEPES)-KOH (pH 7.5). 10% (v/v) glycerol. 50 mM
potassium acetate. I mM dithiothreitol (DTT). and 1 mM EDTAJ. This
yeast suspension can be combined into one or two bottles and collected
by centrifugation as described above for storage at -70'. Following centril'u-
gation. discard the supernatant. weigh the bottle containing the pellet, and
store it at -70) until enough yeast has been collected to proceed to the
extraction process.
Yeast Extract Preparation
The following two procedures for producing yeast extracts can be
adapted to 0.5-5 kg of yeast or even more. Owing to the labor involved
in the purification, we do not recommend beginning with less than 500)
of yeast (wet pellet weight).
Procedure 1
In this procedure. the yeast whole-cell extracts are generated using
methods similar to those described by Sayre et al.' The following protease
inhibitors are used where indicated: i mzM phenylmethylsulfonyl iluoride
(PMSF), 2 mM benzamidine. 2 p.M pepstatin A. 0.6 pM leupeptin. chymos-
tatin (2 p.g/ml), antipain hydrochloride (5 pAg/ml: Sigma, St. Louis. MO).
All procedures are carried out at 40, unless otherwise noted.
1. Remove the yeast pellet from storage to 40 for about I hr to allow
the pellet to thaw partially.
2. Resuspend the pellet in 3x lysis buffer plus protease inhibitors, using
0.5 ml/g (wet weight) of yeast. The pellet can be resuspended using a rubber
policeman or by vigorous swirling of the bottle.
3. Rinse acid-washed glass beads (400-600 pxm; Sigma) with I X lysis
buffer [20% (v/v) glycerol. 50 mM potassium acetate, 150 mM Tris-acetate
(pH 7.9), 1 mM EDTA, 2 mM DTT].
' M. H. Sayre, H. Tschochner. and R. D. Kornberg, J. Biol. Chem. 267(32), 23376 (1992).
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4. Add glass beads and the cell suspension to a Bead-beater (Biospec
Products). Add the glass beads to the chamber of the Bead-beater until it is
50-60% full. Fill the remaining space with the yeast-lysis buffer suspension.
Assemble the chamber and seal. Fill the reservoir with an ice-salt-water
bath. Use about 40 g of NaCI for the bath.
5. Run the beater 20 times for 30 sec. Allow 90 sec between runs to
permit cooling of the chamber. Add more ice during the run if necessary. A
digital controller/timer (VWR Scientific) is useful for automating this step.
6. Disassemble the chamber. Let the beads settle to the bottom and
remove the lysate while minimizing the amount of bead carryover. Although
tedious, pipetting the lysate works well. Rinse the beads further with 30-60
ml of 3x lysis buffer and decant the supernatant. The chamber can be
refilled with yeast-lysis buffer solution for another round of lysis. The
beads should be discarded after two rounds of lysis.
7. Spin the lysate in a Sorvall GSA rotor at 10,000 rpm for 20 min at
40 to pellet cell debris.
8. Adjust the supernatant slowly to 0.5 M in potassium acetate using a
stock solution of 5 M potassium acetate with stirring, and stir gently for
30 min.
9. Spin the extract at 41.000 rpm in a Beckman (Fullerton, CA) Ti 50.2
rotor for 90 min. The lipid at the top of the tube is removed with a cotton-
tipped applicator or by aspiration. Carefully remove the supernatant by
pipetting, taking care to avoid the opaque and brown material at the bottom
of the tube. The yield should be about 340-370 ml of 20- to 25-mg/mi
protein extract for 500 g of starting material. Extracts can be frozen at -70".
Procedure 2
The freeze-thaw procedure described below is extensively modified from
the procedure of Dunn and Wobbe.' This procedure requires large amounts
of liquid nitrogen, and it is important to take appropriate safety precautions.
Handle the liquid nitrogen in a well-ventilated area, use appropriate con-
tainers, and wear protective clothing, glvoes, and safety goggles. Because
this procedure has the potential to be quite messy, generous use of bench
paper is recommended. Note that the form of holoenzyme purified by this
procedure from BJ926 cells grown in rich medium does not contain TFIIB.
All steps in this procedure are at room temperature unless otherwise spec-
ified.
9 B. Dunn and C. R. Wobbe, Cell disruption using liquid nitrogen. In: "Current Protocols
in Molecular Biology" (F. M. Ausubel er al.. eds.), pp. 13.5-13.6. John Wiley & Sons, New
York, 1994.
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1. Mix 500 g of frozen yeast with 500 ml of buffer containing 100 mM
potassium acetate, 40 mM K-HEPES (pH 7.6), 2 mM Na-EDTA, 2 mM
DTT plus 2x protease inhibitors, and thaw the mixture in a 65* water bath.
Do not allow the temperature of the suspension to exceed 40.
2. Pour the thawed suspension into 4-liter containers of liquid nitrogen
while stirring with a plastic pipette. Pour the suspension into the liquid
nitrogen at a speed that yields popcorn-size pellets of frozen cells. Drain
the excess liquid nitrogen from the frozen pellets.
3. Place the frozen pellets in the 1-liter stainless steel chamber of a
commercial Waring blender (VWR Scientific) until it is half full. Replace
the lid, and blend for 2-4 min until the mixture has the consistency of a
fine powder. It may be necessary to stir the mixture occasionally with a
pipette to prevent clumping. Repeat the blending until all of the cells have
been .processed.
4. Thaw the disrupted cells at 650 in a beaker with stirring until the
extract has the consistency of a viscous milkshake. In 750-mi batches, blend
the lysate for 10 sec; wait 10 sec, and blend again for 10 sec.
5. Repeat steps 2-4. The number of cycles required for maximal cell
breakage depends on the strain and growth conditions. For example, com-
mercial yeast (Red Star) rehydrated for 30 min in 2% (w/v) glucose requires
only one cycle, while BJ926 grown in a fermenter requires four cycles.
6. Spin the extract in a Sorvall H6000A rotor at 5000 rpm for 1 hr at
40. Decant the supernatant and pour it through cheesecloth. Add 1/8 vol
of glycerol and 1/8 vol of 5 M potassium acetate and stir at 4* for 15 min.
7. Spin the extract for 30 min at 13,000 rpm in a Sorvall GSA rotor at
40. Pour the supernatant through cheesecloth at 40. At this point, the extract
can be stored temporarily at -70" if necessary.
8. Spin the extract for 90 min at 4* at 40,000 rpm in a Beckman 50 Ti rotor
or at 42,000 rpm in a Beckman 45 Ti rotor. Remove lipids by aspiration, and
recover the supernatant by pipetting.
9. The typical yield for this extraction procedure is 400 ml, with a
protein concentration of 25-35 mg/ml. Extracts can be frozen at -70*.
Chromatography
The steps outlined here are scaled for 400 ml of extract with a protein
concentration of approximately 25 mg/ml. The fractions can be stored at
-20 or -70* between any chromatographic step in this sequence.
1. Prepare a column with Bio-Rex 70 resin 100-200 mesh (Bio-Rad,
Richmond, CA). It is important to prepare this resin according to manufac-
turer directions and to equilibrate it with buffer A (100). Buffer A contains
4'." "
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20% (v/v) glycerol, 20 mM HEPES-KOH (pH 7.5), 1 mM DTT, 1 mM
EDTA, and protease inhibitors. Buffer A (100) is buffer A plus 100 mM
potassium acetate. As the protein is eluted in steps from this column, the
exact column dimensions are not important: however, wider columns (>4-
cm diameter) facilitate a faster flow rate. We use a 5 x 17 cm column.
Typically, the column is loaded at 20-25 mg of protein per milliliter of
column bed. Total onput onto this column should not exceed 50 mg of
extract protein per milliliter of column bed.
2. If using an extract obtained with procedure 1, dilute the whole-cell
extract 1:5 in buffer A so that the potassium acetate concentration is
reduced to 100 mM. Load the extract onto the Bio-Rex 70 (Bio-Rad)
column at a flow rate of 10 ml/min. Wash the column with buffer A (100)
until no further protein can be eluted from the column, usually two to
three column volumes. The protein concentration in the column eluate
should be monitored by mini-Bradford assays, using a minimum of each
fraction. The Bio-Rad protein assay is convenient for this; 10 ýtl of each
fraction is added to 325 Al of Bio-Rad protein assay solution.
3. Elute the column with a step wash of buffer A (300) (buffer A plus
300 mM potassium acetate) until no further protein elutes from the col-
umn (approximately two to three column volumes). Although the Bio-Rex
70 flowthrough and buffer A (300) fractions are not used further in this
protocol, they may provide a source of other factors and can be saved at
-700"
4. Elute the column with a step wash of buffer A (600) until no further
protein elutes from the column. The RNA polymerase II holoenzyme
should elute in this step. The holoenzyme is not yet sufficiently purified to
be assayed for activity at this stage; it can be assayed for activity after
chromatography on hydroxylapatite (see step 8). The presence of the holo-
enzyme can be monitored by Western blot using antibodies to SRB2, SRB4,
SRB5, and SRB6. RNA polymerase II can be assayed in a similar fashion
using a monoclonal antibody directed against the largest subunit of RNA
polymerase II (Promega. Madison, WI). The column can be further eluted
with a step wash of buffer A (1000). Eighty percent of the holoenzyme
eluting from the column should be in the buffer A (600) fraction.
5. Dilute the Bio-Rex 70 (600) fraction 1: 6 with buffer B [20% (v/v)
glycerol, 20 mM Tris-acetate (pH 7.9), 1 mM DTT, 1 mM EDTA, 0.01%
(v/v) Nonidet P-40 (NP-40) and protease inhibitors] to reduce the salt
concentration to 100 mM. Load the solution onto DEAE-Sephacel (Phar-
macia, Piscataway, NJ) resin at a flow rate of 4 ml/min. Again, column
shape is not particularly important here, as stepwise elutions are used; we
use a 2.5 x 8.5 cm column. The column should contain about 1 ml of bed
volume per 5 mg of onput protein.
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6. Wash the column extensively with buffer B (100) (buffer B plus
100 mM potassium acetate) and then elute with step washes of buffer B
(400) and buffer B (650). The holoenzyme will elute from this column in
the 400 mM potassium acetate step and can be monitored by Western blot
analysis. TFIIE, which is not a component of yeast holoenzvmes and is
required for assays of holoenzyme activity, can be prepared from the 650
mM eluate.'0
7. The next step involves chromatography on a BioGel HTP hydroxyl-
apatite column. Prepare the resin by incubating in buffer C [20% (v/v)
glycerol. 10 mM potassium phosphate (pH 7.7), 100 mMV potassium acetate,
1 miMV DTT, 0.01% (v/v) NP-40. and protease inhibitors]. It will take approx-
imately 10 ml to swell 1 g of BioGel HTP.
8. Load the DEAE-Sephacel buffer B (400) fraction directly onto a
1.5 x 6.5 cm BioGel HTP hydroxylapatite column at a flow rate of 1 ml/
min. The fraction does not need to be dialyzed or diluted prior to loading
onto the column. Wash the column with 20 ml of buffer C (EDTA). Buffer
C is 20% (v/v) glycerol, 10 mM:, potassium phosphate (pH 7.7), 100 mM
potassium acetate, 1 mM DTT. 0.01% (v/v) NP-40, and protease inhibitors.
Buffer C (EDTA) contains 0.25 mM EDTA. Elute with a 120-mi linear
gradient of buffer C (EDTA) to buffer D [buffer D is identical to buffer
C (EDTA) except that it contains 300 mM potassium phosphate, pH 7.7].
Assay fractions for transcriptional activity (see below) and for the presence
of holoenzyme protein, using Western blot analysis. The holoenzyme should
elute from this column in a peak corresponding to 68 to 112 mM po-
tassium phosphate.
9. Dialyze the holoenzyme peak from the BioGel HTP (Bio-Rad)
against buffer E (100). Buffer E is the same as buffer B except the EDTA
is 0.25 mVM; buffer E (100) is buffer E plus 100 mM potassium acetate.
Centrifuge the dialyzed material in a Sorvall SS34 rotor at 10,000 rpm for
20 min at 40. Load the supernatant (approximately 11 mg protein in 20 ml)
onto a Mono Q HR 5/5 FPLC column (Pharmacia) at a flow rate of 0.5
mimin. Elute the column with a 15-mi linear gradient from buffer E (100)
to buffer E (2000). Assay fractions for transcriptional activity and the
presence of holoenzyme protein. The holoenzyme elutes from this column
at 0.95 M potassium acetate.
10. Pool the peak fractions containing holoenzyme activity and dilute
them 1: 6 with buffer F. Buffer F is the same as buffer A except the EDTA
concentration is 0.25 mM. Load this material (approximately 1.1 mg of
protein in 10 ml) onto a Mono S HR 5/5 FPLC column (Pharmacia), and
elute with a 10-ml gradient from buffer F (100) to buffer F (1000) at a flow
to M. H. Savre, H. Tschochner, and R. D. Kornberg, J. Biol. Chem. 267(32), 23383 (1992).
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rate of 0.5 ml/min. Assay fractions for transcriptional activity and. the
presence of holoenzyme protein. The holoenzyme should elute from this
column at 450 mM potassium acetate.
11. Dilute the pooled peak fractions (approximately 0.6 mg in 8 ml)
1:4 in buffer E and immediately load onto a 1.5 x 1.5 cm DEAE-Sephacel
column, wash with buffer E. and elute with a 12-ml gradient from buffer
E (100) to buffer E (1000) at a flow rate of 0.3 mI/min. Assay fractions
for transcriptional activity and the presence of holoenzyme protein. The
holoenzyme elutes from this column at 400 mM potassium acetate.
This holoenzyme preparation should be approximately 90% pure. The
total yield of the holoenzyme should be about 0.5 mg and the purification
should be approximately 10.000-fold. Holoenzyme preparations have been
stored in this buffer at -70 ° for up to 2 years without appreciable loss
of activity.
Assay for Holoenzyme Activity
All forms of RNA polymerase II holoenzyme described thus far lack
the general transcription factors TBP and TFIIE, and these factors must
be added to obtain transcription in vitro. Protocols for the purification of
recombinant TBP and yeast TFIIE have been published.10"' TFIIB is also
required for transcription by some holoenzyme preparations. Holoenzyme
and factor preparations should be dialyzed against a low-salt buffer, such
as buffer F, to reduce the salt content prior to assay. Alternatively, the salt
concentration can be determined by conductivity measurements, and the
salt concentration in the transcription assay buffer can be adjusted accord-
ingly. The following assay is a modification of that described in Ref. 12.
.1. Make up 2x transcription buffer. lx transcription buffer contains
50 mM HEPES-KOH (pH 7.3), 100 mM potassium glutamate, 15 mM
magnesium acetate, 5 mM EGTA, 100 ng of GAL4 G-template, 3 mM
DTT, enzyme-grade acetvlated bovine serum albumin (BSA, 50 j.g/ml;
Promega), and 10% (v/v) glycerol. Transcription buffer is made up at 2x
concentration to allow for the addition of further components (holoenzyme,
TBP, TFIIE, activator, etc.). If TBP, TFIIE. or holoenzyme are in solutions
containing glycerol, the glycerol content in the reaction must be adjusted ac-
cordingly.
2. Assemble the transcription reactions. The transcription reactions will
have a 25-pl final volume, but for preincubation, they are assembled in a
" S. Buratowski. S. Hahn. L. Guarente. and P. A. Sharp. Cell 56, 549 (1989).
'2 N. F. Lue and R. D. Kornberg. Proc. Natl. Acad. Sci U.S.A. 84(24), 8839 (1987).
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volume of 22 j.l at 24' and contain 20-40 ng of TBP. 20-40 ng of TFIIE,
and I .jg of holoenzyme. The remaining 3 ~.1 of volume will contain the
nucleotides added to initiate the reactions following the preincubation.
Activators such as GAL4-VPI6 are added at a concentration of 10 ~A1M
before the preincubation step.
3. Preincubate the reactions at 240 for I hr.
4. Initiate the transcription reactions by addition of 3 g1 of 3.33 mt'l
ATP. 3.33 mMI CTP, 15 ,u.1I UTP. and [a-32PIUTP (1.65 mCilml: 3000 Ci/
mmol). The reactions are incubated at 24" for 40 min.
5. Terminate the transcription reaction by adding 100 ul of 10 mM Tris
8.0. 5 mil/l EDTA. 0.3 l i NaC1. and RNase T, (2000 units/ml: Mannheim.
Indianapolis, IN).
6. Prepare the transcripts for analysis by extracting the reactions twice
with a 1:1 mixture of Tris-buffered phenol and chloroform. Precipitate
RNA by addition of 2.5 vol of ethanol and incubation on dry ice-ethanol
for 20 min, and pellet by high-speed centrifugation in a microcentrifuge
for 15 min. Wash the pellet with 70% (v/v) ethanol. Allow to dry for several
minutes and resuspend it in 10 l of sample buffer [(0.1 x TBE. 80% (v/v)
formamide. 0.01% (v/v) xylene cyanol. and 0.01% (w/v) bromphenol blue].
7. Analyze the transcripts by subjecting them to electrophorcsis on a
6% (w/v) acrylamide [19: 1 (v/v) acrylamide: bisacrylamide ratio]-7 NI urea
gel in lx TBE buffer at 3(0 V'cm. Heat the resuspended pellets at 80) for
10 min, cool them briefly on ice, and spin to collect any condensation prior
to loading the samples. The gel should be prerun at least 15-30) min before
loading samples. Following electrophoresis, dry the gel and expose to auto-
radiography. The transcripts from the GAL4 G-less template are 350-375
nucleotides long.
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THE RNA polymerase II holoenzyme consists of RNA polymerase
II, a subset of general transcription factors, and regulatory pro-
teins known as SRB proteins"' 2. The genes encoding SRB proteins
were isolated as suppressors of mutations in the RNA polymerase
II carboxy-terminal domain (CTD)3"4. The CTD and SRB proteins
have been implicated in the response to transcriptional regula-
tors'-". We report here the isolation of two new SRB genes,
SRBIO and SRBIJ, which encode kinase- and cyclin-like proteins,
a
SRB10 MYQRPMQVQGQQQAQSFVGKKNTIGSVHGKAPML 4ANNDVFTIGPYRARKDRMRVSVWSIEVI
cdc2 MJJKV
CDC28 MSGEM RL
respectively. Genetic and biochemical evidence indicates that the
SRB10 and SRBI proteins form a kinase-cyclin pair in the holo-
enzyme. The SRBI0/I 1 kinase is essential for a normal transcrip-
tional response to galactose induction in vivo. Holoenzymes
lacking SRB10/11 kinase function are strikingly deficient in CTD
phosphorylation. Although defects in the kinase substantially affect
transcription in vivo, purified holoenzymes lacking SRB10/11 kin-
ase function do not show defects in defined in vitro transcription
systems, suggesting that the factors necessary to elicit the regula-
tory role of the SRB10/11 kinase are missing in these systems.
These results indicate that the SRBI0/11 kinase is involved in
CTD phosphorylation and suggest that this modification has a role
in the response to transcriptional regulators in vivo.
To identify new components of the RNA polymerase II holo-
enzyme, we isolated extragenic suppressors of a Saccharomyces
cerevisiae RNA polymerase II CTD truncation mutation4 .
Recessive suppressing mutations were identified in two genes,
SRBIO and SRBII. Genetic analysis indicated that the CTD
and the two SRB gene products are involved in the same process
in transcription initiation. The mutant alleles srbl0-1 and srbll-
I suppressed the conditional phenotypes of CTD truncation
mutations but not the conditional phenotypes of other RNA
polymerase II mutations. Genomic DNA clones containing
SRBIO and SRBI I were isolated by genetic complementation
and the complementing clones with the smallest inserts were
sequenced (Fig. 1).
GY AA K RQINSGTNSANGSSLNGTNAKIPQFDSTQPK 110
.------------------------------- 22
D------------------------------ 28
SRB10 SSS SMDMQANTNA RN LKDEGVTP RTTREDVSPHYNSQKQTLIKKPLTVFY I KT DGVEQLHY
CDCZ8 --------------- GQ ------- G .--------------------------------
cdII
NKHLTT 
.... 
FtRSNC:KI.
IV
SRB10 K CHM BYEH IH F HLO P 8 KR MIPkI L DSm\INMkTL t2KVV••M=
S-CDP- G RA TGAT DI m I U NI - -"
CDC28 ...ADI... '
V VI Vii
SRB10 Z PA S• I I& LQMh EAKLDSKKTVPFOVN(R LE K LEKY- QITK Y-NLATWYHSAGR H 435
SRB1 KDFN(bIPVsENV ENVFGEGLTYKYPARR IHTN DNDIMNLGSRTKNNTQASGITAGAAANALGGLGVNRRILAAAAAAAAAVSGNNASDEPSRKKNRR 541
cdc2 H~R~ IT -DFH 297
CDC28 = 298
b
SRB11
DmcycC
HmcycC
SRB11
DmcycC
HmcycC
CQLFPQ GLNIMDS NGIEQSITKNIPITHRDLHYE -LRIYC n-L
MVAPRPL RRVVLF YQGKLCS F ---------------------------------- njW -rLnfflWZM
1 AL M I IK&RI LY WT CPO LVSEARTbEE.ENk1 SIM I&iICQjAaU~inYAItSEE ITIUEAAATIVEED1IF I iyM M IRH
SRB11 LK PFI DDLQNC
OmcycC
HmcycC ------- I 'F it N------- V -MS BIL tLKE
SRB11 H KYH IKF TY RLSA
DmcycC DIIQM I
HmcycC Q FDRK24AT , SEGEQGPNGSQNSSYSQS
FIG. 1 Sequence of SRB10 and SRB11 proteins and alignment with
related kinases and cyclins. a, SRB10 sequence alignment with the S.
pombe Cdc2 and S. cerevisiae CDC28 proteins. Identical amino-acid
residues are shown as white letters on a black background. Roman
numerals indicate the 11 conserved kinase subdomains. Primer exten-
sion analysis of poly(A)- mRNA revealed that the SRB1O transcript is
initiated at position +12 in the open reading frame originally predicted
for UME5 (ref. 13). Thus the amino-acid sequence of SRB1O/UME5
shown here lacks the 14 amino-terminal amino acids originally reported
for UME5 13. b, SRB11 sequence alignment with Drosophila (DmcycC)
and human (HmcycC) cyclin C proteins.
METHODS. Genomic DNA clones containing SRB1O and SRB11 were
isolated by exploiting their ability to reverse the suppressing phenotype
of the recessive srb alleles in cells containing the truncated CTD allele(rpblA104). A wild-type genomic DNA library constructed in a yeast
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URA3 centromeric plasmid4 was transformed into yeast cells containing
the CTD truncation mutation rpblA104 and srbl0-1 or srbll-1. Ura +
transformants were then screened for phenotypes characteristic of the
rpblA 104 CTD truncation mutant: lack of growth at 12 "C and inability
to use pyruvate as a carbon source. Genomic clones containing SRB1O
(pSL201) and SRB11 (pJZ11-1) were sequenced. SRB10 and SRB11
were physically mapped to chromosome XVI (A clones 3168 and 4122)
and to chromosome XIV (A clone 3634), respectively, using the prime
A clone grid filters of the yeast genome (from L. Riles and M. Olson).
Sequence comparison and alignments were made with the BLAST net-
work service and the DNA Star Megalign program, respectively. The
nucleotide sequence data for SRB10O and SRB11 can be found in the
EMBL, GenBank and DDBJ nucleotide sequence databases under the
accession numbers U20222 and U20221, respectively.
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SRBIO encodes a 541-amino-acid protein kinase related to the
Cdc2 kinases' " (Fig. la). SRBIO is identical to UME5, described
recently as a regulator of meiosis-specific genes". SRB O/UME5
protein sequence is -40% identical to the S. cerevisiae CDC28
and S. pombe Cdc2 proteins and highly similar to PH085, CTK1
and KIN28 (refs 14-16, respectively), members of the yeast
Cdc2-related subfamily of serine/threonine protein kinases.
SRBll encodes a 323-amino-acid protein which is -28%
identical and 58% similar in sequence to the human"7 and
Drosophila'8 cyclin C proteins (Fig. lb). Residues 75-184 of
SRBI1 are 37% identical to those of the 'cyclin box' of the
human and Drosophila proteins; this region is conserved in
cyclins and may be involved in the interaction between kinase
and cyclin subunits' 9-21
We investigated whether SRBI10 and SRB I could be compo-
nents of the RNA polymerase II holoenzvme. Western blot ana-
lysis with anti-SRB10 antibodies revealed that essentially all of
the SRB10 in cell extracts copurified with the RNA polymerase
II holoenzyme at each step of the purification procedure. The
results in Fig. 2a show that RNA polymerase II and the SRB2,
FIG. 2 SRB10 and SRB11 are components of the RNA polymerase II
holoenzyme. a, RNA polymerase II holoenzyme was purified as
described'. Holoenzyme loaded onto a Mono-S column, the last chrom-
atographic step in the purification procedure, was eluted with a
0.1-1.0 M gradient of potassium acetate. The onput (OP) and flow
through (FT) and a portion of every other fraction eluting between 0.1
and 0.9 M potassium acetate were analysed for holoenzyme activity(top panel) and for the presence of RNA polymerase II and SRB proteins
by western blot analysis. The western blot for SRB11 was done with an
RNA polymerase II holoenzyme purified independently from cells with
an epitope-tagged SRB11 protein; the purification and transcriptional
properties of this holoenzyme were identical to the holoenzyme lacking
the epitope tag. b, Co-immunoprecipitation of SRB4, SRB10 and SRB11
with SRB5. Purified RNA polymerase II holoenzyme was immunoprecipi-
tated using affinity-purified anti-SRB5 or anti-HSP70 antibodies. The
supernatant (S), wash (W) and precipitate (P) were analysed by western
blotting using antibodies against specific SRB proteins. Lanes: 1 and 4,
supernatant from immunoprecipitation with anti-SRB5 and anti-HSP70
antibodies; 2 and 5, washes of immunoprecipitated material; 3 and 6,
precipitated material. c, Recombinant SRB10 interacts with a gluta-
thione-S-transferase (GST)-SRB11 fusion protein in affinity chromato-
graphy. Radiolabelled SRB10 or CDC28 was produced in an in vitro
transcription/translation system and loaded onto GST-SRB11 and GST
columns. Fractions were subjected to SDS-PAGE. OP, 0.5% of onput;
FT, 0.5% of flowthrough; W, 10% of final wash; E, 10% of elution with
reduced glutathione.
METHODS. Holoenzyme purification and in vitro transcription assays
have been described1. The mAb 8WG16 (Promega) was used to detect
RPB1 in western blots, rabbit anti-SRB antibodies to detect SRB2,
SRB4, SRB5, SRB6 and SRB10, and mAb 12CA5 to detect an influenza
haemaglutinin (HA) epitope tag introduced at the N terminus of
SRB11 . Bands were visualized by secondary probing with alkaline-
phosphatase-conjugated secondary antibodies (Pierce) or by chemi-
luminescence with horseradish-peroxidase-conjugated secondary anti-
body (Amersham). Immunoprecipitations were done with holoenzyme
purified from an HA-tagged SRB11 strain (Z689) in buffer containing
50 mM HEPES-KOH, pH 7.3, 15 mM magnesium acetate, 100 mM pot-
assium acetate, 1 mM EGTA, 10% glycerol, 0.1 mM DTT, 0.1% NP-40.
Anti-rabbit antibody linked to dynabeads (Dynal) was used as the secon-
dary reagent in the immunoprecipitation. For column chromatography,
a GST-SRB11 fusion was constructed (pMV123) using pGEX-2T (Phar-
macia) and recombinant GST-SRB11 and GST were purified from E.
coli as described27. Columns containing 250 pj GST-beads were loaded
with 40-50 pg GST-SRB11 or GST, and equilibrated with transcription
buffer8. 25 pl labelled in vitro translated SRB10 or CDC28 (Promega
TNT coupled system) was incubated with the immobilized proteins over-
night at 4 'C, washed with transcription buffer +1% Triton X-100, and
eluted with 10 mM reduced glutathione, 50 mM Tris-HCI, pH 8, 1%
TritonX-100, 0.1 mM PMSF. Figures were prepared from digital replicas
of primary data scanned using a UMAX UC840 Max Vision digital
scanner.
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SRB4, SRB5, SRB6 and SRBIO0 proteins co-elute in the final
purification step of the holoenzyme. Because we were unable to
generate anti-SRBI I antibodies, an independent purification was
carried out using a lysate from cells containing epitope-tagged
SRBll; all of the epitope-tagged SRB 1 copurified precisely
with the RNA polymerase II holoenzyme (Fig. 2a). Thus, essen-
tially all of the SRB10 and SRBI in cell extracts is associated
with the holoenzyme. Immunoprecipitation experiments con-
firmed that SRBIO and SRBI I are tightly associated with the
holoenzyme (Fig. 2b). Thus, genetic and biochemical analysis
indicates that all six SRB proteins identified so far (SRB2, 4, 5,
6, 10 and 11) are components of the transcription initiation
complex, the RNA polymerase II holoenzyme.
The sequences of SRBIO and SRB11, together with genetic
evidence that the two gene products are involved in the same
function, indicate that they may form a kinase-cyclin pair. The
recombinant proteins bound to one another on a column (Fig.
2c) and interacted in a two-hybrid system22 (data not shown),
indicating that SRB10 and SRBI I are components of a kinase-
cyclin pair in the holoenzyme.
a
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FIG. 3 SRBIO and SRB11 mutants are deficient in transcriptional
responses at a GAL10 promoter in vivo. The relative ability of wild-type
cells and srblO and srb11 mutants to respond to galactose induction
was measured by expressing lacZ under the control of a GAL1O UAS-
containing promoter, as described6 . Extracts were prepared from
induced or uninduced cells and the results of f-galactosidase assays
are expressed as fold induction. Strains assayed were wild type (WT);
Z690 (srbl0-3) cells encoding an SRB10 protein in which Asp 290 had
been replaced with Ala; Z687 (srblOA1) cells in which SRB10 is
deleted; Z688 (srbllAl) cells in which SRB11 is deleted; Z437
(srb2dl) cells in which SRB2 is deleted: Z551 (rpblA 104) cells enco-
ding an RNA polymerase II CTD truncation mutant with 11 heptapeptide
repeats; L5191 (cdc28-1N) cells encoding a mutant form of CDC28.
METHODS. The GAL10 UAS-CYC1-lacZ fusion plasmid pLGDS5, galac-
tose induction procedures and P-galactosidase assay have been
described 6. Complete deletions of the SRB10 and SRB11 coding
sequences (srblOAl and srbllA) were constructed using a single-
step disruption method28. The gene encoding the SRB10 D290A muta-
tion (srblO-3) was constructed by oligonucleotide mutagenesis. and the
Z690 mutant was generated by replacing the wild-type SRBIO gene
with srblO-3, as described28. The srbl0 and srbll mutant strains are
conditionally viable; they exhibit mild cold-sensitive, temperature-
sensitive, and slow growth phenotypes.
Mutations in the RNA polymerase II CTD and in SRB2
reduce the response of the transcription apparatus to regulators
in vivo3 -7, so we investigated the effects of mutations in SRBIO
or SRB11 in vivo (Fig. 3). A fl-galactosidase reporter vector
with a GALIO UAS-containing promoter was introduced into
cells with CTD and srb mutations and the cells were subjected
to induction by galactose. The results revealed that cells lack-
ing SRB10 or SRB11 function respond poorly to galactose.
The defect was most pronounced (100-fold) in cells containing
a point mutation (srbl0-3) that inactivates the kinase function
GALl0 CYC1
UAS TATA lacZ
7000-
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2000-
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of SRBIO without affecting its stable incorporation into the
holoenzyme. We infer that the defect is in transcriptional
induction rather than in messenger RNA stability because
mutations in SRBIO UME5 do not destabilize vegetative
mRNAs and actually increase meiotic mRNA stability
twofold". SRBIO and SRBII mutant cells are slow growing,
but control experiments show that slow growth does not
inhibit iinduction by galactose (Fig. 3). The poor response of
srbl0O and srbll mutant cells to transcriptional induction in
vivo is consistent with the association of these two gene
FIG. 4 CTD phosphorylation and transcription in vitro with wild-type and
mutant RNA polymerase II holoenzymes. a, Purified holoenzyme lacking
SRB10 function exhibits reduced CTD phosphorylation. Wild-type (W)
and mutant (M) holoenzymes were assayed for their ability to phos-
phorylate the CTD of the RNA polymerase II large subunit or recombinant
CTD added to the holoenzyme preparations. The mutant RNA poly-
merase II holoenzyme contains SRB10O protein in which Asp 290 has
been replaced with Ala. Phosphorylation of the endogenous RNA poly-
merase II CTD was reduced -10-fold and -5-fold for recombinant CTD,
in the mutant holoenzyme. b, Western blots showing that the two holo-
enzyme preparations contain similar amounts of the largest subunit of
RNA polymerase II (RPB1) and SRB proteins. c, Wild-type and SRB10
mutant holoenzymes exhibit similar basal and activated transcription
in vitro. Lanes: 1, wild-type holoenzyme (W); 2, wild-type holo-
enzyme+GAL4-VP16; 3, SRB10 mutant holoenzyme (M); 4, SRB10
mutant holoenzyme + GAL4-VP16. The large transcript is derived from
the pGALA template, which lacks a GAL4 binding site, and the small
transcript is from pGAL x 6, which contains six GAL4-binding sites.
METHODS. RNA polymerase II holoenzymes were purified from wild-type
and srblO-3 mutant cells as described". Kinase assays were carried
out at 24 oC with 100 ng holoenzyme in 15 pl buffer containing 20 mM
HEPES, pH 7.6, 8 mM MgSO4, 2.5 mM EGTA, 5% glycerol, 2 mM DTT
and a mixture of phosphatase inhibitors (1 mM NaN3, 1 mM NaF,
0.4 mM NaV03, 0.4 mM NaV0 4 and 0.1 mg ml-1 phosvitin). Recombi-
nant GST-CTD (100 ng) was added to a subset of the reactions; GST
itself is not phosphorylated by holoenzyme preparations (not shown).
Transcription was performed as described29 with the following modifi-
cations: 100 ng pGALA and pGAL x 6 templates30 were used per
reaction; factors and DNA were preincubated for 15 min before adding
nucleotides; and the stop mixture contained 12.5 U ml-1 ribonuclease
T1. TFIIE was prepared as described29 except that the second BioRex
column was omitted and a Mono-S column step was added at the end.
a
Kinase assay
Holoenzyme: W M W M
rCTD: - - -
RPB1 - l
rCTD-
Western blots
Holoenzyme: W M
RPB1
SRB2
SRB5
SRB10
491
Transcription
Holoenzyme: W W M M
GAL4-VP16: - + - +
- GAL4 site -
+ GAL4 site -
NATURE - VOL 374 • 9 MARCH 1995
4b
~d~,o"l
S',P~o
195
LETTERS TO NATURE
products with CTD function, which was previously implicated
in such responses.
The RNA polymerase II CTD is found in an unphosphoryla-
ted form in transcription initiation complexes but is extensively
phosphorylated during elongation "1.23. Thus, CTD phosphoryla-
tion may regulate some event in transcription initiation. We
tested whether SRB10/1I kinase has a role in CTD phosphoryla-
tion in the holoenzyme using purified RNA polymerase II holo-
enzyme from -wild-type and srblO mutant cells. Figure 4 shows
that CTD phosphorylation was reduced ~10-fold in the srbl0O
mutant holoenzyme, indicating that the SRB10 kinase must be
important for CTD phosphorylation; the reduced response of
SRB10-deficient holoenzyme to galactose induction in vivo may
therefore reflect its diminished ability to phosphorylate the CTD.
The yeast general transcription factor TFIIH is present in the
holoenzyme'. and the TFIIH-associated kinase24"25 may account
for the residual CTD phosphorylation in the mutant holo-
enzyme.
The activities of wild-type and SRB10-mutant RNA polymer-
ase II holoenzymes were compared in a reconstituted transcrip-
tion assay (Fig. 4c); levels of basal and GAL4-VP16-activated
transcription were similar for both holoenzymes. We could not
find any defect in transcription in vitro comparable to the loss
of CTD phosphorylation in vitro or of galactose induction in
vivo. These results suggest that factors necessary to elicit the
regulatory role of SRB10 are missing or not functional in our
in vitro transcription systems. Alternatively, the holoenzymes
may contain additional kinases that compensate for the loss of
SRB10 function in these systems.
We have identified a kinase-cyclin pair in the RNA polymerase
II holoenzyme. shown that it is involved in transcriptional regu-
lation in vivo and in CTD phosphorylation in vitro. Although
the exact role of CTD phosphorylation in transcriptional regula-
tion is not known, our results demonstrate that the response of
the transcription initiation apparatus to at least some regulatory
signals in vico involves the SRB kinase-cyclin pair. El
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Summary
We report genetic and biochemical evidence that the
RNA polymerase II carboxy-terminal domain (CTD) in-
teracts with a large multisubunit complex that contains
TATA-binding protein (TBP) and is an integral part of
the transcription initiation complex. The isolation and
characterization of extragenic suppressors of S. cere-
visiae RNA polymerase II CTD truncation mutations
led us to identify SRB2, SRB4, SRB5, and SRB6 as
genes involved in CTD function in vivo. SRB2 was pre-
viously isolated and shown to encode a 23 kd TBP-
binding protein. The four SRB proteins and a portion
of cellular TBP are components of a high molecular
weight multisubunit complex that is tightly bound to
RNA polymerase II. This SRB-TBP complex binds spe-
cifically to recombinant CTD protein. In vitro transcrip-
tion and template commitment assays confirm that
SRB2 and SRB5 are components of a functional preini-
tiation complex and are required for efficient transcrip-
tion initiation.
Introduction
Regulated transcription initiation by RNA polymerase II in
higher eukaryotes involves the formation of a complex with
general transcription factors at promoters (reviewed by
Sawadogo and Sentenac, 1990; Roeder, 1991; Sharp,
1991; Gill and Tijan, 1992; Zawel and Reinberg, 1992).
One of these factors, transcription factor lID (TFIID), con-
tains the TATA-binding protein (TBP), which is able to bind
directly to promoter DNA and permits the ordered assem-
bly of the remaining components of the transcription initia-
tion complex. These components include RNA polymer-
ase II and the initiation factors TFIIA, TFIIB, TFIIE, TFIIF,
TFIIH, and TFIIJ. Sequence-specific DNA-binding pro-
teins appear to regulate the establishment and activity of
transcription initiation complexes, possibly through inter-
actions with TFIIB and TBP and additional factors that
make up TFIID.
Several high molecular weight complexes containing
TBP have been identified in extracts from human and Dro-
sophila cells (reviewed by Gill and Tjian, 1992; Pugh and
Tjian, 1992; Sharp, 1992). One of these complexes is
TFIID, which contains at least eight TBP-associated fac-
tors (TAFs) (Pugh and Tjian, 1991; Tanese et al., 1991;
Timmers and Sharp, 1991; Zhou et al., 1992). A second
complex is the RNA polymerase I promoter selectivity fac-
tor, SL1, which contains TBP and three TAFs (Comai et
al., 1992). A third complex is a component of the RNA
polymerase III factor TFIIIB, which consists of TBP and
two TAFs (Taggart et al., 1992; Lobo et al., 1992; White
and Jackson, 1992). Some of the TAFs associated with
these complexes appear to function as transcriptional co-
activators by providing a functional link between se-
quence-specific regulators and TBP (Pugh and Tjian,
1990; Dynlacht et al., 1991; Pugh and Tjian, 1991; Tanese
et al., 1991; Taggart et al., 1992; Zhou et al., 1992; Hoey
et al., 1993).
The RNA polymerase II carboxy-terminal domain (CTD)
is another component of the transcription apparatus that
can bind to TBP (Usheva et al., 1992). The CTD is a highly
conserved and apparently unique feature of the largest
subunit of RNA polymerase II (reviewed by Corden, 1990;
Young, 1991). The CTD contains 26-52 repeats, depend-
ing on the organism, of the consensus heptapeptide se-
quence Tyr-Ser-Pro-Thr-Ser-Pro-Ser. Deletion mutations
that remove most or all of the CTD are lethal to cells (Nonet
et al., 1987b; Allison et al., 1988; Zehring et al., 1988;
Bartolomei et al., 1988). CTD partial truncation mutations
cause defects in growth and inducible gene expression
in vivo (Nonet et al., 1987b; Bartolomei et al., 1988; Allison
and Ingles, 1989; Scafe et al., 1990; Peterson et al., 1991)
and produce substantial defects in transcription initiation
in vitro (Liao et al., 1991). A subset of the RNA polymerase
II molecules in yeast and in mammalian cells have highly
phosphorylated CTDs (Cadena and Dahmus, 1987; Kolod-
ziej et al., 1990). RNA polymerase II molecules lacking
phosphorylation on the CTD are preferentially recruited
into the initiation complex (Laybourn and Dahmus, 1990;
Lu et al., 1991). Another important feature of RNA polymer-
ase 11 molecules recruited into the initiation complex is
their association with RNA polymerase-associated pro-
teins (RAPs) (Burton et al., 1988; Buratowski et al., 1991;
Conaway et al., 1991; Flores et al., 1991). Two mammalian
proteins, RAP30 and RAP74, have been identified as com-
ponents of the general transcription factor TFIIF (Flores
et al., 1988).
The transcriptional machinery of higher and lower eu-
karyotes appears to be highly conserved. RNA polymer-
ases I, II, and III are similar in subunit structure and func-
tion in higher and lower eukaryotes (Young, 1991). The
yeast RNA polymerase II factors b, d, and e (Flanagan et
al., 1990; Feaver et al., 1991; Tschochner et al., 1992)
are homologous in structure and function to mammalian
factors TFIIH/8, TBP, and TFIIB/a (Peterson et al., 1990;
Conaway and Conaway, 1991; Gerard et al., 1991; Cona-
way et al., 1991; Ha et al., 1991; Serizawa et al., 1992),
respectively. Both yeast and human TBP support activa-
tion by both GAL4-VP 16 and GCN4 (Kelleher et al., 1992).
As mentioned above, TBP is a component of multisubunit
complexes involved in transcription by all three nuclear
RNA polymerases in mammals. In yeast, TBP has been
identified as a component of the RNA polymerase III tran-
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scription factor TFIIIB (Buratowski and Zhou, 1992; L6pez-
de-Le6n et al., 1992; Kassavetis et al., 1992), but no yeast
counterparts of the TBP-containing complexes SL1 or
TFIID have yet been described.
At least four proteins that associate with TBP have been
identified through genetic approaches in yeast. The prod-
uct of the SUA7 gene is the yeast homolog of the mamma-
lian factor TFIIB (Pinto et al., 1992). TDS4/PCF4/BRF1 is
related to TFIIB and is a component of TFIIIB (Buratowski
and Zhou, 1992; Colbert and Hahn, 1992; L6pez-de-Le6n
et al., 1992; Kassavetis et al., 1992). The SPT3 gene was
identified as a mutation that could suppress the effect of
retrotransposon insertions into RNA polymerase II promot-
ers. Genetic and biochemical evidence indicates that
SPT3 interacts with TBP (Eisenmann et al., 1992). An ex-
tragenic suppressor of RNA polymerase II CTD truncation
mutations, SRB2-1 (SRB, suppressor of RNA polymerase
B), encodes a protein that binds TBP and is incorporated
into the RNA polymerase II transcription initiation complex
(Koleske et al., 1992). Because SPT3 and SRB2 both inter-
act physically with TBP, and mutations in these genes
affect transcription by RNA polymerase II, both are good
candidates for yeast RNA polymerase II TAFs. Further-
more, the identification of a putative yeast TAF as a sup-
pressor of an RNA polymerase II CTD truncation suggests
that the CTD might be used to identify additional TBP-
associated components of the RNA polymerase II tran-
scription initiation complex in yeast.
We report here genetic and biochemical evidence that
the yeast RNA polymerase II CTD interacts with a large
multisubunit complex that contains TBP. A genetic selec-
tion was used to isolate and characterize genes encoding
proteins that influence CTD function. Antibodies gener-
ated against recombinant proteins encoded by four of
these SRB genes were used to identify and purify a high
molecular weight complex that contains TBP and at least
a dozen additional polypeptides, all bound to RNA poly-
merase II. A similar complex can be purified via its interac-
tion with recombinant CTD protein. We show that com-
ponents of this complex are incorporated into the RNA
polymerase II transcription initiation complex.
Results
Suppressors of RNA Polymerase II CTD
Truncation Mutations
To identify components of the transcription apparatus that
affect CTD function, extragenic suppressors of a Sacchar-
omyces cerevisiae RNA polymerase II CTD truncation mu-
tant were isolated. The cold-sensitive phenotype of cells
containing RNA polymerase II CTDs with only 11 intact
heptapeptide repeats (rpblA 104) was exploited to obtain
85 independent suppressing isolates, of which approxi-
mately one-third were dominant and two-thirds recessive.
The dominant suppressing isolates were chosen for fur-
ther study. Genetic analysis revealed that all of the domi-
nant mutations occurred in four SRB genes: SRB2, SRB4,
SRB5, and SRB6 (C. M. T. and J. Zhang, unpublished
data). Additional analysis revealed that SRB4, SRB5, and
SRB6 are newly identified genes, whereas SRB2 had pre-
viously been isolated in a similar genetic selection (Nonet
and Young, 1989).
Two genetic assays were performed to obtain support
for a functional relationship between the SRB gene prod-
ucts and the CTD (Figure 1). The ability of the suppressing
alleles of SRB4, SRB5, and SRB6 to suppress all of the
phenotypes associated with the CTD truncation mutation
rpblA 104 was investigated. These phenotypes include
cold- and temperature-sensitive growth, inositol auxotro-
phy, and the inability to utilize pyruvate as a carbon source.
Cells containing either SRB4-1, SRB5-1, or SRB6-1 sup-
press all of these defective phenotypes (Figure 1B), as
does SRB2-1 (Nonet et al., 1989).
To assess whether the suppressing activities of SRB4-1,
SRB5-1, and SRB6-1 are specific to CTD mutations, we
investigated the ability of the SRB alleles to suppress the
conditional phenotypes associated with mutations else-
where in RNA polymerase II (Figure IC). SRB4-1, SRB5-1,
and SRB6-1 generally do not suppress the conditional and
auxotrophic phenotypes associated with RPB1 point muta-
tions. SRB4-1, SRB5-1, and SRB6-1 do suppress the cold-
sensitive phenotype of the rpbl-14 mutation. This is the
same type of suppression specificity shown by SRB2-1,
and this argues that SRB2, SRB4, SRB5, SRB6, and the
CTD are involved in the same process in transcription initi-
ation.
Cloning and Sequence Analysis of SRB4, SRB5,
and SRB6
We isolated genomic DNA clones containing SRB4-1,
SRB5-1, and SRB6-1 by taking advantage of their ability
to suppress dominantly the cold-sensitive phenotype of a
cell containing the CTD truncation mutation rpblJ104.
Genomic DNA was isolated from strains containing the
dominant suppressing alleles of SRB4, SRB5, and SRB6.
Libraries were constructed in a yeast centromeric plasmid
containing the URA3 gene as a selectable marker. These
libraries were transformed into yeast cells containing the
cold-sensitive CTD truncation mutation, and genomic
clones were isolated from Ura* transformants able to grow
at 120C. The mutant genes were further localized by con-
structing subgenomic libraries with fragments of the
SRB4-1, SRB5-1, and SRB6-1 genomic inserts and again
selecting for Ura* transformants able to grow at 120C.
Genomic clones with the smallest inserts were identified
and sequenced.
The wild-type allele of SRB4 was cloned from a wild-type
genomic DNA library. Wild-type SRB5 and SRB6 alleles
were obtained by plasmid gap repair in vivo (Rothstein,
1991). Plasmids containing the wild-type SRB4, SRB5, and
SRB6 genes did not suppress the cold-sensitive pheno-
type of CTD truncation mutants, confirming that in each
case the correct locus was cloned. SRB4, SRB5, and
SRB6 were physically mapped using the prime X clone
grid filters of the yeast genome (provided by L. Riles and
M. Olson, Washington University). SRB4 maps to the right
arm of chromosome V, approximately 40 kb from the cen-
tromere (X clones 5961 and 6224). SRB5 maps to the right
arm of chromosome VII, approximately 30 kb centromere
proximal to SPT6 (I clones 5146 and 4624). SRB6 maps
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tion of the suppressing mutations. The predicted SRB4
protein is 687 amino acids long and has a molecular mass
of 78 kd (Figure 2A). SRB5 is predicted to be 307 amino
acids in length with a molecular mass of 34 kd (Figure
2B). The predicted SRB6 protein is 121 amino acids long
and has a molecular mass of 14 kd (Figure 2C). A search
of sequence data banks revealed that SRB4, SRB5, and
SRB6 do not have significant sequence similarity to pre-
viously identified proteins. One notable feature of the SRB
proteins is their acidic content. The predicted pK, values
of SRB2, SRB4, SRB5, and SRB6 are 5.2, 5.1, 4.7, and
4.6, respectively.
The suppressing mutations in all three genes were iden-
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Figure 1. Genetic Characterization of SRB4-1, SRB5-1, and SRB6-1
(A) Diagram of RPB1 conditional mutations used to isolate and charac-
terize suppressors of rpbld 104 mutations. The positions of the condi-
tional mutations utilized in this study are indicated, except for those
of rpbl-4, rpbl-6, and rpbl-12, which have not been determined.
(B) Growth phenotypes of cells containing an RPB1 CTD truncation
mutation and SRB4-1, SRB5-1, and SRB6-1. Cells were spotted on
YEPD medium and incubated at 120C, 240C, and 380C (panels 1-
3), on SC medium containing pyruvate as a sole carbon source (panel
4), and on minimal medium with or without inositol (panels 5 and 6).
Isogenic wild-type, SRB4-1, SRB5-1 and SRB6-1 backgrounds con-
tained either wild-type RPB1 (27 repeat CTD) or rpbli 104 (11 repeat
CTD).
(C) Influence of SRB4-1, SRB5-1, and SRB6-1 on the growth pheno-
types of cells containing various conditional RPB1 mutations. Isogenic
wild-type, SRB4-1, SRB5-1, and SRB6-1 backgrounds containing
RPB1 alleles indicated on the left were assayed for growth by spotting
on YEPD medium and incubating at 120C, 24 0C and 380C. Similar
experiments revealed that SRB4-1, SRB5-1, and SRB6-1 do not sup-
press the growth defects of cells containing rpbl-10, rpbl-12, or
rpbl-18.
to the right arm of chromosome II, approximately 75 kb
centromere distal to CDC28 (X clone 4796).
DNA fragments containing SRB4, SRB5, and SRB6
were sequenced, and the open reading frames were es-
tablished by unidirectional deletion analysis and identifica-
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LQSLNESKDLLRASPNKLSSILQNEHDYWNKIMQS
ISNKDVIPKIRDRTSGQKLLAIKYGYEDSGSTYKH
DRGIANIRNNIESQNLDLIPHSSSVFKGTDFVHSV
KKPLRVRIPTKIESEDDYILSGESVMDRDSESERA
ETKDIRKQIQLLKKIIPEKELMYQIKKECALLISY
GVSIENENKVIIELPNEKFEIELLSLDDDSIVNHE
QDLPKINDKRANLMLVMLRLLLVVIFKKTLRSRIS
SPHGLINLNVDDDILI IRPILGKVRFANYKLLLKK
IIKDYVLDIVPGSSITETEVEREQPQENKNIDDEN
ITKLNKEIRAPDKLLNIPRRELKINLPLTEHKSPN
LSLMLESPNYCNALIHIKPSAGTEANAVSPDTTPS
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SRB6
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Figure 2. Predicted Amino Acid Sequences of SRB4, SRB5, and
SRB6 Proteins
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Figure 3. SRB2 and SRB5 Are Required for Efficient Transcription In
Vitro
(A) The template, pGAL4CG- (Lue et al., 1989), contains a CYC1 TATA
element downstream of a single GAL4-binding site that directs expres-
sion of a G-less transcript.
(B and C) Nuclear extracts made from wild-type cells (Z561) or srb5,d
mutant cells (Z562) were tested for their ability to synthesize specific
transcripts from the pGAL4CG- template in the presence or absence
of recombinant SRB2 (250 ng) and/or SRB5 (250 ng). Transcription
reactions were carried out in the absence (B) or presence (C) of recom-
binant GAL4-VP16 (150 ng). The film shown in (B) was exposed five
times longer than that in (C). Quantitation of the results indicates that
the level of specific transcripts produced by srb5A extracts is 50-fold
less than that produced by wild-type extracts in the absence of added
SRB proteins. Addition of both SRB2 and SRB5 to srb5,d extracts
restored transcript levels to approximately 40% of those observed in
wild-type extracts.
(D and E) Nuclear extracts made from wild-type cells (Z561) or srb2A 1,
srb5d1 mutant cells (Z563) were tested for their ability to synthesize
specific transcripts from the pGAL4CG- template in the presence or
absence of recombinant SRB2 (250 ng) and/or SRB5 (250 ng). Tran-
scription reactions were carried out in the absence (D) or presence
(E) of recombinant GAL4-VP16 (150 ng). The film shown in (D) was
exposed five times longer than that in (E). Quantitation of the results
indicates that the level of specific transcripts produced by srb2, srb5zA
PQAL~ca
tified by comparing the complete sequences of the cloned
wild-type and suppressing alleles of SRB4, SRB5, and
SRB6. In each case, the alterations were single-point, mis-
sense mutations. The mutation in SRB4-1 changes glycine
353 to cysteine. The SRB5-1 mutation changes threonine
22 to isoleucine, and the SRB6-1 mutation changes aspar-
agine 86 to lysine.
To determine whether the SRB genes are essential for
cell viability, the entire coding region of each of the SRB
genes was deleted to produce srb442, srb5l1, and
srb6A 1. SRB4 and SRB6 are essential. SRB5, like SRB2,
is not essential, but cells lacking the gene exhibit the slow
growth, cold-sensitive, and temperature-sensitive pheno-
types characteristic of CTD truncations.
SRB2 and SRB5 Are Required for Efficient
Transcription In Vitro
Although yeast cells lacking SRB4 or SRB6 are not viable,
cells lacking SRB2 or SRB5 are viable despite striking
defects in growth, and it is this feature that facilitates inves-
tigation of the transcriptional activity of SRB2 and SRB5
proteins using nuclear extracts in vitro. Previous studies
had revealed that SRB2 is required for efficient basal and
activated transcription initiation in vitro (Koleske et al.,
1992). The role of SRB5 was investigated similarly and
was also found to be required for efficient basal and acti-
vated transcription initiation in vitro (Figure 3). Nuclear
extracts were prepared from wild-type and srb5d 1 cells
and tested for their ability to synthesize a specific tran-
script in the presence and absence of purified recombinant
SRB5 and GAL4-VP16 proteins. Extracts from wild-type
cells produced two specific transcripts of 375 and 350 nt,
and the addition of GAL4-VP16 produced a 35-fold in-
crease in the levels of these transcripts. Extracts from
srb5A 1 cells required additional factors in order to synthe-
size significant levels of specific transcripts, in both the
presence and the absence of GAL4-VP16 (Figures 3B
and 3C). Complementation of the srb5A 1 extract required
both purified recombinant SRB2 and SRB5; the addition
of SRB5 alone failed to complement. Western blot analysis
revealed that the level of SRB2 protein is greatly reduced
in extracts prepared from srb5A 1 cells.
To confirm and extend these results, additional tran-
scription assays were performed using nuclear extracts
prepared from cells lacking SRB2 and SRB5 (Figures 3D
and 3E). The results obtained using extracts from cells
lacking both SRB proteins were identical to those obtained
with extracts from srb5A 1 cells. These extracts exhibited
no defects in promoter-independent transcription elonga-
tion assays (data not shown). These results indicate that
both SRB2 and SRB5 are required for efficient basal and
activated transcription initiation in vitro. If activated tran-
scription is simply a stimulation of the basal process, then
extracts is 50-fold less than that produced by wild-type extracts in the
absence of added SRB proteins. Addition of both SRB2 and SRB5 to
srb2A, srb5A extracts restored transcript levels to approximately 40%
of those observed in wild-type extracts.
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SRB2 and SRB5 can be considered basal transcription
factors. However, if the mechanism of transcriptional acti-
vation is more complex, then these SRB proteins may
have additional roles in activated transcription.
Formation of a Stable Preinitiation Complex
Involves SRB2 and SRB5
A template commitment assay was used to investigate
whether both SRB2 and SRB5 participate in the formation
of a transcription initiation complex (Figure 4). Extracts
prepared from cells lacking SRB2 and SRB5 were used
for performing this assay. Two templates were employed
that contained identical promoters but differed in G-less
cassette length. Specific transcripts of 375 and 350 nt
were produced from the long template, while transcripts
of 275 and 250 nt were produced from the short template.
We first performed an experiment to confirm that SRB2
is required for efficient formation of a stable preinitiation
complex (Figure 4A), as reported previously (Koleske et
al., 1992). The two templates were incubated separately
with nuclear extract and SRB5, and a limiting amount of
SRB2 protein was added to 1 of the 2 reaction mixtures.
After a 60 min preincubation, the 2 reactions were mixed
together. Immediately after mixing and every 10 min there-
after, aliquots were removed and nucleoside triphos-
phates were added to permit RNA synthesis. The reaction
was stopped after 7 min to minimize multiple rounds of
transcription. Control experiments are shown in lanes
1-4. When srb2A 1, srb5A 1 extracts were preincubated
with SRB2 and SRBS5 along with either the long template
(Figure 4A, lane 1) or short template (Figure 4A, lane 2),
transcripts of the predicted size were produced. When
both long and short templates were present in the preincu-
bation mixture, similar levels of long and short transcripts
were obtained (Figure 4A, lane 3). Virtually no transcript
was detected when both templates were preincubated
with the extract in the presence of SRB5 alone (Figure
4A, lane 4). When SRB2 was added to the long template
mixture, long transcripts were predominant after the two
extracts were mixed (Figure 4A, lanes 5-8). There was no
appreciable increase in signal from the short template
after 30 min of mixing with the long template. Similarly,
when SRB2 was added to the short template mixture, tran-
scripts were produced predominantly from the short tem-
plate with no appreciable increase in signal from the long
template after 30 min of mixing (Figure 4A, lanes 9-12).
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Figure 4. SRB2 and SRB5 Are Essential for
Efficient Preinitiation Complex Formation
(A) SRB2 is necessary for formation of a stable
preinitiation complex. The templates used in
the template commitment assay each con-
tained a CYC1 TATA element downstream of
a single GAL4-binding site that directs expres-
sion of a G-less transcript. The long (L) tem-
plate (pGAL4CG-) contained a G-less cassette
of 400 nt, and the short (S) template (pCT108)
contained a G-less cassette of 300 nt. The two
templates were incubated separately with nu-
clear extracts from srb2A 1, srb5J cells
(Z563), SRB5 (250 ng) and GAL4-VP16 (150
ng). A limiting amount of SRB2 protein (25 ng)
was added to 1 of the 2 reaction mixtures. After
a 60 min preincubation, the 2 reactions were
mixed together, and aliquots were removed at
10 min intervals and transcriptionally compe-
tent complexes were assayed by the addition of
nucleoside triphosphates. The reactions were
terminated after 7 min to minimize reinitiation.
Control experiments are shown in lanes 1-4.
Extracts from srb2A 1, srb5d 1 cells were prein-
cubated with SRB2, SRB5, and GAL4-VP16
along with short and long template, individually
(lanes 1-2) or in combination (lane 3). In lane
4, both templates were incubated in the pres-
ence of SRB5 and GAL4-VP16 but in the ab-
sence of SRB2. After mixing of preincubation
reactions, aliquots were removed and nucleo-
side triphosphates were added at the indicated
times (lanes 5-12).
(B) SRB5 is necessary for formation of a stable
preinitiation complex. The template commit-
ment assay was performed as in (A), except
that preincubations were performed in the
presence or absence of limiting amounts of
SRB5 (75 ng) and excess of SRB2 (250 ng).
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To determine whether SRB5 is required for efficient pre-
initiation complex formation, a similar experiment was per-
formed (Figure 48). This time, the two templates were
incubated separately with extract and SRB2, and a limiting
amount of SRB5 was added to 1 of the 2 reaction mixtures.
The remaining steps were performed as described above.
The results of the controls (Figure 48, lanes 1-4) were
identical to those in Figure 4A. Lanes 5-12 in Figure 4B
show that transcripts were predominantly obtained from
the template that was preincubated in the presence of
SRB5 and that there was no significant increase in signal,
even after 30 min, from the template incubated in the ab-
sence of SRB5.
The template commitment results indicate that both
SRB2 and SRBS5 are required for formation of a stable
preinitiation complex and that SRB2 and SRB5 act stoi-
chiometrically in the initiation reaction. These conclusions
are based upon two observations. First, the template pre-
incubated in the presence of all necessary factors was
preferentially transcribed, upon mixing, relative to the
other template, which was incubated in the absence of
either SRB2 or SRB5. Second, following mixing, there was
no appreciable increase in signal from the template incu-
bated in the absence of either SRB2 or SRBS5. If SRB2 or
SRB5 acted subsequent to initiation, the templates would
be transcribed equally well; since up to 30 min of incuba-
tion was allowed after template mixing, there was ample
time for any catalytic activity to be carried out on the sec-
ond template. The observation of little to no increase in
second template transcription, even after 30 min, indicates
that SRB2 and SRB5 became stably associated with the
first template during preincubation.
When the experiment in Figure 4A was performed using
excess SRB2 in the preinitiation step, transcription in-
creased with time from the template that was preincubated
in the absence of SRB2 (data not shown). Similarly, when
the experiment in Figure 4B was performed using excess
SRB5 in the preincubation step, transcription increased
with time from the template that was preincubated in the
absence of SRB5 (data not shown). This indicates that
much of the template that was preincubated in the ab-
sence of SRB2 or SRB5 was still available for transcription
and that SRB2 and SRB5 continued to be active for an
extended period in the reaction mixture. These data sug-
gest that SRB2 and SRB5 are integral components of the
preinitiation complex.
SRB Proteins, TBP, and RNA Polymerase Are
Components of a 1.2 Md Complex
The ability of mutations in SRB2, SRB4, SRB5, and SRB6
to specifically suppress the growth phenotypes of cells
with CTD truncations indicates that the products of these
genes are involved in the same functional process as the
CTD. Template commitment assays suggest that SRB2
and SRB5 are components of the transcription initiation
complex. These functional studies led us to investigate
whether the SRB proteins interact physically with one an-
other. Cells were constructed that produce functional, epi-
tope-tagged SRB4, SRB5, or SRB6 proteins, and tran-
scriptionally competent nuclear extracts were prepared
from these cells. When SRB4, SRB5, or SRB6 were immu-
noprecipitated, SRB2 and 5%-10% of the TBP in the ex-
tract were coprecipitated, as revealed by immunoblotting
(A. J. K., unpublished data). This observation suggested
that the four SRB proteins and TBP are components of a
multisubunit complex and led us to attempt purification
of the SRB proteins from wild-type cells by conventional
chromatography.
Whole-cell extracts from wild-type cells were fraction-
ated through a series of seven chromatography columns,
and rabbit polyclonal antibodies generated against recom-
binant SRB2, SRB4, SRB5, and SRB6 and against recom-
binant TBP were used to monitor these proteins during
purification (Figure 5). Essentially all of the SRB2, SRB4,
SRB5, and SRB6 in the whole-cell extract cofractionated
through the seven purification steps. Approximately 20
additional polypeptides, including a portion of the TBP in
the extract, cofractionated with the four SRB proteins. A
subset of these additional polypeptides were identified as
RNA polymerase II subunits by Western blot analysis.
The high molecular weight complex containing TBP,
SRB proteins, and RNA polymerase II appeared to be quite
stable. The proteins in this complex remained tightly asso-
ciated in fractions exposed to a variety of strong ion ex-
changers at salt concentrations up to 1.1 M potassium
acetate and upon gel filtration in buffers containing 400
mM potassium acetate. Figure 5C shows, for example,
the elution profile of TBP, SRB proteins, and RNA polymer-
ase II from the Mono S column. We estimated that the
complex was purified approximately 10,000-fold by quanti-
tative Western blot analysis. The complex appeared to be
purified to near homogeneity, since the composition of the
complex did not change on chromatography subsequent
to the Mono S column.
Gel filtration on Superose 6 revealed that these approxi-
mately two dozen polypeptides comigrate as a complex
at a position corresponding to a native molecular mass of
about 1.2 Md. The sum of the apparent molecular weights
of the polypeptide bands that appear to be components
of the complex is 1.4 Md, consistent with the size predicted
by gel filtration. Since RNA polymerase II accounts for
approximately 0.5 Md, the remaining complex has a mass
of 0.7-0.9 Md.
The components of the 1.2 Md complex have both SRB
and RNA polymerase activities in vitro. Figure 6 shows
that the 1.2 Md complex can complement a nuclear extract
Slacking SRB2 and SRB5. The specific activity of native
SRB2 and SRB5 in the complex was 100-fold that of re-
combinant SRB2 and SRB5 proteins in this assay. The
RNA polymerase activity of the complex is comparable to
that obtained with similar amounts of the purified enzyme
in nonspecific transcription assays (not shown).
A CTD Column Specifically Retains a
TBP-Containing Multisubunit Complex
The presence of RNA polymerase II and SRB proteins
in a TBP-containing multisubunit complex, together with
evidence that the CTD interacts with TBP (Usheva et al.,
1992), suggested that the SRB-TBP complex may physi-
cally interact with RNA polymerase II via the CTD. To in-
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Figure 5. Purification of the SRB Complex
(A) Fractionation scheme.
(B) The left panel shows a silver-stained SDS-polyacrylamide (1
gel containing approximately 1 gg of protein from each fraction of
SRB complex purification. Lane 1, whole-cell extract; lane 2, Bi4
70; lane 3, DEAE-Sephacel; lane 4, hydroxylapatite; lane 5, M
0; lane 6, Mono S; lane 7, DEAE-Sephacel. The positions of
polymerase II subunits, SRB proteins, TBP, and additional polyl
tides that are candidate subunits of the complex are indicated
markers.
The right panel shows Western blot analysis of 1 gg of SRB comj
protein from the DEAE-Sephacel fraction loaded onto a SDS-p
acrylamide (15%) gel and probed with antibodies against SRB
TBP proteins. The antibody probes were: lane 1, polyclonal anti-SR
lane 2, polyclonal anti-SRB4; lane 3, polyclonal anti-SRB5; lan
polyclonal anti-SRB6; and lane 5, polyclonal anti-TBP.
(C) Western blot analysis reveals that SRB proteins, RNA polymer
II, and TBP coelute from a Mono S column. Semipurified SRB com;
vestigate this possibility, yeast whole-cell extract was
loaded onto columns containing recombinant glutathione
S-transferase (GST)-CTD fusion protein or GST alone,
the columns were washed extensively, and bound protein
was eluted with low concentrations of guanidine hydro-
chloride (Figure 7). Guanidine hydrochloride (0.3 M) was
used for elution because proteins specifically bound to
the GST-CTD column could not be eluted with buffers
containing high salt concentrations (2 M potassium ace-
tate). The proteins that specifically bound the GST-CTD
affinity column include the four SRB polypeptides, TBP,
and at least a dozen additional polypeptides, many of
which appear to be components of the TBP-containing
multisubunit complex purified by conventional chromatog-
raphy.
The TBP-containing complex purified by CTD affinity
chromatography differs from the conventionally purified
complex principally in lacking RNA polymerase II subunits.
The additional differences in the components of the two
complexes may be due to proteins that bind to the CTD
but are not components of the SRB complex purified by
conventional chromatography. Identifying the precise num-
ber of functional components and determining whether
some components are modified or processed products of
others will require further molecular genetic characteriza-
tion. Nonetheless, these data indicate that the four SRB
proteins and TBP are components of a multisubunit com-
plex that interacts physically with the RNA polymerase
II CTD.
Discussion
We have obtained genetic and biochemical evidence for
functional and physical interactions between the RNA
polymerase II CTD and a high molecular weight multisub-
unit complex containing TBP in yeast. Evidence for this
TBP-containing complex was obtained initially through a
genetic selection and subsequently through two indepen-
dent biochemical purifications. The isolation and genetic
characterization of four dominant extragenic suppressors
of RNA polymerase II CTD truncation mutations indicated
that at least four SRB gene products are involved in the
same function as the RNA polymerase II CTD. Large multi-
subunit complexes containing the four SRB proteins and
TBP could be purified from yeast, both by conventional
chromatography and by CTD affinity chromatography. The
TBP-containing complexes purified by the two procedures
5 are similar, except that the complex purified by conven-
orex tional chromatography also contains RNA polymerase II.'
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(0.8 mg of total protein) from the Mono Q column was loaded onto a
Mono S column and eluted with a 0.1-1.0 M gradient of potassium
acetate as described in Experimental Procedures. The onput and flow-
through material (1/25) and every other eluate fraction (1/50) were
analyzed by Western blot for the presence of RPB1, SRB4, SRB5,
SRB2, TBP, and SRB6. The SRB complex eluted in a peak correspond-
ing to approximately 0.4 M potassium acetate.
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Figure 6. The Purified Complex Contains SRB2 and SRB5 Activities
Nuclear extracts from wild-type (Z561) or srb2A 1, srb5d 1 cells (Z563)
were tested for their ability to synthesize specific transcripts from the
pGAL4CG- template in the presence of recombinant GAL4-VP16 fu-
sion protein (150 ng). Recombinant SRB2 and SRB5 were added to
reactions as follows: lane 3, 500 ng of SRB2; lane 4, 500 ng of SRB5;
lane 5, 62.5 ng of both SRB2 and SRB5; lane 6, 125 ng of SRB2 and
SRB5; lane 7, 250 ng of SRB2 and SRB5; lane 8, 500 ng of SRB2
and SRB5. Purified SRB complex was added to reactions as follows:
lane 9, 250 ng; lane 11, 62.5 ng; lane 12, 125 ng; lane 13, 250 ng;
lane 14, 500 ng. One microgram of SRB complex contained approxi-
mately 20 ng of SRB2 and 25 ng of SRB5, as estimated by quantitative
Western analysis with known amounts of recombinant SRB2 and
SRB5 proteins.
SRB Suppressors of CTD Mutations
The SRB2 gene was previously isolated as a dominant,
gain of function suppressor of RNA polymerase II CTD
truncation mutations and was subsequently shown to en-
code a TBP-associated factor (Koleske et al., 1992). Rea-
soning that additional extragenic suppressors might be
obtained that could encode TAFs or other components of
the transcription initiation complex, we isolated approxi-
mately 30 dominant suppressing isolates of CTD trunca-
tion mutations, and found that all occur in SRB2, SRB4,
SRB5, and SRB6. Mutations in these four SRB genes spe-
cifically suppress CTD truncation mutations, 'indicating
that the CTD and the SRB gene products are involved in
the same functional process during initiation.
Features of Yeast SRB-TBP Complex
A large multisubunit complex containing TBP, SRB pro-
teins, and RNA polymerase II was identified using conven-
tional purification approaches. RNA polymerase II, the
SRB proteins, and TBP cofractionated with additional pro-
teins through seven chromatographic purification steps.
The purified complex behaves on gel filtration as if it has
a native molecular mass of approximately 1.2 Md, consis-
tent with the combined molecular weights of the roughly
two dozen protein components of the complex, which add
up to 1.4 Md, assuming a subunit stoichiometry of 1. The
complex appears to be quite stable; its components re-
main tightly associated even when exposed to strong ion
exchangers at salt concentrations above 1 M. The specific
acitivity of SRB2 and SRB5 in the purified complex is 100-
fold higher than that of recombinant SRB2 and SRB5 pro-
teins, and RNA polymerase II within the purified complex
has a specific activity that is comparable to that of purified
RNA polymerase II in promoter-independent transcription
elongation assays. These data suggest that the purified
complex represents a physiologically relevant association
between TBP, RNA polymerase II, and SRB proteins.
Three features of the complex-- its high molecular weight,
stability in high salt, and association with TBP-are char-
acteristic of some multisubunit TFIID complexes de-
scribed in mammalian and Drosophila cells (Samuels et
al., 1982; Conaway et al., 1991; Zhou et al., 1992).
Yeast cells contain approximately 10,000 genes, and at
any one time a portion of these genes contain a transcrip-
tion initiation complex assembled at the promoter. Quanti-
tative Western blot analysis suggests that there are about
1000 molecules per cell of each of the SRB proteins and
that essentially all of the SRB proteins in yeast cell lysates
are incorporated into the SRB-TBP complex (A. J. K.,
unpublished data). The complex contains a molecule of
RNA polymerase II, which accounts for approximately 2%
of the total RNA polymerase II found in these cells; the
rest of the enzyme may be actively engaged in transcript
elongation or in recycling. About 5%-10% of total cellular
TBP is associated with the high molecular weight complex.
These data suggest that transcription initiation complexes
containing the SRB proteins occur at approximately 1000
yeast promoters at any one time. It is not yet clear whether
the SRB complex is involved in transcription initiation at
all promoters utilized by RNA polymerase II.
RNA polymerase II appears to interact with the SRB-
TBP complex via the CTD. A TBP-containing complex
lacking RNA polymerase II can be purified by its ability to
bind tightly to the CTD. The CTD was previously shown
to interact directly with TBP (Usheva et al. 1992), and we
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A TBP-Associated Complex Binds to the RNA Polymerase
(Left panel) Silver-stained SDS-polyacrylamide (15%) gel containing
the TBP-containing complex purified by conventional chromatography
(lane 1) and proteins in a TBP-containing complex purified by CTD
affinity chromatography (lane 2). Yeast whole-cell extract was loaded
on GST-CTD and GST control (lane 3) columns, the columns were
washed, and proteins were eluted with 0.3 M guanidine hydrochloride.
The positions of RNA polymerase II subunits, SRB proteins, TBP, and
additional polypeptides that are candidate subunits of the complex
purified by conventional chromatography are indicated.
(Right panel) Western blot analysis of proteins isolated by CTD affinity
chromatography. The antibody probes were: lane 1, polyclonal anti-
SRB2; lane 2, polyclonal anti-SRB4; lane 3, polyclonal anti-SRB5; lane
4, polyclonal anti-SRB6; lane 5, polyclonal anti-TBP.
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Figure 8. Model of Preinitiation Complex Containing the SRB-TBP-
RNA Polymerase II Complex
The diagram is drawn to emphasize physical relationships between
the RNA polymerase II CTD and TBP and between TBP and SRB2
and SRB5. The nomenclature for general transcription factors from
higher eukaryotes is used. The relative positions of RNA polymerase
II, TBP, TFIIA, and TFIIB are based upon DNAase I footprint analysis
(Buratowski et al., 1989). Other aspects of the arrangement of the
proteins in the complex are purely hypothetical. It is not clear whether
TFIIA and TFIIB are components of the purified SRB-TBP-RNA poly-
merase II complex.
have confirmed these results. Thus, the interaction be-
tween the CTD and the SRB-TBP complex probably in-
volves a physical interaction with TBP itself. However,
components of the complex other than TBP may also inter-
act directly with the CTD. In addition, some components
of the conventionally purified complex may interact with
RNA polymerase II at sites other than the CTD; this may
account for the some of the differences in polypeptides
associated with the SRB-TBP-RNA polymerase II com-
plex and those that bind the CTD column.
The mammalian RNA polymerase II CTD also appears
to interact functionally with high molecular weight forms
of TFIID. Assembly of a mammalian initiation complex with
native rat TFIID(r) can be blocked by monoclonal anti-CTD
antibodies but is not blocked if initiation complexes are
assembled with recombinant TBP (Conaway et al., 1992).
These data imply that mammalian TBP-associated pro-
teins affect the interaction between the CTD and TBP
when the native form of TFIID is employed. This interpreta-
tion is consistent with our observation that SRB compo-
nents of the yeast SRB-TBP complex influence CTD func-
tion in vivo.
Are the yeast SRBs homologs of mammalian and Dro-
sophila TAFs? TAFs are not yet well defined, and at least
two criteria have been used to describe them. TAFs can
be described simply as proteins tightly associated with
TBP. Using this definition, SRB proteins are yeast TAFs.
Some mammalian and Drosophila TAFs can act as coacti-
vators; coactivators are necessary for high levels of acti-
vated but not basal transcription in vitro. While it is not clear
that all TAFs have coactivating activity, some investigators
equate TAFs with coactivating factors. It is not yet clear
whether components of the SRB-TBP complex are coacti-
vators. SRB2 and SRB5 themselves affect both activated
and basal transcription in a crude in vitro transcription
system, in contrast with the criteria attributed to coactiva-
tors that have been defined using partially purified factors.
Whether or not the yeast SRBs are "coactivators," the data
indicate that SRB proteins are involved in the regulation
of transcription initiation, as they are required to obtain
fully activated levels of transcription from specific genes
in vivo (Koleske et al., 1992). The SRB proteins identified
thus far do not appear to be among the proteins that are
essential for specific transcription initiation in a defined
yeast in vitro transcription system (R. Kornberg, personal
communication). However, the use of purified factors for
reconstituted transcription in vitro may obviate a require-
ment for factors, like SRB proteins, that play important
roles in transcription initiation in vivo.
An important aspect of the yeast multisubunit complex
described here is the genetic and biochemical evidence
that indicates that it. is physiologically significant. How-
ever, we have only limited clues to the structure of the
complex. Thus far, the evidence indicates that the RNA
polymerase II CTD interacts with TBP which, in turn, is
associated with a complex of proteins that include SRBs
(Figure 8). SRB2 and SRB5 can bind directly to TBP
(Koleske et al., 1992; C. M. T., unpublished data). Other
components of this complex may contact these SRB pro-
teins, TBP, and/or RNA polymerase II. It is not yet clear
whether the complex we have purified assembles inde-
pendently of promoter DNA in vivo or has dissociated from
promoters upon cell disruption. Indeed, it is possible that
the SRBs are brought to the initiation complex in associa-
tion with RNA polymerase II independently of TBP.
The TBP-Containing Complex As
Central Processor
The RNA polymerase II CTD has been implicated in the
response of the transcription apparatus to positive and
negative regulatory signals at prdinoters in vivo (Allison
and Ingles, 1989; Scafe et al., 1990; Peterson et al., 1991;
Buermeyer et al., 1992). CTD truncations magnify tran-
scriptional defects in a variety of GAL4 activation mutant
strains, whereas extension of the CTD suppresses these
defects (Allison and Ingles, 1989). Similarly, there is a pro-
gressive loss in the ability to induce transcription of spe-
cific yeast genes, such as GAL10, as the CTD is truncated
from 27 to 11 repeats; sensitivity to CTD truncations maps
to the upstream activating sequences (Scafe et al., 1990).
Transcription of the TATA-less mammalian promoter of
the dihydrofolate reductase gene in vitro is CTD depen-
dent, and deletion analysis suggests that the Spl-binding..
site and the initiator element confer the requirement for
the CTD (Buermeyer et al., 1992). Elimination of at least
one negative regulatory factor, SIN1, can partially sup-
press transcriptional defects that are due to CTD trunca-
tion (Peterson et al., 1991).
A large multisubunit complex containing TBP could act
as a central processor to receive and act on both positive
and negative transcriptional regulatory signals. Some TAF
proteins from higher eukaryotes can function as transcrip-
tional coactivators, apparently by serving as a link between
DNA-binding activator proteins and TBP. Additional com-
ponents of TFIID may respond to negative regulatory sig-
1. Yeast StrainsTable
Strain
BJ926
Z22
Z26
Z28
Z425
Z551
Z552
Z553
Z554
Z555
Z556
Z557
Z558
Z559
Z560
Z561
Z562
Z563
Z564
Z565
Z566
nals. In yeast, the CTD and SRB proteins have been impli-
cated in the response of the transcription apparatus to
regulatory signals at promoters in vivo and in vitro (Allison
and Ingles, 1989; Scafe et al., 1990; Peterson et al., 1991;
Liao et al., 1991; Koleske et al., 1992). Thus, the SRB-
TBP complex may process multiple signals at promoters
and govern the decision to initiate transcription.
Experimental Procedures
Genetic Manipulations
Yeast strains and plasmids are listed in Tables 1 and 2, respectively.
Yeast medium was prepared as described (Nonet and Young, 1989),
except pyruvate medium, which consists of synthetic complete (SC)
medium with 2% pyruvic acid (Sigma) as a carbon source. Yeast trans-
formations were done using a lithium acetate procedure (Schiestl and
Gietz, 1989). Plasmid shuffle techniques were performed as described
by Boeke et al. (1987), using 5-fluoroorotic acid (5-FOA) as a selective
agent against URA3 plasmids.
Extragenic suppressors of the cold-sensitive phenotype of Z551
were isolated as previously described (Nonet and Young, 1989). Domi-
nant suppressors were identified by mating to Z26, selecting against
the presence of pRP112 (Nonet et al., 1987b) using 5-FOA and
assaying growth at 120C on YEPD. Diploids able to grow at 120C
contained a dominant suppressor. Isogenic wild-type, SRB4-1, SRB5-
1, and SRB6-1 strains containing various RPB1 alleles (rpbl-4, rpbl-5,
rpbl-6, rpbl-10, rpbl-12, rpbl-13, rpbl-14, rpbl-15, and rpbl-18) on
LEU2 CEN plasmids (Scafe et al., 1990) were constructed using Z26,
Z555, Z556, and Z557 and plasmid shuffle techniques. Isogenic wild-
type, SRB4-1, SRB5-1, and SRB6-1 strains containing rpbl-1 on a
URA3 CEN plasmid, pRP1-1[U] (Nonet et al., 1987a), were constructed
by transforming Z551, Z552, Z553, and Z554 with pRP1-1 [U], followed
by growth in SC-Ura medium to permit loss of pC6 (Nonet et al.,
1987b). Growth assays were performed by suspending similar num-
bers of cells in water and transferring equal volumes to agar plates
with a 48 prong apparatus.
Deletions of SRB4, SRB5, and SRB6 were created by a single step
disruption method (Rothstein, 1991). Z558 was transformed with the
desired DNA fragment and plated on the proper selective medium.
Southern analysis was used to confirm that a single copy of the desired
SRB gene had been deleted. The diploid was sporulated and tetrads
(more than 20) were dissected on YEPD plates and scored for nutri-
tional auxotrophies and growth at a variety of temperatures. Z565 was
created by transformation with the EcoRI-Xbal fragment of pCT54
containing the srb4,A2::HIS3 fragment and plating on SC-His medium.
Two spores or fewer from each tetrad were viable, and these were all
histidine auxotrophs, indicating that SRB4 is essential. To confirm that
SRB4 is essential, Z565 was transformed with pCT15 (URA3 SRB4),
tetrads were dissected, and His' Ural segregants were streaked to
5-FOA plates. They were unable to grow on 5-FOA-containing medium,
confirming that SRB4 is essential. Z559 was created by transformation
with the EcoRI-Sphl fragment of pCT37 containing the srb5,d ::URA3-
hisG fragment and plating on SC-Ura medium. Segregants scored
2:2 for uracil prototrophy and all uracil prototrophs exhibited cold-
sensitive, temperature-sensitive, and slow growth phenotypes, indicat-
ing that SRB5 deletion strains are conditionally viable. Z564 was cre-
ated by transformation with the Bglll-BamHI fragment of pCT38
containing the srb6Al::URA3hisG fragment and plating on SC-Ura
medium. Two spores or fewer from each tetrad were viable, and these
spores were all uracil auxotrophs, indicating that SRB6 is essential.
To confirm that SRB6 is essential, Z564 was transformed with pCT66
(LEU2 SRB6), tetrads were dissected, and Z566 was created by placing
a Ura+ Leu+ segregant onto 5-FOA to select for the excision of the
URA3 gene (Alani et al., 1987). Z566 was transformed with pCT40
(URA3 SRB6), grown in SC-Ura medium to permit loss of pCT66, and
then tested for growth on 5-FOA plates. No growth was observed on
5-FOA, confirming that SRB6 is essential.
Several strains were constructed for producing yeast nuclear ex-
tracts for in vitro transcription assays. Z425 was mated to Z560, and
tetrads were dissected to produce the wild-type Z561, srb5,1 1::URA3-
hisG strain Z562, and srb2A 1::HIS3, srb5Al::URA3hisG strain Z563.
Z562 and Z563 displayed identical temperature-sensitive, cold-sensi-
tive and slow growth phenotypes.
DNA Methods
DNA manipulations were performed according to Sambrook et al.
(1989). Site-directed mutagenesis was performed as described in Kun-
kel et al. (1987). Polymerase chain reaction (PCR) amplifications to
produce pCT54 (srb4A2), pCT37 (srb5d 1), and pCT38 (srb6S 1) were
performed with Taq DNA polymerase (Perkin Elmer) in 100 g1 of buffer
(provided by the manufacturer) supplemented with 1.0 mM MgC12 and
200 ýiM dNTP for a total of 25 cycles. Primer concentrations were 0.5
iM with 50 ng of DNA and cycling was at 94 0C (1.0 min), 500C (1.0
min), and 720C (2.5 min).
Library Construction and Cloning
Yeast genomic DNA libraries were prepared from strains Z28 (wild
type), Z552 (SRB4-1), Z553 (SRB5-1), and Z554 (SRB6-1). Genomic
Cell
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Alias Genotype
Mat a/Mat a trpllTRPl prcl-1261prc1-126 pep4-31pep4-3 prpl-11221prbl-1122 canllcanl
N114 Mat a ura3-52 his3A200 Ieu2-3,112
N247 Mat a ura3-52 his3zd200 leu2-3,112 rpb1A 187::HIS3 (pRP112[URA3 RPB11])
RY4 Mat a/MAT a mal-lmal- gai2/gal2
YTK73 Mat a his3A•200 leu2-3,112 ura3-52 trp 1A1 lys2-801 srb2A 1::HIS3
N400 Mat a ura3-52 his3d200 leu2-3,112 rpbld A187::HIS3 (pC6[LEU2 rpbld 104])
CTY3 Mat a ura3-52 his3A200 leu2-3,112 rpblA 187::HIS3 SRB4-1 (pC6 [LEU2 rpb l A104])
CTY8 Mat a ura3-52 his3Jd200 leu2-3,112 rpbld 187::HIS3 SRB5-1 (pC6 [LEU2 rpbld 104])
CTY9 Mat a ura3-52 his34200 leu2-3,112 rpblA 187::HIS3 SRB6-1 (pC6 [LEU2 rpbld 1041)
CTY15 Mat a ura3-52 his3z200 leu2-3,112 rpbld 187::HIS3 SRB4-1 (pRP112 [URA3 RPB1])
CTY20 Mat a ura3-52 his3A200 leu2-3, 112 rpbl 187::HIS3 SRB5-1 (pRP112 [URA3 RPB1])
CTY21 Mat a ura3-52 his3A200 leu2-3,112 rpblA 187::HIS3 SRB6-1 (pRP112 [URA3 RPB1])
CTY143 Mat alMAT a ura3-521ura3-52 his3,d2001his3A200 leu2-3,11211eu2-3,112
CTY144 Mat a/MAT a ura3-521ura3-52 his3,d2001his3A,200 leu2-3, 11211eu2-3, 112 srb5,z I::URA3hisGISRB5
CTY 148 Mat a ura3-52 his3A 200 leu2-3, 112 srb5A 1::URA3hisG
CTY151 Mat a ura3-52 his3z4200 leu2-3,112 lys2-801
CTY153 Mat a ura3-52 his3zJ200 leu2-3,112 lys2-801 srb5,d ::URA3hisG
CTY154 Mat a ura3-52 his3A200 leu2-3,112 lys2-801 srb2zd 1::HIS3 srb5A 1::URA3hisG
CTY158 Mat alMat a ura3-521ura3-52 his3d 2001his34200 leu2-3, 11211eu2-3, 112 srb6A 1::URA3hisGISRB6
CTY176 Mat alMat a ura3-52/ura3-52 his3A,2001his3,d200 leu2-3, 11211eu2-3, 112 srb4eA2::HIS31SRB4
CTY184 Mat a ura3-52 his3,1200 leu2-3,112 srb6,d 1::hisG (pCT66 [LEU2 SRB6])
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Table 2. Plasmids
Plasmid Description
pCT3 URA3 CEN plasmid. pUN55 (Elledge and Davis, 1988) with Hpal-Nael fragment removed, Xhol site in polylinker destroyed
by digestion and blunting, and Xhol linker (CCGCTCGAGCGG) inserted into Smal site of polylinker
pCT108 pGAL4CG- (Lue et al., 1989) with 300 bp G-less cassette created by ligating Smal G-less cassette from pJJ460 (Woontner
et al., 1991) with Smal vector fragment of pGAL4CG-.
pDC127 pQE9 (Qiagen) with 6xHIS-GST-12CA5 fusion. An oligonucleotide encoding the 12CA5 epitope flanked by a Bglll and a
BamHI site was cloned into same of pSP72 (Promega), followed by insertion into BamHI of pGEX-2T (Pharmacia).
GST-12CA5 fusion was amplified by PCR and inserted into BamHI-Sall-digested pSP72. GST-12CA5 fusion was then
cloned into pQE9.
pDC130 pQE9 (Qiagen) with 6xHIS-GST-12CA5-CTD fusion. A Kpnl RPB1 containing fragment from pV14 (Nonet et al., 1987b) was
inserted into same of pSP72 (Promega), followed by insertion of the BamHI fragment encoding the CTD and 98
N-terminal adjoining amino acids of RPB1 into pDC127.
SRB4
pCT4 pCT3 with 9 kb genomic (Z28) Sau3A fragment containing SRB4 inserted at Xhol site.
pCT8 pCT3 with 8 kb genomic (Z552) Sau3A fragment containing SRB4-1 inserted at Xhol site.
pCT15 pCT3 with 2.5 kb subgenomic (pCT4) Sau3A fragment containing SRB4 inserted at Xhol site.
pCT16 pCT3 with 2.8 kb subgenomic (pCT4) Sau3A fragment containing SRB4 inserted at Xhol site.
pCT48 pCT15 with BstXI-SnaBI SRB4-1 C-terminus fragment from pCT8 replacing same SRB4 fragment.
pCT54 srb4A2::HIS3, created by ligation of SRB4 Sall-BamHI from pCT16 with Sall-BamHI of pSP72 (Promega), followed by PCR
with the oligonucleotides TAATATCCTGAGTCACTCCT and TATGGCTTTTAAGCTGCTTA and ligation of PCR product
with Smal HIS3 kan fragment from 82179 (G. R. Fink, Whitehead).
pCT107 pGEX-2T (Smith and Johnson, 1988) with GST-SRB4 fusion. Ndel site at ATG of SRB4 created by ligation of SRB4 Sall-
Xbal from pCT15 with Sall-Xbal of pBSIISK(-) (Stratagene), followed by site-directed mutagenesis. Ndel (partial/blunt)-
SnaBI SRB4 containing fragment was then ligated with BamHI (blunt)-digested pGEX-2T.
SRB5
pCT14 pCT3 with 9 kb genomic (Z553) Sau3A fragment containing SRB5-1 inserted at Xhol site.
pCT20 pCT3 with 1.9 kb subgenomic (pCT14) Sau3A fragment containing SRB5-1 inserted at Xhol site.
pCT32 pCT20 with unique Sacl site in insert, created by removal of Narl (blunt)-Sacll (blunt) fragment from vector.
pCT37 srb5 1::URA3hisG, created by ligation of SRB5-1 EcoRI-BamHI from pCT20 with EcoRI-BamHI of pSP72 (Promega), followed
by PCR with the oligonucleotides TAATCATTGGCACCTGGGCA and CTTTTCTTCTTAATATGGAA and ligation of PCR
product with Bglll (blunt)-BamHI (blunt) URA3 ken hisG cassette from B2178 (G. R. Fink).
pCT39 pCT32 containing SRB5, obtained by gap repair of vector containing fragment of pCT32 Sacl-Xhol digest.
pCT98 pET-3a (Studier and Moffat, 1986) with SRB5. Ndel site at ATG of SRB5 created by ligation of SRB5 EcoRIl-BamHI from
pCT39 with EcoRIl-BamHI of pBSIISK(-) (Stratagene), followed by site-directed mutagenesis. Ndel-EcoRI (blunt)
SRB5-containing fragment was then ligated with Ndel-BamHI (blunt)-digested pET-3a.
SRB6
pCT26 pCT3 with 3 kb genomic (Z554) Sau3A fragment containing SRB6-1 inserted at Xhol site.
pCT29 pCT3 with 1.0 kb subgenomic (pCT26) Sau3A fragment containing SRB6-1 inserted at Xhol site.
pCT38 srb6,d ::URA3hisG, created by ligation of SRB6-1 EcoRI-BamHI from pCT29 with EcoRI-BamHI of pSP72 (Promega), followed
by PCR with oligonucleotides TAAAAAGGCGGTATTTATCT and CATATAGTGCCTGGTTGCTC and ligation of PCR
product with Bglll (blunt)-BamHI (blunt) URA3 kan hisG cassette from B2178 (G. R. Fink).
pCT40 pCT29 with SRB8, obtained by gap repair of vector containing fragment of pCT29 Ball-Sphl digest.
pCT66 LEU2 CEN pUN105 (Elledge and Davis. 1988) with SRB6, created by ligation of SRB6 BamHI (blunt)-Sall (blunt) from pCT40
with Smal-digested pUN105.
pCT116 pGEX-2T (Smith and Johnson, 1988) with GST-SRB6 fusion. Ndel site at ATG of SRB6 created by ligation of SRB6 Sall-
Xbal from pCT40 with Sall-Xbal of pBSIISK(+) (Stratagene), followed by site-directed mutagenesis. Ndel (blunt)-Xbal
SRB6-containing fragment was then ligated with BamHI (blunt)-digested pGEX-2T.
DNA was isolated as described by Phillippsen et al. (1991), partially
digested with Sau3A, and separated on a 0.7% agarose gel, 8-12 kb
fragments were purified by electroelution, and the ends were partially
filled in with d(AG)TP using Klenow. The URA3 centromeric plasmid
pCT3 was digested with Xhol, and the ends were partially filled in
with d(CT)TP to make them compatible with the ends of the Sau3A-
digested genomic DNA. Following ligation, DH5a cells made com-
petent by the method of Hanahan (Hanahan et al., 1991) were
transformed. Libraries contained approximately 150,000 individual re-
combinants with an average insert size of approximately 10 kb. Sub-
genomic DNA libraries were prepared from pCT4 (SRB4), pCT14
(SRB5-1), and pCT26 (SRB6-1) in a manner similar to that described
above for the genomic DNA libraries. Plasmid insert DNA was par-
tially digested with Sau3A and separated on a 1.5% agarose gel, and
1-3 kb fragments were purified by gene clean (BIO 101), and the ends
were partially filled in with d(AG)TP using Klenow. Fragments were
ligated with pCT3 prepared as described above and transformed into
DH5a cells. Subgenomic libraries contained approximately 20,000 in-
dividual recombinants with an average insert size of 2 kb.
Genomic clones of SRB4-1 (pCT8), SRB5-1 (pCT14), and SRB6.1
(pCT26) were isolated by transformation of the respective genomic
library into Z551, plating to SC-Ura medium and placing plates at
120C following a 12 hr recovery period at 300C. Approximately 1 in
2000 primary transformants was able to grow at 120C. For each library
transformed, the genomic clone was isolated by the method of Hoffman
and Winston (1987), from over 12 Ura* colonies able to grow at 120C,
and was retested for the ability to suppress the cold-sensitive pheno-
type of Z551. A genomic clone of SRB4 (pCT4) was isolated from the
wild-type Z28 library using a recessive SRB4 allele, which has a tight
temperature-sensitive phenotype in combination with a CTD truncation
allele of 11 repeats. The presence of pCT4 restores a leaky tempera-
ture-sensitive phenotype to this strain at 38°C. Subgenomic clones
made from pCT4 (SRB4), pCT14 (SRB5-1), and pCT26 (SRB6-1) were
selected as described above in order to isolate pCT15 and pCT16
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(SRB4), pCT20 (SRB5-1), and pCT29 (SRB6-1), respectively. pCT15
and pCT16 differ only in the amount of DNA downstream of SRB4.
pCT39 was created from pCT32 in vivo by transforming Z22 with Sacl-
Xhol-digested pCT32 DNA and isolating the plasmid from a Ural trans-
formant that had repaired the plasmid with wild-type SRBS5 sequences
from the chromosome (Rothstein, 1991). Similarly, SRB6 was isolated
using Ball-Sphl-digested pCT29 DNA to create pCT40.
Sequence Analysis
Insert DNAs from pCT15, pCT20, and pCT29 (containing SRB4, SRBS-
1, and SRB6-1, respectively) were completely sequenced on each
strand. Unidirectional deletions were constructed using the Erase-a-
Base system (Promega), and double-stranded sequencing with di-
deoxynucleotides and Sequenase (US Biochemical) was carried out
as described by the manufacturer, using T3 and T7 promoter primers.
The suppressing mutations in SRB4, SRB5, and SRB6 were deduced
by sequencing using oligonucleotide primers that spanned the entire
open reading frames. Positive numbering of the DNA begins with the
predicted start site of translation. pCT15 (SRB4) and pCT48 (SRB4-1)
were sequenced, and the SRB4-1 mutation was identified as a G to
T transversion (nucleotide 1057) that changed amino acid 353 from
Gly to Cys. pCT39 (SR85) and pCT32 (SRB5-1) were sequenced, and
the SRB5-1 mutation was identified as a C to T transition (nucleotide
65) that changed amino acid 22 from Thr to lie. pCT40 (SRB6) and
pCT29 (SRB6-1) were sequenced, and the SRB6-1 mutation was identi-
fied as a C to G transversion (nucleotide 258) that changed amino acid
86 from Asn to Lys. Sequence comparison analysis was performed at
the National Center for Biotechnology Information using the BLAST
network service (Altschul et al., 1990).
Purification of Recombinant Proteins
Purification of SRB2 has been previously described (Koleske et al.,
1992). SRB5 protein was purified from the bacterial strain BL21(DE3)
pLysS (Studier and Moffatt, 1986) carrying the plasmid pCT98 in the
same manner in which SRB2 was purified. SRB4 and SRB6 were
purified as fusions to GST from DH5a carrying pCT107 and pCT116,
respectively, according to the method of Smith and Johnson (1988).
GAL4(1-147)-VP16 protein was purified as described by Chasman et
al. (1989) from XA90 carrying pJL2. GST-fusion proteins for CTD affin-
ity purification were purified from DH5a carrying pDC 127 or pDC 130 by
affinity chromatography on glutathione-agarose (Sigma) and Ni-NTA
agarose (Qiagen), and then by ion exchange chromatography on SP
Sepharose (Pharmacia) to an approximate purity of 95%.
In Vitro Transcription
Promoter-dependent in vitro transcription was carried out as described
by Liao et al. (1991). Three hundred nanograms of template were used
for promoter-dependent in vitro transcription reactions, except the tem-
plate commitment assays, in which 600 ng of template was used per
reaction. Optimal activity was obtained using 100 pg of Z561 protein,
150 ig of Z562 protein, and 150 pg of Z563 protein. Transcripts were
quantified using a Fuji Bio-image analyzer. Promoter-independent
transcription assays were performed according to Nonet et al. (1987b).
Purified SRB complex used in in vitro transcription assays was purified
as described below. Eluate from the second Biorex 70 column was
dialyzed in buffer A(50) (buffer A containing 50 mM potassium acetate)
and concentrated 4-fold by centrifugation through Centricon 10 filter
units (Amicon).
Purification of SRB Complex
Yeast strain BJ926 (Buchman et al., 1988) was grown at 300C to ODao0
of 4.0-4.5 in 1 x YNB medium (0.15% Difco yeast nitrogen base, 0.5%
ammonium sulfate, 200 pIM inositol, 2% glucose). The level of the SRB
complex appeared to be elevated in cells grown in minimal medium
(A. J. K., unpublished data), and this observation was exploited to
facilitate purification of the TBP-containing SRB complex. Cells were
collected by centrifugation and washed in ice cold buffer (20 mM
HEPES KOH [pH 7.5], 10% glycerol, 50 mM potassium acetate, 1 mM
dithiothreitol [DTT], and 1 mM EDTA). Whole-cell extract was prepared
from 480 g of cell paste as described by Sayre et al. (1992). Protease
inhibitors used where indicated were: 1 mM phenylmethylsulfonyl fluo-
ride, 2 mM benzamidine, 2 ;IM pepstatin A, 0.6 ILM leupeptin, 2 pg/
ml chymostatin, 5 pg/ml antipain HCI (Sigma).
During purification, the SRB complex was monitored by Western
blot using antibodies to SRB2, SRB4, SRB5, and SRB6. Silver staining
of gels was performed as per Blum et al. (1987), with minor modifica-
tions. The gels were fixed for a minimum of 4 hr, and the impregnation
with silver nitrate was performed for 40 min.
Whole-cell extract (8 g of protein in 390 ml) was diluted 1:5 in buffer
A (20% glycerol, 20 mM HEPES KOH [pH 7.5], 1 mM DTT, 1 mM
EDTA, and protease inhibitors). The extract was loaded onto a 5 cm
x 17 cm Biorex 70 (Bio-Rad Laboratories) column at a flow rate of 5
mllmin. The column was washed with buffer A (100) until no further
protein could be eluted from the column. The column was then eluted
with step washes of buffer A (300) and buffer A (600). The SRB complex
eluted in the 600 mM potassium acetate step.
The Biorex 70 (600) fraction (250 mg in 120 ml) was diluted 1:6 with
buffer B (20% glycerol, 20 mM Tris-acetate [pH 7.9], 1 mM DTT, 1
mM EDTA, 0.01% Nonidet P-40, and protease inhibitors) and was
loaded onto a 2.5 cm x 8.5 cm diethylaminoethyl (DEAE)-Sephacel
column (Pharmacia) at a flow rate of 4 mllmin. The column was washed
extensively with buffer B (100) and then eluted with step washes of
buffer B (400) and buffer B (650). The SRB complex eluted from this
column in the 400 mM potassium acetate step.
The DEAE-Sephacel (400) fraction (48 ml) was dialyzed into buffer
C (20% glycerol, 10 mM potassium phosphate [pH 7.7], 100 mM potas-
sium acetate, 1 mM DTT, 0.25 mM EDTA, 0.01% Nonidet P-40, and
protease inhibitors). The dialysate was spun in a Sorvall SS34 rotor
at 10,000 rpm for 20 min and the supernatant (50 mg of protein in 50
ml) was loaded onto a 1.5 cm x 6.5 cm Bio-Gel HTP Hydroxylapatite
at a flow rate of 1 mi/min. The column was washed with 20 ml of
loading buffer and eluted with a 120 ml linear gradient of buffer C to
buffer D (buffer D is identical to buffer C except that it contains 300
mM potassium phosphate [pH 7.71). The SRB complex eluted from this
column in a peak corresponding to 68-112 mM potassium phosphate.
The 20 ml of eluate from the Bio-Gel HTP (Bio-Rad Laboratories)
was dialyzed against buffer E (same as buffer B except 0.25 mM EDTA)
containing 100 mM potassium acetate. The dialyzed material was spun
in a Sorvall SS34 rotor at 10,000 rpm for 20 min, and the supematant
(11 mg protein in 20 ml) was loaded onto a Mono Q HR 5/5 fast protein
liquid chromatography column (Pharmacia) and eluted with a 15 ml
linear gradient from buffer E (100) to buffer E (2000) at a flow rate
of 0.5 mllmin. The SRB complex eluted from this column at 0.95 M
potassium acetate.
Peak fractions containing SRB activity were diluted 1:6 with buffer
F (same as buffer A except 0.25 mM EDTA). This material (1.1 mg of
protein in 10 ml) was loaded onto a Mono S HR 5/5 FPLC column
(Pharmacia) and eluted with a 10 ml gradient from buffer F (100) to
buffer F (1000) at a flow rate of 0.5 mllmin. The SRB complex eluted
from this column at 450 mM potassium acetate. This material (0.6 mg
of protein in 8 ml) was diluted 1:4 in buffer E (0) and loaded onto a
1.5 cm x 1.5 cm DEAE-Sephacel column and eluted with a 20 ml
gradient from buffer E (100) to buffer E (1000) at a flow rate of 0.3 ml
min. The SRB complex eluted from this column at 400 mM potassium
acetate. (Further chromatography revealed that this material was ap-
proximately 90% pure.) This material (0.5 mg of protein in 2 mi) was
diluted 1:4 in buffer F (0) and loaded onto a 1.5 cm x 1 cm Biorex
70 column and was eluted with a 10 ml gradient from buffer F (100)
to buffer F (1000). The SRB complex eluted from this column at 600
mM potassium acetate and was approximately 95% pure. The total
yield of the SRB complex was 0.5 mg, and purification was estimated
to be 10,000-fold.
The SRB complex was subjected to gel filtration chromatography
in buffer F (400) on a Superose 6 HR 10130 FPLC column (Pharmacia).
The estimated molecular size of the SRB complex was determined
by extrapolation of a calibration curve performed with thyroglobulin
(669 kd), apoferritin (443 kd), bovine serum albumin (132 kd, 66 kd),
and carbonic anhydrase (29 kd).
CTD Affinity Purification
Whole-cell extracts were prepared by adding 1.6 1 of 4% glucose to 800
g of Red Star dry yeast, incubating the mixture at room temperature for
45 min, and adding 800 ml of disruption buffer (1.2 M ammonium
sulfate, 0.16M K-HEPES [pH 7.3], 4 mM DTT, and protease inhibitors
[as in the conventional purification above]). Aliquots (200 mi) were
frozen dropwise in liquid nitrogen and blended for 5-10 min in a Waring
RNA Polymerase II-Associated Complex
1373
blender. After thawing at 550C, viscosity was reduced by brief blend-
ing. Disrupted cells were centrifuged for 30 min at 12,000 rpm in a
Sorvall GSA rotor, and the clarified supernatant was filtered through
cheesecloth. One-twentieth volume of a 10% solution of Polymin P
was added, the extract was incubated on ice for 30 min, and the solu-
tion was centrifuged for 30 min at 12,000 rpm in a Sorvall GSA rotor.
The supernatant was collected and brought to 70% saturation with
solid ammonium sulfate and stored at 40C.
An aliquot of the suspension was removed from storage and centri-
fuged at 12,000 rpm in a Sorvall GSA rotor for 30 min. The pellet was
resuspended in 1.5 vol of 1 x transcription buffer (Liao et al., 1991)
plus protease inhibitors and centrifuged at 17,000 rpm in a Sorvall
SS34 rotor for 20 min. The supernatant was then diluted 1:6 in 1 x
transcription buffer plus protease inhibitors and centrifuged at 12,000
rpm in a Sorvall GSA rotor for 30 min. The supernatant was incubated
with 10 g/100 milliliters of cell debris remover (Whatman Labsales)
for 15 min. The cell debris remover was removed by centrifugation
and filtration. The cleared supernatant was then centrifuged at 40,000
rpm in a Beckman 50.2Ti rotor for 1-2 hr.
GST fusion proteins were coupled to Pharmacia activated CH Seph-
arose according to the manufacturer's directions at a concentration
of 5 milligrams of protein per milliliter of matrix. The affinity matrices
were washed with 6 M guanidine hydrochloride followed by I x tran-
scription buffer before use. Twenty milliliters of yeast whole-cell extract
were mixed with 1/10 vol of 1 x transcription buffer plus 10% Triton
X-100 and applied to 100 il of either GST-Sepharose or GST-CTD
Sepharose. The columns were washed with 20 ml of 1 x transcription
buffer plus 1% Triton X-100, followed by 5 ml of 1 x transcription buffer
without Triton X-100. Bound proteins were eluted with 1 x transcription
buffer containing various concentrations of guanidine hydrochloride.
Western Blot Analysis
Western blotting of fractions was performed with polyclonal rabbit anti-
sera raised against whole TBP, SRB2, and SRB5 proteins, a GST-
SRB4 fusion protein, or a GST-SRB6 fusion protein, by standard meth-
ods (Harlow and Lane, 1989). RPB1 was detected via the CTD with
8WG16 monoclonal antibody ascites fluid (Thompson et al., 1989).
Polyclonal anti-TBP, anti-SRB2, anti-GST-SRB4, and anti-SRB5 anti-
sera were diluted 1:1000. Anti-GST-SRB6 antiserum was diluted 1:200.
A 1:1000 dilution of 8WG16 monoclonal antibody ascites fluid was
used. In all cases, bands were visualized by secondary probing with
alkaline phosphatase conjugate secondary antibodies (Promega).
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Summary
The RNA polymerase II holoenzyme contains RNA
polymerase II, a subset of general transcription factors
and SRB regulatory proteins. We report here that SWI
and SNF gene products, previously identified as global
gene regulators whose functions include remodeling
chromatin, are also integral components of the yeast
RNA polymerase II holoenzyme. The SWI/SNF proteins
are components of the SRB complex, also known as
the mediator, which is tightly associated with the RNA
polymerase II C-terminal repeat domain. The SWI/SNF
components provide the holoenzyme with the capacity
to disrupt nucleosomal DNA and thus facilitate stable
binding of various components of the transcription
initiation complex at promoters.
Introduction
Regulation of class II genes involves a complex interplay
among gene-specific activators and cofactors, the gen-
eral transcription apparatus, and chromatin. Gene-spe-
cific activators bind to promoters and stimulate tran-
scription, at least in part, by binding and recruiting the
general transcription apparatus (Chen et al., 1994; Heng-
artner et al., 1995; Ingles et al., 1991; Lin et al., 1991;
Xiao et al., 1994; reviewed by Tjian and Maniatis, 1994;
Sheldon and Reinberg, 1995; Emili and Ingles, 1995;
Carey, 1995). Chromatin structure can affect the tran-
scriptional activity of genes by blocking access of the
transcription apparatus to promoters (Knezetic and
Luse, 1986; Bresnick and Felsenfeld, 1993; Felsenfeld,
1992; Lorch et al., 1988; Workman and Roeder, 1987).
The SWI and SNF proteins are global regulators that
function by antagonizing repression mediated by
nucleosomes, altering chromatin structure to facilitate
binding of the transcription apparatus (C6te et al., 1994;
Hirschhorn et al., 1992; Imbalzano et al., 1994; Kwon
et al., 1994; reviewed by Carlson and Laurent, 1994;
Peterson and Tamkun, 1995; Winston and Carlson,
1992). It is not yet clear how the SWI/SNF proteins are
targeted to promoters, although some gene-specific ac-
tivators may interact directly with these proteins (Yoshi-
naga et al., 1992).
Genetic and biochemical studies in yeast indicate that
the form of the transcription initiation apparatus gener-
ally responsible for mRNA synthesis in vivo is an RNA
polymerase II holoenzyme (Barberis et al., 1995; Hengar-
tner et al., 1995; Kim et al., 1994; Koleske and Young,
1994; Thompson and Young, 1995; reviewed by Carey,
1995; Emili and Ingles, 1995; Koleske and Young, 1995).
This megadalton-sized complex contains RNA polymer-
ase II, general transcription factors, and additional com-
ponents called suppressor of RNA polymerase B (SRB)
regulatory proteins. The SRB proteins are a hallmark of
the holoenzyme. The genes encoding the nine known
SRB proteins were identified through a selection for
factors involved in transcription initiation by RNA poly-
merase II in vivo, and all are required for normal yeast
cell growth. Essentially all of the SRB protein in cells is
tightly associated with the holoenzyme, while approxi-
mately 80% of RNA polymerase II and general transcrip-
tion factors are found independent of this complex
(Koleske and Young, 1995). Experiments with tempera-
ture-sensitive SRB mutants indicate that the RNA poly-
merase II holoenzyme is the form of the transcription
initiation apparatus employed at the majority of class II
promoters in vivo (Thompson and Young, 1995). Other
experiments have shown that recruiting a component
of the SRB complex to promoters, presumably in associ-
ation with the holoenzyme, suffices to obtain activated
levels of transcription in vivo (Barberis et al., 1995).
The yeast SWI genes were first identified as positive
regulators of HO transcription (Stern et al., 1984), and
SWI1, SW12, and SW13 were later shown to be required
for the activation of a broad spectrum of inducible genes
in vivo (Peterson and Herskowitz, 1992; Yoshinaga et
al., 1992). Similarly, the SNFgenes were originally identi-
fied as positive regulators of SUC2 (Neigebom and Carl-
son, 1984), and SNF2, SNF5, and SNF6 were subse-
quently found to be essential for activation of a diverse
set of inducible genes (Laurent and Carlson, 1992;
Laurent et al., 1991; Peterson and Herskowitz, 1992).
Further study revealed that SW12 and SNF2 are the same
gene. Genetic evidence indicated that the SWI and SNF
genes are involved in similar processes in gene activa-
tion (Carlson and Winston, 1992). Indeed, the discovery
that SWI1, SWI2/SNF2, SW13, SNF5, SNF6, and SNF11
proteins copurify in a large complex confirmed that the
SWI/SNF gene products function together (Caims et al.,
1994; C6t6 et al., 1994; Peterson et al., 1994; Treich et
al., 1995). Genetic and biochemical evidence implicated
the SWI/SNF proteins in chromatin remodeling via
nucleosome disruption (Cairns et al., 1994; C6te et al.,
1994; Hirschhorn et al., 1992; Peterson et al., 1994).
Several lines of evidence led us to investigate whether
SWI and SNF proteins are components of the RNA poly-
merase II holoenzyme, and furthermore, whether SWI/
SNF proteins are components of the SRB-containing
protein complex that is tightly associated with the
C-terminal repeat domain (CTD) in the holoenzyme.
First, genetic evidence suggests a functional relation-
ship between the SWI and SNF gene products and the
CTD. Strains containing mutations in SWI genes exhibit
a large number of defects similar to those due to a
truncation of the RNA polymerase II CTD (Nonet et al.,
1987; Peterson and Herskowitz, 1992; Peterson et al.,
1991). In addition, the CTD and the SWI/SNF gene prod-
ucts show similar genetic interactions with mutations in
SIN1 and SIN2, genes that encode chromatin-associ-
ated proteins (Peterson and Herskowitz, 1992; Peterson
et al., 1991). Second, the SRB gene products have func-
tional and physical interactions with the RNA polymer-
ase II CTD (Koleske and Young, 1995), which has been
implicated in the response to activators in yeast and
mammalian cells (Allison and Ingles, 1989; Gerber et al.,
1995; Scafe et al., 1990). Third, the holoenzyme appears
to be responsible for initiating transcription of most, if
not all, class II genes in yeast, and the SWI and SNF
gene products are required for transcriptional induction
of a large number of genes in vivo (Thompson and
Young, 1995; Peterson et al., 1991). Finally, there are
perhaps a dozen polypeptides in purified yeast RNA
polymerase holoenzyme that have yet to be identified.
We report here that the yeast RNA polymerase II holo-
enzyme contains SWI2/SNF2, SW13, SNF5, and SNF11.
The SWI/SNF proteins are components of the SRB
complex, also known as the mediator, which is tightly
associated with the RNA polymerase II CTD. Both the
holoenzyme and the SRB/SWI/SNF complex have ATP-
dependent nucleosome disruption activities previously
ascribed to the SWI/SNF complex. In addition, the holo-
enzyme facilitates the binding of TATA box-binding pro-
tein (TBP) to nucleosomal DNA in an ATP-enhanced
manner.
Results
Anti-SRB and Anti-SWI Antibodies
Coprecipitate Holoenzyme
SRB regulatory proteins are found tightly and exclu-
sively associated with other components of the RNA
polymerase II holoenzyme in cell extracts. If SWI and
SNF proteins are subunits of the RNA polymerase II
holoenzyme, then antibodies against SRB5 should
precipitate both the holoenzyme and SWI/SNF pro-
teins from crude extracts. The results in Figure 1 show
that this is indeed the case. SW12/SNF2, SW13, and
SNF5 proteins coprecipitate with holoenzyme obtained
through SRB5 immunoprecipitation. The fraction of SWI
and SNF proteins immunoprecipitated from the crude
extract appears to be the same as that of the SRB pro-
teins. Control proteins introduced into the crude lysate
did not coprecipitate, indicating that the immunoprecipi-
tate was specific for the holoenzyme. When the immuno-
precipitation experiment was carried out with antibody
against SW13, essentially identical results were obtained(Figure 1). The SWI/SNF and SRB proteins were immu-
noprecipitated from the crude extract with similar effi-
ciency whether the immunoprecipitating antibody used
was directed against SRB5 or SW13. A control experi-
ment with antibody against TGFI failed to precipitate
SWI/SNF or SRB proteins. These results indicate that
a-SRB5 a-SW13
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Figure 1. Immunoprecipitation of RNA Polymerase II Holoenzyme
from Crude Extracts Using Anti-SRB5 and Anti-SWI3 Antibodies
Immunoprecipitations were from a crude DEAE fraction prepared
as described by Hengartner et al. (1995). Immunoprecipitations were
carried out with affinity-purified antibodies against SWI3, SRBS, or
TGF)3. Ovalbumin and HA-tagged GST were added to each reaction
prior to precipitation to serve as controls for specific immunoprecipi-
tation; 1/50 of the onput and flowthrough, and 1/5 of the final wash
and eluate were subjected to SDS-PAGE and analyzed by Western
blotting using specific antibodies.
SRB and SWI/SNF proteins are tightly associated with
one another.
Purified Holoenzyme Contains
SWI/SNF Proteins
The immunoprecipitation results led us to investigate
whether SWI and SNF proteins are components of puri-
fied yeast RNA polymerase II holoenzyme. Antibodies
against selected SWI and SNF proteins were used to
determine whether these proteins coelute with the RNA
polymerase II holoenzyme in the final purification step
of the holoenzyme. The data in Figure 2A demonstrate
that SNF2/SWI2, SNF5, SW13, and SNF11 proteins coe-
lute with other known components of the holoenzyme
and with transcription activity.
The holoenzyme contains stoichiometric amounts of
RNA polymerase II, SRB proteins, and general transcrip-
tion factors. To ascertain whether the SWI/SNF proteins
are stoichiometric components of the holoenzyme, the
amounts of SNF2 and SNF5 were estimated by Western
blot analysis with various amounts of recombinant pro-
teins as standards (Figure 2B). These data indicate that
the purified RNA polymerase II holoenzyme contains
approximately equimolar amounts of SNF2, SNF5, and
SRB5, the latter being a standard against which other
holoenzyme components have previously been com-
pared (Koleske and Young, 1994). Since yeast cells con-
tain between 2000 and 4000 molecules of RNA polymer-
ase II holoenzyme, it appears that there are at least this
number of SW12/SNF2 and SNF5 molecules per cell.
SWI/SNF Proteins Are Components of
CTD-Binding SRB Complexes
Genetic evidence indicates that the SRB regulatory pro-
teins and the RNA polymerase II CTD have related func-
tions in transcription initiation and that these involve
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Figure 2. SWI/SNF Proteins Are Components of Purified RNA Poly-
merase II Holoenzyme
(A) RNA polymerase II holoenzyme eluted from a Mono S column,
the last chromatographic step in the purification procedure (Koleske
and Young, 1994), was analyzed for transcriptional activity and for
the presence of SRB and SWI/SNF proteins by Western blotting.
(B) Quantitative Western blots were used to determine the relative
amounts of SRB5 and SWI/SNF proteins in the holoenzyme. Known
amounts of recombinant GST-SNF2/SWI2 12%1703, GST-SNF5 1_l3,
and SRB5 were subject to SDS-PAGE and Westem blot analysis
along with 2.5 . 1 and 0.5 p.l of purified holoenzyme. There are similar
levels of SNF2/SWl2, SNF5, and SRB5 in the purified holoenzyme
Previous studies have shown that RPB1 and other SRB proteins
are equimolar in purified holoenzyme (Koleske and Young, 1994).
the response to transcriptional regulators (Allison and
Ingles, 1989; Gerber et al., 1995; Scafe et al., 1990;
Koleske and Young, 1995). Since the SWI and SNF pro-
teins are also involved in activation of a wide variety of
genes and since mutations in SWI and SNF genes can
produce phenotypes similar to those observed with mu-
tations in SRB genes, we investigated whether SWI and
SNF proteins are associated with the SRB complex.
The SRB protein complex can be released from the
holoenzyme when the latter is treated with monoclonal
antibodies against the CTD, and this preparation has
been called mediator (Kim et al., 1994). We previously
prepared a mediator complex according to the proce-
dure of Kim et al. (1994), confirmed that it has the coacti-
vator activity described by these investigators, and
showed that the mediator contains all of the SRB pro-
teins (Hengartner et al., 1995). When this mediator prep-
aration was assayed for the presence of SNF2/SWI2,
SNF5, and SW13 proteins by Western blot, all three SWI/
SNF proteins were found (Figure 3).
The SRB complex can also be isolated from crude
extracts using a recombinant CTD column (Thomp-
Figure 3. SWI/SNF Proteins Are Present in Mediator Purified Using
8WG16 Monoclonal Antibodies
Mediator was Western blotted along with holoenzyme and core
polymerase and probed for the presence of SWI/SNF proteins. The
mediator preparation was previously assayed (Hengartner et. al.,
1995) and shown to have all transcriptional activities previously
described (Kim et. al., 1994).
son et al., 1993). An SRB complex was purified exten-
sively by using a recombinant glutathione S-transferase
(GST)-CTD column, followed by chromatography with
Mono S and Mono Q columns (Figure 4A). The SRB,
SWI, and SNF proteins bind to a GST-CTD column, but
not to a control GST column, indicating that they bind
specifically to the CTD (Figure 4B). Sliver staining and
Western blotting confirm that both a multiprotein com-
plex containing SRB proteins and each of the three as-
sayed SWI/SNF proteins coelute from the Mono Q col-
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Figure 4. An SRB/SWI/SNF
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(A) Schematic diagram of the purification.
(B) SRB, SWI, and SNF proteins bind specifically to a GST-CTD
column. Western blot analysis of proteins eluted from a GST column
and from a GST-CTD column. TFIIE was a negative control for
specific retention, as it does not bind GST or GST-CTD.
(C) Silver stain of fractions across the final Mono Q column.
(D) Western blot analysis of SRB and SWI/SNF proteins across the
final Mono 0 column.
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Figure 5. Components of the RNA Poly-
merase Holoenzyme and the SRB/SWVSNF
Complex
(A) Silver stain of purified RNA polymerase II.
Bands that correspond in size to RNA poly-
merase core subunits, SRB, SWI, and SNF
proteins, and general transcription factor IIB,
IIF, and IIH subunits are indicated.
(B) Silver stain of the SRB/SWI/SNF complex.
Bands that correspond in size to SRB, SWI,
and SNF proteins are indicated.
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umn (Figures 4C and 4D). There are approximately 25
polypeptides in this complex, and several correspond in
size to previously identified SRB, SWI, and SNF proteins
(Figure 5). No signals were obtained when Western blots
containing the SRB/SWI/SNF complex were probed with
antibodies against RNA polymerase II, TBP, TFIIB, orthe
TFB1 subunit of TFIIH (data not shown). These results
indicate that the SRB complex is in fact an SRB/SWI/
SNF complex and, furthermore, that the SWI and SNF
proteins interact with the holoenzyme, at least in part
through their association with RNA polymerase II CTD.
Nucleosome Disruption Activity in Holoenzyme
and SRB/SWI/SNF Complex
Previous evidence that SWI1, SWI2, SWI3, SNF5, SNF6,
and SNF11 gene products can be isolated as a large
multisubunit complex capable of altering nucleosome
structure led us to investigate whether the purified RNA
polymerase II holoenzyme and the SRB/SWI/SNF com-
plex were able to alter nucleosome structure. Mono-
nucleosome particles were reconstituted from purified
histone octamers and a DNA fragment containing two
copies of an artificial phasing sequence (Shrader and
Crothers, 1989). Digestion of the mononucleosomes
with DNase I showed a 10 bp cleavage ladder typical of
a rotationally phased nucleosome (Figure 6). Fractions in
the last chromatographic step in the purification of the
holoenzyme were mixed with mononucleosomes and
assayed for the ability to alter nucleosome structure,
which can be visualized by changes in the accessibility
of the nucleosome to DNase I cleavage. Figure 6A dem-
onstrates that a nucleosome disruption activity coeluted
with the RNA polymerase holoenzyme. The ability of the
SRB/SWI/SNF complex to alter nucleosome structure
was assayed in a similar experiment using fractions from
the last step in the SRB/SWI/SNF purification (Figure
6C). The results show that nucleosome disruption activ-
ity coeluted with the SRB/SWI/SNF complex. Further
analysis of the RNA polymerase II holoenzyme and SRB/
SWI/SNF complex showed that the nucleosome disrup-
tion activity was ATP dependent (Figures 6B and 6D), as
was previously shown for purified SWI/SNF complexes
(C6te et al., 1994; Imbalzano et al., 1994; Kwon et al.,
1994). In addition, purified core RNA polymerase II
showed no nucleosome alteration capability (data not
shown). These data indicate that the SRB/SWI/SNF
complex contributes chromatin remodeling activity to
the RNA polymerase II holoenzyme.
Purified Holoenzyme and the SRB/SWI/SNF
Complex Disrupts Plasmid Chromatin
To characterize further the nucleosome disruption capa-
bilities of the holoenzyme and the SRB/SWI/SNF com-
plex, we employed a supercoiling reduction assay (Fig-
ure 7). In this assay, chromatin is assembled onto a
relaxed closed-circular plasmid that is subsequently pu-
rified by glycerol gradient centrifugation. Each assem-
bled nucleosome introduces approximately one nega-
tive supercoil to the plasmid, which can be resolved by
agarose gel electrophoresis after the removal of his-
tones. When no protein is added to the nucleosome-
assembled plasmid, it is highly supercoiled. Fractions
from the last column of the holoenzyme purification (see
Figure 2A) were tested for their ability to disrupt nucleo-
some structure and thereby reduce supercoiling in the
presence of added topoisomerase I. As can be seen in
Figure 7A, this activity coelutes with holoenzyme tran-
scription activity, with the SRB and SWI/SNF proteins
(see Figure 2A), and with nucleosome-core disruption
activity (see Figure 6A). The supercoiling reduction activ-
ity was dependent on ATP (Figure 7A, compare fraction
61 plus and minus ATP), as has been shown for the
human SWI/SNF complex (Kwon et al., 1994). Repeating
the experiment using fractions from the last column of
the SRB/SWI/SNF complex shows that this complex
also has an ATP-dependent supercoiling reduction ac-
tivity (Figure 7B).
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Figure 6. An ATP-Dependent Nucleosomal Disruption Activity Coe-
lutes with the Holoenzyme and the SRB/SWI/SNF Complex
(A) Fractions from the last column of holoenzyme purification (Figure
2A) were assayed for nucleosomal disruption. The peak of nucleoso-
mal disruption activity is in fractions 59-63, coincident with the peak
of transcriptional activity.
(B) Purified RNA polymerase II holoenzyme (fraction 60) was titrated
for activity with and without 4 mM ATP, as indicated.
(C) Fractions from the final column of the SRB/SWI/SNF complex
purification (Figure 4) were assayed for nucleosomal disruption. The
Holoenzyme Facilitates the Binding of TBP
to Nucleosomes
Previous work has shown that both yeast and human
SWI/SNF complexes can facilitate transcription factor
binding to nucleosomal DNA containing the relevant fac-
tor-binding site (C6te et al, 1994; Imbalzano et al, 1994;
Kwon et al, 1994). We tested whether the holoenzyme
could increase the binding of TBP to a mononucleosome
containing a TBP-binding site. With holoenzyme and
ATP present, TBP and TFIIA bound to the mononucleo-
some at TBP concentrations of 4 x 10-6 M (Figure 8A,
lane 7), while no TBP/TFIIA binding was observed in the
absence of holoenzyme (Figure 8A, lane 6).
This holoenzyme-facilitated TBP binding might be
caused by the stabilizing effects of the additional pro-
tein-protein and protein-DNA interactions that occur in
the presence of RNA polymerase and general transcrip-
tion factors, by the ATP dependent nucleosome disrup-
tion effects of SWI/SNF, or by a combination of both
effects. To address this issue, we tested whether facili-
tated TBP binding was ATP dependent and observed
partial protection of the TATA region on the mono-
nucleosome when ATP is withheld or when ATP yS is
used instead of ATP (Figure 88, lanes 4 and 6). However,
addition of ATP enhanced the TBP binding as indicated
by the increased protection from DNase I cleavage over
the TATA box, the extension of the footprint in the 5'
direction, and the appearance of a hypersensitive band
in the 3' direction (Figure 8B, lane 5). Thus, it appears
that the holoenzyme can partially stabilize binding of
TBP and TFIIA to a mononucleosome in the absence of
ATP. However, the full effect of holoenzyme-facilitated
TBP bindirng requires ATP, presumably because it in-
volves the POTP-dependent nucleosome disruption activ-
ity of the SWI/SNF proteins.
Discussion
The RNA polymerase II holoenzyme contains SWI and
SNF gene products, previously identified as global gene
coactivators. The SWI and SNF proteins are compo-
nents of an SRB/SWI/SNF complex, also known as the
mediator, which is tightly associated with the RNA poly-
merase II CTD. Both the holoenzyme and the SRB/SWI/
SNF complex have nucleosome disruption activities pre-
viously ascribed to the SWI/SNF complex. In addition,
the holoenzyme facilitates the binding of TBP to nucleo-
somal DNA in an ATP-enhanced manner.
Diverse Transcriptional Activators Require
SWI/SNF Function In Vivo
Mutations in SWI1, SW12/SNF2, SW13, SNF5, and SNF6
cause a substantial reduction in the ability to activate
transcription of a wide variety of well-studied genes
in yeast cells, including HO (Stern et al., 1984), SUC2
(Neigeborn and Carlson, 1984), Ty (Happel et al., 1991),
peak of nucleosomal disruption activity is in fractions 23 and 24,
which is also where the bulk of SRB and SWI/SNF proteins elute.
(D) The SRB/SWI/SNF complex (fraction 24) was titrated for activity
with and without 4 mM ATP, as indicated.
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Figure 7. The Holoenzyme and the SRB/SWI/
SNF Complex Reduce the Superhelical Den-
sity of Chromatin-Assembled Plasmids in an
ATP-Dependent Manner
Fractions from the last column of holoenzyme
purification (A) and from the last column of
SRB/SWI/SNF complex purification (B) were
assayed in the presence or 4 mM A I . Peak
fractions of purified holoenzyme and SRB/
SWI/SNF complex were assayed with and
without 4 mM ATP present as described in
Experimental Procedures. The symbols o, *,
and x indicate nicked circular plasmid DNA,
linear DNA, and highly supercoiled circular
DNA, respectively.
IN01 (Peterson et al., 1991), and ADH1 and ADH2 (Pe-
terson and Herskowitz, 1992; Taguchi and Young, 1987).
For example, ADH1 and SUC2 gene expression is re-
duced by about an order of magnitude in strains in which
SWI1, SW12, or SW13 has been deleted (Peterson and
Herskowitz, 1992). Experiments with reporter constructs
have revealed that the SWI and SNF gene products
are required for normal responses to a variety of gene-
specific activators in yeast such as GAL4, Drosophila
fushi tarazu, mammalian glucocorticoid and estrogen
receptors, and LexA-GAL4 and LexA-Bicoid fusion pro-
teins (Peterson and Herskowitz, 1992; Laurent and Carl-
son, 1992; Yoshinaga et al., 1992).
We have proposed that the RNA polymerase II holoen-
zyme is recruited to promoters by activators in vivo
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Figure 8. Holoenzyme Facilitates Binding of yTBP and yTFIIA to a
Nucleosome Containing a TATA Box in an ATP-Enhanced Manner
(A) Increasing amounts of yTBP in the presence of yTFIIA and 4 mM
ATP were tested for the ability to bind to a TATA box containing
nucleosome with and without holoenzyme present.(B) Nucleosomes were incubated with and without holoenzyme, 4
mM ATP or 4 mM ATP-yS, yTBP and yTFIIA, as indicated.
(Koleske and Young, 1994). Ptashne and colleagues
have shown that recruiting a component of the SRB
complex to promoters, presumably in association with
the holoenzyme, suffices to obtain activated levels of
transcription in vivo (Barberis et al., 1995; M. Ptashne,
personal communication). Thus, evidence that LexA fu-
sions with SW12/SNF2, SNF5, SNF6, and SNF11 proteins
are sufficient to activate transcription of a target gene
in vivo (Laurent et al., 1990, 1991; Treich et al., 1995)
might now be interpreted in terms of holoenzyme recruit-
ment to the target promoter.
We propose that recruitment of the holoenzyme to a
specific promoter in vivo provides a means to facilitate
TBP binding, regardless of the nucleosome structure at
that promoter. The holoenzyme can enhance binding of
TBP and TFIIA to a mononucleosome in vitro in the
absence of ATP (Figure 8), a result compatible with evi-
dence that the polymerase and general transcription
factor components of the holoenzyme provide addi-
tional protein-protein and protein-DNA interactions that
should stabilize TBP binding (Buratowski, 1994). Holo-
enzyme-facilitated TBP binding to a mononucleosome
is greater in the presence of ATP, which presumably
reflects the ATP-dependent nucleosome disruption ac-
tivity of the SWI/SNF proteins. These observations are
consistent with the idea that SWI/SNF protein function is
necessary at the subset of promoters whose chromatin
structure is particularly restrictive for TBP binding.
SWI/SNF in the Holoenzyme Accounts
for Previous Genetic Observations
The presence of SWI/SNF proteins in the RNA polymer-
ase II holoenzyme and the observation that these pro-
teins are components of a subcomplex that interacts
with the RNA polymerase II CTD explain several previous
observations. SWI/SNF proteins are necessary for tran-
scription activation of many genes in yeast cells (re-
viewed by Winston and Carlson, 1992; Carlson and
Laurent, 1994; Peterson and Tamkun, 1995); CTD trun-
cation adversely affects the response to activators in
yeast and mammalian cells (Allison and Ingles, 1989;
Scafe et al., 1990; Gerber et al., 1995). Cells with RNA
polymerase II CTD truncation mutations, cells with cer-
tain SRB mutations, and cells with SWI1, SW12, or SW13
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mutations exhibit remarkably similar phenotypes (Pe-
terson and Herskowitz, 1992; Thompson et al., 1993;
Hengartner et al., 1995). The association of the SRB/
SWI/SNF complex with the CTD accounts for the obser-
vation that cellular defects due to CTD mutations and
SWI mutations can be alleviated by mutations in SIN1
and SIN2, which encode an HMG1-related protein and
histone H3, respectively (Kruger and Herskowitz, 1991;
Peterson et al., 1991; Peterson and Herskowitz, 1992).
SRB/SWI/SNF Complex Is Associated
with the RNA Polymerase II CTD
The SRB/SWI/SNF complex is tightly associated with
the RNA polymerase II CTD. Independent attempts to
purify various SRB proteins by column chromatography
have always led us to purify the same multiprotein com-
plex: the RNA polymerase II holoenzyme (Koleske and
Young, 1994; Koleske et al., 1996; Hengartner et al.,
1995; Liao et al., 1995; reviewed by Koleske and Young,
1995). Only very small amounts of SRB protein can be
detected that are not associated with the holoenzyme.
Two different methods have been described that permit
partial purification of an SRB subcomplex. An SRB com-
plex can be isolated using a CTD affinity column
(Thompson et al., 1993) or by releasing it from a holoen-
zyme preparation by using monoclonal anti-CTD anti-
bodies (Kim et al., 1994). Because neither of these prep-
arations is homogeneous, we further purified the SRB
complex obtained by CTD affinity chromatography (Fig-
ure 4). The SRB and SWI/SNF proteins coelute in the
final step of the purification.
We also found that the SRB complex isolated by
anti-CTD antibody release contains SWI and SNF pro-
teins. Kim et al. (1994) demonstrated that reconstitution
of the response of the holoenzyme to activators required
the presence of a subcomplex that could be isolated
from holoenzyme with anti-CTD antibodies, which con-
tained SRB2, SRB4, SRB5, and SRB6, and was called
the mediator of activation. Our own studies with the
mediator, which was purified precisely as described by-
Kim et al. (1994) and has chromatographic and transcril-
tional properties identical to those originally described
for this subcomplex, revealed that it contained all nine
of the known SRB proteins (Hengartner et al., 1995).
Thus, the mediator preparation and the SRB complex
obtained by CTD affinity chromatography contain very
similar, if not identical, complexes.
We have shown that the RNA polymerase II holoen-
zyme, and its SRB/SWI/SNF subcomplex, contain SWI2/
SNF2, SWI3, SNF5, and SNF11. Although we do not
have direct biochemical evidence that SWI1l and SNF6
are present in the holoenzyme, other genetic and bio-
chemical data indicate that it is highly likely that SWIl
and SNF6 are also subunits of these complexes (Cairns
et al., 1994; C6at et al., 1994; Laurent and Carlson, 1992;
Laurent et al., 1991; Peterson and Herskowitz, 1992).
Are There Multiple SWI/SNF Complexes?
Large multisubunit complexes containing yeast SWI and
SNF proteins have been purified to varying extents
(Cairns et al., 1994; C6t6 et al., 1994; Peterson et al.,
1994). Characterization of two of these preparations by
Western blot analysis did not reveal the presence of
SRB proteins (Peterson et al., 1994; Cairns et al., 1994).
This suggests that the purification procedures employed
in these studies separated the SRB and SWI/SNF pro-
teins or that SWI/SNF complexes can exist independent
of the holoenzyme.
Since SWl2/SNF2 and SNF5 are stoichiometric com-
ponents of the holoenzyme and since yeast cells contain
2000-4000 molecules of RNA polymerase II holoen-
zyme, there are at least 2000 molecules of SWI2/SNF2
and SNF5 molecules per cell. Based on their SWI/SNF
complex purification, C6t6 et al. (1994) estimated that
there are between 50 and 150 copies of the SWI/SNF
complex in yeast cells. One interpretation of these re-
sults is that most SWI/SNF protein resides in the RNA
polymerase II holoenzyme, and the form of SWI/SNF
complex purified by C6te et al. (1994) is the small amount
of SWI/SNF protein that is in the process of assembly
into holoenzyme or, alternatively, it represents a sub-
complex that can be dissociated from the holoenzyme.
The ability to immunoprecipitate very similar holoen-
zyme complexes from crude yeast fractions using anti-
SRB and anti-SWI antibodies suggests that most of the
SWI/SNF protein in these fractions is associated with
the holoenzyme. If the SRB and SWI/SNF proteins were
in separate complexes, then the relative ratios of SRB
and SWI/SNF proteins would differ in the anti-SRB and
anti-SWI immunoprecipitates. However, the similar rela-
tive ratios of SRB and SWI/SNF proteins found in immu-
noprecipitates obtained with anti-SRB and anti-SWI an-
tibodies (Figure 1) indicate that the SRB and SWI/SNF
proteins are components of the same complex in the
crude extract.
SWI/SNF Function Is Highly Conserved
in Eukaryotes
SWI/SNF proteins and their functions appear to be
highly conserved in eukaryotes. Putative homologs of
SNF2/SW12 include Drosophila brahma and human
hbrm and hBRG1, which have been cloned and impli-
cated in transcriptional regulation (Tamkun et al., 1992;
Khavari et al., 1993; Muchardt and Yaniv, 1993). A mam-
malian homolog of SNF5, called INII, has also been
cloned (Kalpana et al., 1994). A human SWI/SNF com-
plex has been partially purified that has nucleosome
disruption activities similar to those of the yeast SWI/
SNF complex (Imbalzano et al., 1994; Kwon et al., 1994).
The human SWI/SNF complex contains both hBRG1 and
INI1 proteins (Kalpana et al., 1994; G. R. S., unpublished
data), as would be expected based on the yeast results.
Like the yeast SWI/SNF complex, the human SWI/SNF
complex facilitates the binding of activators to nucleo-
somal DNA.
Implications for Mechanisms Involved
in Transcriptional Activation
Our evidence indicates that the RNA polymerase II holo-
enzyme consists of core RNA polymerase II, all the
general transcription factors other than TBP and TFIIA,
and a CTD-associated SRB/SWI/SNF subcomplex. The
presence of the SRB/SWI/SNF subcomplex in the RNA
polymerase II holoenzyme has implications for the
mechanisms involved in transcription activation in vivo.
Dynamic competition between chromatin proteins and
an activator for a specific DNA site could be resolved
in favor of the activator once the SWI/SNF-containing
holoenzyme was recruited to the promoter. In this
model, the activator and the holoenzyme both contribute
to stable transcription initiation complex formation; the
activator recruits the holoenzyme by binding to a subset
of its components, and the SWI/SNF components of the
holoenzyme enhance the stability of the activator-DNA
interaction by destabilizing nucleosomes. This model is
attractive because it provides a simple solution to the
question of how SWI/SNF proteins are brought to pro-
moters and it accounts for the coactivating and nucleo-
some disruption activities observed in vivo and in vitro
for the SWI and SNF proteins.
Experimental Procedures
Immunoprecipitations
All immunoprecipitations were done as described (Hengartner et
al., 1995). In brief, 50 p1 of the DEAE 400 fraction was diluted 1:4
with modified transcription buffer (MTB) (50 mM HEPES-KOH [pH
7.3], 100 mM potassium acetate, 25 mM MgAc, 5 mM EGTA, 1 p.M
DTT, 10% glycerol, 0.01% NP-40, 1 mM PMSF, 2 mM benzamidine,
2 pM pepstatin A, 0.6 p.M leupeptin, and 2 p.g/ml chymostatin) minus
the postassium acetate. We added 4 Ag of ovalbumin, 4 Ag HA-
GST, and 2 p.g of BSA to each reaction prior to the addition of
antibody and then added 0.4 p.g of affinity-purified a-SRB5, 0.15
Ag of affinity-purified a-SWI3, or 1.5 Ag of affinity-purified oL-TGFO
to the respective reactions and allowed them to incubate 2 hr at
4OC; 15 p.I of goat anti-rabbit covalently linked to magnetic beads
(Dynal) were then added and incubated for 1 hr at 40C with constant
agitation. Beads were precipitated with a magnet and washed three
times in 200 i1 of MTB buffer. The final wash contained no NP-40.
Proteins were eluted off the magnetic beads by boiling in 20 p. of
sample buffer.
Western Blotting
All Western blots were performed as described (Koleske and Young,
1994). Proteins were detected with the following antibodies: SRB2,
SRB4, SRB5, SRB6 (Thompson et al., 1993), SRB8, SRB9 (Hengart-
ner et al., 1995), SRB10, SRB11 (Liao et al., 1995), SWI2/SNF2, SNF5
(gift of B. Laurent), SW13 (gift of C. Peterson), SNF11 (gift of I. Treich
and M. Carlson), TFIlEu, and TFIIE3 (C. J. W. and R. A. Y., unpub-
lished data). Quantitative Western blots were performed as de-
scribed (Koleske and Young, 1994). Recombinant standards were
SRB5 (Thompson and Young, 1995), GST-SNF2/SW12,251 -1 03, and
GST-SNF5_1,3 (gifts of B. Laurent). GST proteins were purified as
described (Smith and Johnson, 1988). Concentrations of recombi-
nant proteins were determined using a colorimetric assay (Bio-Rad)
with bovine serum albumin as a standard.
Purification of Holoenzyme and Mediator
Holoenzyme was purified as described (Koleske and Young, 1994).
Transcription assays for holoenzyme were done as described
(Koleske and Young, 1994). Mediator was purified as described
(Hengartner et al., 1995).
SRB/SWI/SNF Complex Purification
Whole-cell extract was prepared from Red Star yeast as described
(Thompson et al., 1993). We centrifuged 1.2 liters of the ammonium
sulfate pellet for 30 min at 5,000 rpm in an RC3B centrifuge (Sorvall).
The pellet was resuspended in 900 ml of buffer A (20 mM K-HEPES
[pH 7.6], 1 mM EDTA, 1 mM DTT, 20% glycerol, and protease inhibi-
tors [Thompson et al., 1993]). The suspension was centrifuged again
for 30 min at 5,000 rpm in an RC3B centrifuge (Sorvall). The supema-
tant was mixed with 200 g (dry) of BioRex 70 and stirred for 20 min.
The suspension was packed into a column with a 5 cm diameter
and washed with 1.5 liters of buffer A plus 100 mM KOAc. Bound
proteins were eluted with buffer A plus 600 mM KOAc. Fractions
containing protein were pooled, frozen in liquid nitrogen, and stored
at -70'C until use. Eluates from two BioRex columns (320 ml, 1.0
g of protein) were thawed and pooled; 320 ml of buffer A plus 2%
Triton X-100 were added, and the mixture was centrifuged for 30
min at 12,000 rpm in a GSA rotor (Sorvall). The supematant was
loaded onto a 15 ml CTD affinity column prepared as described
(Thompson et al., 1993) at a flow rate of 200 ml/hr. The column was
washed with 100 ml of buffer A plus 300 mM KOAc plus 1% Triton
X-100, or 100 ml of buffer A plus 300 mM KOAc. Bound proteins
were eluted with buffer A plus 300 mM KOAc plus 1 M urea at a
flow rate of 25 ml/hr. Fractions containing protein (3.7 mg) were
pooled, frozen in liquid nitrogen, and stored at -700C. The CTD
column was equilibrated with buffer A plus 300 mM KOAc plus 1%
Triton X-100, and the flowthrough was loaded again. The column
was washed and eluted as before. Fractions containing protein (1.8
mg) were pooled, frozen in liquid nitrogen, and stored at -70uC.
The CTD eluates were pooled, diluted with 1.5 vol of buffer A plus
0.01% NP-40, and centrifuged for 10 min at 17,000 rpm in an SS-
34 rotor (Sorvall). The supematant was loaded onto a Mono S HR
5/5 (Pharmacia) at a flow rate of 0.3 mI/min. The column was washed
with 3 ml of buffer A plus 120 mM KOAc plus 0.01% NP-40. Bound
proteins were eluted with a 20 ml gradient of buffer A plus 0.01%
NP-40 from 120 mM to 1000 mM KOAc. Fractions were frozen in
liquid nitrogen and stored at -70-C until use. Fractions containing
SRB4 and SRB5 as assayed by Western blotting were pooled and
diluted with 2 vol of buffer B (20 mM Tris OAc [pH 7.6] plus 20%
glycerol plus 1 mM DTT plus 0.01% NP-40 plus protease inhibitors).
The mixture was centrifuged for 5 min in a microcentrifuge. The
supernatant was loaded onto a Mono Q HRR 5/5 column (Pharmacia)
at a flow rate of 0.3 mVmin. The column was washed with 1 ml of
buffer B plus 200 mM KOAc. Bound proteins were eluted with a 40
ml gradient of buffer B from 200 mM to 2000 mM KOAc. The yield
of SRB complex was approximately 100 p.g. We analyzed 1 pI of
each fraction by silver staining and 7.5-10 p.1 of each fraction by
Western blotting.
Nucleosomal Disruption and Facilitated
Transcription Factor Binding Assays
The PH MLT (Figure 6) orPH MLT(+3) (Figure 8) restriction fragments
were assembled into rotationally phased mononucleosome parti-
cles, purified by glycerol gradient centrifugation, and assayed as
described (Imbalzano et al., 1994). At the nucleosome concentra-
tions and reaction conditions employed in this and previous studies,
nucleosomes were determined to be stable on the basis of resis-
tance to micrococcal nuclease, the appearance of a 10 bp repeat
pattern upon DNase I digestion, and exhibition of reduced mobility
upon electrophoresis in native polyacrylamide gels. We have not
observed the appearance of free DNA due to nucleosome dissocia-
tion in any of our experiments.
In Figure 6, holoenzyme fractions were the same as those used
in Figure 1A. In Figure 6A, 0.3 I1 of each fraction was assayed in
the presence of 4 mM ATP. For the titration of holoenzyme, 0 1l,
0.015 p.l, 0.05 p.I, 0.15 g1, and 0.5 prl of fraction 60 was used, respec-
tively, with and without 4 mM ATP as indicated. SRB/SWI/SNF frac-
tions were the same as those used in Figures 3C and 3D. In Figure
6C, 1.7 p11 of each fraction was assayed in the presence of 4 mM
ATP. For the titration in Figure 6D, 0 p.I, 0.07 0I, 0.2 p., 0.7 p.I, and
2.0 p. of fraction 24 was used, respectively, with and without 4 mM
ATP as indicated.
For Figure 8, binding of yeast TBP (yTBP) and yTFIIA to nucleo-
somes containing the PH MLT(+3) restriction fragment was per-
formed as previously described (Imbalzano et al., 1994). In Figure
8A, all reactions contained 4 mM ATP. Following a 30 min incubation
at 30"C in the presence or absence of holoenzyme (as indicated),
increasing amounts of yTBP in the presence of yTFIIA were added.
TBP concentrations were 0 (lanes 1, 3, and 10), 0.04 pM (lanes 2,
4, and 9), 0.4 p.M (lanes 5 and 8), and 4 p.M (lanes 6, 7). yTFIIA (1.5
I.M) was also added to all reactions. In Figure 8B, reactions were
treated with holoenzyme, alone (lanes 2 and 4), in the presence of
4 mM ATP (lanes 3 and 5), or in the presence of 4 mM ATPyS (lane
6) for 30 min at 300C, followed by addition of 4 p.M yTBP in the
presence of 1.5 ýpM yTFIIA.
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Recombinant yTBP was purified as described (Hoey et al., 1990),
except that the heparin peak was further purified on a Mono S HR5/
5 FPLC column (Pharmacia). Recombinant yTFIIA was purified as
described (Ranish et al., 1992).
Supercoiling Reduction Assay
Plasmid chromatin was assembled and purified as described (Kwon
et al., 1994). Reactions, total volume 12.5 id1, contained chromatin
(2 ng of DNA), 1 U of topoisomerase I (Promega), 2.5 ±1 of 30%
glycerol gradient buffer, 7 1i of buffer A minus KCI, 7 mM MgCI 2,50-100 mM KOAc (final), 4 mM ATP where indicated, and 2 pl of
holoenzyme Mono S fractions or 1 ý.I of SRB/SWI/SNF complex
Mono Q fractions. Reactions were stopped after 90 min at 300C by
addition of 6 ILI of stop buffer (3% SDS, 100 mM EDTA, 50 mM
Tris-HCI [pH 8.0], 25% glycerol, 2 mg/ml proteinase K). Reactions
were incubated for 90 min at 37'C and resolved on a 2% agarose
gel (50 mM Tris-phosphate [pH 7.3], 1mM EDTA) for 40 hr, at 40 V.
Gels were dried and exposed to film.
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